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Nucleophosmin (NPM) is a multifunctional nucleolar protein strongly implicated 
in  cancer,  where  its  expression  and  gene  integrity  are  frequently  altered.    NPM 
cytoplasmic mutation (NPMc+) was recently discovered as the single most frequent 
mutation in acute myeloid leukemia to date.  There is significant debate on whether 
NPM is an oncogene or tumor suppressor.  To directly study the role of NPM in 
cancer, I helped characterize a mouse knockout model of Npm.  We have shown that 
Npm
+/-  mouse  embryonic  fibroblasts  are  more  susceptible  to  oncogenic 
transformation,  and  Npm
+/-  mice  develop  features  of  human  myelodysplastic 
syndrome which eventually progress to myeloid and lymphoid malignancies.  These 
data demonstrate that Npm is a tumor suppressor in vitro and in vivo.  Furthermore, 
since relatively little is known about NPMc+, I carried out classical transformation 
assays and generated a transgenic mouse model to assess the oncogenic potential of 
NPMc+.  I find that NPMc+ transforms primary mouse embryonic fibroblasts when its 
senescence response is evaded, and transgenic mice of NPMc+ develop features of 
myeloproliferation  and  other  tumors  but  not  acute  myeloid  leukemia.    These  data 
suggest that NPMc+ can act as an oncogene only in the appropriate genetic milieu.  In 
addition, this transgenic model can serve as a tool to identify mutations that cooperate 
with NPMc+ in leukemogenesis and therapeutic regimens that target NPMc+. 
To further elucidate the molecular mechanisms of NPM in tumorigenesis, I tested 
whether  aberrant  ribosome  function  could  contribute  to  the  increased  cancer 
susceptibility found in Npm
+/- cells.  Using polysome microarray and a method of  
determining  ribosome  composition,  my  data  suggest  that  aberrant  ribosome 
stoichiometry  and  cap-independent  differential  translation  of  growth  promoting 
mRNAs precedes oncogenisis in Npm
+/- mouse embryonic fibroblasts.  These findings 
open a novel paradigm for investigating whether aberrant ribosome quality could lead 
to cancer. 
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PREFACE 
 
There is only one thing worse than coming home from the lab to a sink full 
of dirty dishes, and that is not going to the lab at all! 
Female physicist Dr. Chien-Shiung Wu 
 
There are several factors that affected the choice of my thesis topic and gave me 
the motivation to carry out the sometimes mundane and often futile day-to-day chores 
at the bench:  
1)  NPM as an emerging “hot” cancer gene having a high impact in cancer therapy 
2)  Availability  of  well  established  tools/methodologies  in  the  lab  for  studying 
NPM 
3)  Hematology as an experienced field of research for my advisor 
4)  My  curiosity  concerning  the  hypothesis  that  cancer  cells  have  aberrant 
ribosomes, and my desire to use NPM as a paradigm to test this idea 
 
In the first part of my thesis, I will present my collaborative work in showing that 
Npm is a tumor suppressor followed by my work on assessing the oncogenic potential 
of the NPMc+ mutant.  NPMc+ has become extremely important in the cancer field as 
it was found to be the most frequent mutation in leukemia just when I started my 
graduate studies.  My in vitro and in vivo studies on NPMc+ showing that it is a bona-
fide oncogene has significance not only on therapeutic targeting, classification and 
diagnosis of AML, but also the understanding of molecular mechanisms that leads to 
leukemogeneis in NPMc+ AML.  Chapter 2, adapted with a new section at the end, 
goes beyond my original publication to try to address the mechanisms of NPMc+-
induced senescence.   xiv 
In the second part, I will present my attempts to prove the “aberrant ribosomes in 
cancer”  hypothesis.    While  none  of  the  data  in  this  part  has  been  published,  this 
hypothesis remains a source of inspiration for my graduate studies.  NPM is one of the 
few genes directly implicated in both cancer and ribosome biogenesis.  By using the 
Npm
+/- model with increased cancer susceptibility, I have the unique opportunity to 
test  if  aberrant  ribosomes  and  aberrant  ribosome  function  exist  in  cells  preceding 
oncogenesis, and whether this altered ribosome function could provide an explanation 
for oncogenesis.  This was my hope to expand beyond the “one-gene one-thesis” mode 
and demonstrate a new concept in defining the hallmarks of cancer.  This part is more 
theoretical, but surely more provocative.  
Due to the different hypotheses and work presented, Part I and Part II will be 
introduced separately.  I have performed experiments and generated all figures except 
Figures 3, 4B-D, 5, 6B-G, 7, 15, 18B-C, 20C, 40B, 41D, 43 and 44.  Rather, I have 
contributed  to  the  above-mentioned  figures  by  helping  to  confirm  the  results, 
designing the experiment, discussion, or providing mice and other reagents. 
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PART I.  
 
NPM AND NPMc+: THE RISE OF KEY CANCER GENESCHAPTER 1 
NUCLEOPHOSMIN IS A HAPLOINSUFFICIENT TUMOR SUPPRESSOR 
 
The Middle is the best place to be. 
                                                                               LaoZi 
 
Abstract 
Nucleophosmin  is  a  multifunctional  nucleolar  protein  strongly  implicated  in 
human cancer where its expression and gene integrity are frequently altered.  There is 
significant debate on whether Npm is an oncogene or tumor suppressor.  To directly 
study the role of Npm in tumorigenesis, we generated a knockout mouse model and 
show that Npm is a haploinsufficient tumor suppressor in vitro and in vivo.  Npm
+/- 
MEFs  are  more  susceptible  to  oncogenic  transformation  and Npm
+/-  mice  develop 
features of human MDS (a pre-leukemic disease) that eventually progress to myeloid 
and lymphoid malignancies.  This is relevant because the region to which NPM maps 
is often lost or translocated in a number of human hematopoietic malignancies.  In 
particular, as the pathogenesis of human MDS is not well understood and few mouse 
models for MDS exist, our Npm
+/- mice can serve as a powerful tool to study the 
mechanisms  and  progression  of  MDS  to  AML  and  to  test  potential  therapeutic 
regimens.   
 
Introduction 
Nucleophosmin (NPM, B23, NO38 or numatrin) was first identified as one of the 
most abundant nucleolar phosphoproteins
1.  Its nucleolar localization, and the fact that 
it  shuttles  between  the  nucleus  and  cytoplasm  led  to  the  earliest  proposal  that  it 
facilitates ribosome biogenesis
2 and the assembly of pre-ribosomal particles
3.  Along  
  3 
with the finding that it is rapidly accumulated in response to mitogenic stimuli, and 
that it is significantly more abundant in tumor and growing cells than in normal resting 
cells
4,  5, NPM was soon thought to be a regulator of cell growth, proliferation and 
transformation.  Since then, the number of reports published on NPM has increased 
exponentially giving us a glimpse of the complex and multi-faceted roles of NPM.  
However one thing has become clear: NPM is strongly implicated in human cancer, 
where its expression and gene integrity are frequently altered.   
 
NPM gene structure and family 
The human NPM1 gene (Figure 1) contains 12 exons that can be alternatively 
spliced to give three isoforms among which isoform 1 is the most predominant type in 
all tissues
6 and results in the longest transcript.  In contrast, the shorter isoforms 2 and 
3 lack an alternative in-frame exon and utilize an alternate 3’ exon, respectively.  In 
the mouse, Npm1 is an essential gene whose inactivation in the germ line leads to a 
series  of  developmental  defects  and  embryonic lethality  at  mid-gestation
7.    NPM1 
belongs to the nucleophosmin/ nucleoplasmin family (NPM1-3) of nuclear chaperones 
that  binds  to  histones  and  modulates  chromatin  condensation  and  decondensation 
events.  It is by far the best-studied family member due to its connection with cancer 
and all NPM mentioned in this thesis refers to the isoform 1 of NPM1.   
 
NPM is a multifunctional shuttling protein 
NPM  is  an  abundant  and  evolutionarily  conserved  protein  of  about  37kD  that 
mainly localizes to the nucleoli, although it constantly shuttles between the nucleus 
and the cytoplasm
3,  8.  Under native conditions, NPM exists as an oligomer
9,  10.  It 
contains a N-terminal oligomerization domain for homo- and hetero-dimerization, a 
basic nucleic acid binding domain showing high binding affinity to single-stranded   
  4 
 
 
 
 
 
 
Figure  1.  NPM  isoforms  and  families.  NPM1  belongs  to  the  nucleophosmin/
nucleoplasmin (NPM1-3) family of nuclear chaperons.  Isoform 1 of NPM1 is the
most predominant type in all tissues and results in the longest transcript.   Exons
encoding  for  translated  regions  of  NPM1,  NPM2,  and  NPM3  proteins  are
schematically  represented  by  pink,  blue,  and  green  boxes,  respectively.   Exons
encoding for untranslated regions are depicted by grey boxes.  Introns are indicated
by black lines.  Adapted from Frehlick et al., BioEssays 2007; 29:45-59.
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nucleic acids, an acidic histone binding region for its chaperone activity, two nuclear 
localization signals (NLS) and two nuclear export signals (NES), and an aromatic C-
terminal domain containing a crucial nucleolar localization signal (NoLS) (Figure 2A).  
Through  these  molecular  domains,  NPM  is  able  to  bind  to  many  partners  in 
distinct  cellular  compartments  (see  review
11).    These  include  nucleolar  factors 
(nucleolin, fibrillarin, snoRNPs, ribosomal proteins), transcription factors (IRF1, YY1, 
NFκB), histones (H3, H4, H2B), and regulators of mitosis (NUMA, NEK2A), cell 
proliferation (DNA polymerase α), and response to oncogenic stress (ARF and p53).  
NPM also associates with both DNA and RNA.  Furthermore, it forms complexes with 
the second messenger PIP3 in the nucleus in response to anti-apoptotic factors.  To add 
to  the  complexity,  NPM  itself  is  found  phosphorylated,  acetylated,  glutamylated, 
polyribosylated  and  ubiqutinylated  by  other  factors;  these  post-translational 
modifications can all affect the activity of NPM (see review
12). 
By shuttling between cellular compartments, NPM takes part in various cellular 
processes  (see  review
11).    These  include  transport  of  pre-ribosomal  particles  and 
ribosome  biogenesis,  the  response  to  stress  stimuli  such  as  UV  irradiation  and 
hypoxia,  the  maintenance  of  genomic  stability  through  the  control  of  centrosome 
duplication and the participation in DNA repair processes, and the regulation of DNA 
transcription through chromatin remodeling.  Finally, NPM regulates the activity and 
stability of crucial tumor-suppressors such as p53 and ARF (Figure 2B). 
Although this list of roles seems endless, most of them have been supported by 
only biochemical or in  vitro data.  The earliest works on NPM were biochemical 
studies showing its role in ribosome biogenesis and as a molecular chaperon for both 
proteins and nucleic acids
12.  For example, NPM can bind to and have a measurable 
endonuclease activity on 28S rRNA.  It prevents the aggregation of proteins during 
thermal denaturation, and it is capable of nucleosome assembly and increasing   
  6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NES 
Figure  2.  The  NPM1  gene  encodes  for  a  protein  involved  in  multiple 
functions.  A,  The  NPM1  gene  contains  12  exons.    MB,  metal  binding 
domain; Ac, acidic domain; NLS, nuclear localization signal; NES, nuclear 
export  signal;  NoLS,  nucleolar  localization  signal.  B,  Localizations  and 
functions of NPM.  The inset shows that NPM mainly resides at the granular 
regions  of  the  nucleolus Modified  from  Falini,  B.  et  al.,  Blood 
2007;109:874-885. 
NPM 
Nucleoli
n 
A 
B  
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acetylation-dependent transcription in vitro.  The role of NPM as a stress response 
gene by stabilization of p53 is limited to cell line studies such as NIH3T3 and HeLa 
using overexpression systems
13-15.  The role of NPM at the centrosome is controversial 
as one group found its presence in the purified centrosomes
16 while another did not
17.  
Deciphering and validating the individual functions of NPM is made more difficult as 
the interaction/functional domains of NPM are not clearly mapped. Thus, it becomes 
critical to establish an in vivo model to more clearly define the physiological roles of 
NPM, and dismiss those roles that are consequential and not causal, or simply an 
overexpression artifact.   
 
How does NPM contribute to oncogenesis? 
Although I will dwell on a possible novel connection between NPM’s ribosomal 
role  and  cancer  in  Chapter  2,  the  most  well  known  role  of  NPM  in  cancer  is  its 
maintenance  of  genomic  stability  and  its  regulation  of  tumor  suppressors  p53  and 
ARF.  
During  mitosis  the  nucleolus  goes  through  reversible  disassembly
18,  and  many 
nucleolar  proteins  including  NPM,  translocate  from  the  nucleolar  remnants  to  the 
cytoplasm
19.    In  particular,  NPM  relocates  to  the  chromosome  periphery,  to 
cytoplasmic entities called nucleolus-derived foci (NDF)
20, and migrates to the poles 
of the mitotic spindle
21.  Phosphorylation of NPM by mitotic kinases have been shown 
to  regulate  its  localization  during  mitosis
22,  23.    NPM  has  also  been  previously 
proposed to be a constituent of the centrosome, and one of the substrates of the CDK2-
cyclin E complex phosphorylated at the initiation of centrosome duplication
16.  The 
protein has been shown to specifically associate with the unduplicated centrosome 
and, upon CDK2/cyclin E-mediated phosphorylation on Threonine 199, to dissociate 
from  the  centrosome,  enabling  its  duplication
16,  24,  25.    Although  further  in  vivo  
  8 
evidence in mammalian cells is still needed to fully establish a direct role for NPM 
and the CDK2-cyclin E complex at the centrosome at G1-S transition, the presence of 
NPM  at  the  mitotic  spindle  poles  has  been  seen  repeatedly,  and  it  is  proposed  to 
protect the cell from centrosome hyper-amplification and to enable the cell to progress 
through G2-M
21-23.  Importantly, Npm loss leads to centrosome amplification in vitro
7 
and in vivo
26. 
In addition, NPM is found to suppress apoptosis by functional inhibition of p53 
but can also stabilize p53 during conditions of cellular stress.  For example, when 
overexpressed in malignant hematopoietic cells, an NPM mutant that lacks the p53-
interacting domain does not prevent apoptosis in response to stress stimuli, unlike the 
overexpression of wild-type NPM
27.  This is supported by the fact that NPM inhibits 
hypoxia-induced p53 phosphorylation at serine 15
28.  Thus NPM can be seen as a 
negative  regulator  of  p53  function  under  certain  conditions.    However,  upon 
“nucleolar stress” triggered by DNA damage, NPM translocates to the nucleoplasm, 
and binds to the negative regulator of p53, MDM2, inhibiting MDM2’s function
29.  
NPM can also bind to and regulate the cellular localization of pro-apoptotic protein 
GADD45α in the p53-GADD45α pathway, resulting p53 induced apoptosis through 
GADD45α stabilization
30.  Overexpression of NPM is also thought to also trigger a 
p53-dependent  cellular  senescence
31.    Finally,  p53  is  stabilized  in  Npm
-/-  MEFs
7.  
Together these data suggest NPM as a positive regulator of p53 function under other 
conditions.    NPM  also  associates  with  ARF  with  high  stoichiometry  within  the 
nucleolus,  and  stabilizes  ARF  by  retarding  both  proteosome-dependent  and 
proteosome-independent  degradation
32.    For  example,  the  stability  of  ARF  is 
significantly increased in cells that overexpress endogenous NPM, and ARF level is 
reduced in Npm
hy/hy MEFs or cells expressing NPM short-hairpin RNAs
32, 33.  
  
  9 
Is NPM an oncogene or tumor suppressor? 
Since NPM has proved to have proliferative as well as growth-suppressive roles in 
the  cell,  there  is  significant  debate  on  whether  NPM  is  an  oncogene  or  a  tumor 
suppressor. 
On the one hand, the overexpression of NPM has been observed in various tumors, 
such  as  gastric
34,  colon
35,  ovarian
36,  and  prostate
37  carcinoma.    Overexpression  of 
NPM  can  also  transform  NIH3T3  cells in  vitro
38.    Furthermore,  the  locus  5q35.1 
containing NPM1 and several other genes is found to be amplified in cancers (NCBI 
CancerChromosomes).  The role of NPM in supporting cell growth can be attributed 
to its participation in the synthesis of ribosomes and its inhibition of apoptosis through 
IRF-1
38, PKR
39, and p53
28.  It also mediates the anti-apoptotic activity of NGF by 
functioning as a receptor for nuclear PIP3
40.  Finally, NPM is a transcriptional target 
of the Myc oncogene
41,  42, and it has been correlated with the stimulation of DNA 
polymerase-α activity
43. Thus, NPM seems to function as a proto-oncogene and in fact 
has been used as a tumor marker in the clinics
44, 45.  However, it is still not known 
whether the overexpression of NPM would lead to transformation in vivo in transgenic 
models.   
On the other hand, The NPM gene is involved in a number of tumor-associated 
chromosomal  translocations  which  lead  to  the  formation  of  novel  fusion  proteins 
associated  with  severe  hemopoietic  malignancies:  It  is  fused  with RARα  in  Acute 
Promyelocytic  Leukemia  (APL)
46,  with ALK  in  Anaplastic  Large–Cell  Lymphoma 
(ALCL)
47,  48, and with MLF1 in Myelodysplasia (MDS), Acute Myeloid Leukemia 
(AML) and Chronic Myelogenous Leukemia (BC-CML)
49.  Furthermore, the NPM 
gene  is  lost  in  ~50%  of  patients  with  de  novo MDS  (Look  T,  unpublished  data).  
Strikingly, mutated NPM (NPMc+) was found to be the hallmark in a large subgroup 
of AML.  Although these fusion proteins and mutants could have novel oncogenic  
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functions, a common feature in all these cases is that the total amount of NPM is 
decreased due to the reduction of the NPM gene dosage to heterozygosity.  NPM 
functional loss could be exacerbated by the potential dominant negative effect of the 
aberrant products on the remaining wild type NPM protein
50, resulting in centrosome 
amplification and/or degradation of Arf and p53 as aforementioned.  Therefore, the 
loss of NPM expression and function also seems to contribute to tumorigenesis. 
We propose a coherent explanation for these seemingly contradictory findings: 
NPM belongs to a class of important growth regulators whereby its overexpression or 
downregulation can both contribute to oncogenesis.  However, NPM likely functions 
as a tumor suppressor in vivo, as more cases for loss rather than gain of the locus has 
been found in human cancers (CancerChromosomes, NCBI).  This hypothesis has a 
clinically significant implication: while downregulation of NPM to its normal level in 
NPM-overexpressed tumors may inhibit cell growth, further reduction of its level to 
heterozygosity  may  exacerbate  cancer.    Therefore  if  NPM  has  to  be  used  as  a 
molecular target for cancer suppression
51, 52, its level has to be delicately controlled.    
To  test  this  hypothesis,  I  first took  part  in  studying  tumorigenesis  in  a  mouse 
hypomorphic Npm mutant series (Npm
+/-, Npm
hy/hy and Npm
-/- with decreasing levels 
of the protein) previously generated in our lab.  Subsequently I crossed Npm
+/- mice 
with NPM/RARα transgenic mice to better recapitulate human acute promyelocytic 
leukemia (5;17) where NPM is reduced to hemizygosity, and to further test the tumor 
suppressive role of NPM.   
 
Results and Discussion 
Generation of Npm hypomorphic series 
The Npm
-/- allele was generated by replacing exon 2 to 7 with an in-frame GFP 
coding sequence.  Targeting of the gene resulted in total abrogation of the Npm1 gene  
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expression and concomitant expression of the GFP protein.  The NPM
hy/hy allele was 
generated  by  targeting  a  neomycin  cassette  (NEO)  within  Npm1  intron  6.    In  the 
presence of the NEO cassette, homozygosity for the hypomorphic allele reduced Npm1 
expression levels due to transcriptional interference.  Generation of this hypomorphic 
series [Npm
+/- < Npm
hy/hy < Npm
-/-] in which Npm gene levels can be decreased to 50% 
(Npm
+/-), 10-30% (Npm
hy/hy) or 0% (Npm
-/-) compared to the wild-type gene in all 
tissues allowed us to investigate the physiological role of Npm in vivo, but for my 
thesis I focused on determining whether Npm loss can contribute to tumorigenesis. 
 
NPM
+/- MEFs are more susceptible to oncogenic transformation and NPM
+/- mice 
develop features of human MDS
∗ 
As NPM gene dosage is reduced by half in cancer cells harboring chromosomal 
rearrangements at the NPM locus, we asked whether NPM could be a haploinsufficient 
tumor suppressor. 
After  long-term  culture  of  MEFs  using  a  3T9  protocol,  we  observed  that  the 
proliferative rates of Npm
+/- MEFs were lower than wild type cells at early passage 
(P2-P6) (Figure 3A).  However, a few passage later (P5-P8), Npm
+/- cells invariably 
overcame the growth arrest and showed an immortal phenotype with noticeably higher 
proliferation rates.  In contrast, wild type MEFs grew faster at early passages but much 
slower  than  Npm
+/-  MEFs  upon  immortalization  (Figure  4A).    At  later  passages, 
Npm
+/-  MEFs  showed  a  greater  ability  to  form  transformation  foci  in  low-density 
seeding assays (Figure 4B).  In a p53 null background, not only were Npm
+/- MEFs 
fully rescued in their growth defects at early passage (P3-P5) but they grew faster than  
                                                 
∗ Portions of this section adapted from Silvia Grisendi, Rosa Bernardi, Marco Rossi, Ke Cheng, Luipa 
Khandker, Katia Manova, Pier Paolo Pandolfi, “Role of nucleophosmin in embryonic development and 
tumorigenesis”. Nature (2005) 437(7055):147-153. 
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Figure 3. A, p53 rescues Npm
+/- growth defect at early passage (P4). B, Focus-
forming  assay  on  Npm
+/+p53
-/-  and  Npm
+/-p53
-/-  MEFs.  Inset  shows  a 
representative image of the results. C, Senescence of Npm
+/+ and Npm
-/- MEFs 
at P8. D, Mandelian ratio of viable progeny born with different genotypes. 
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Figure 4. Npm
+/- cells are more susceptible to oncogenic transformation.  
A, Proliferation rates of Npm
+/+ and Npm1
+/- MEFs during serial passaging, 
shown as population doublings. Results show the average of 8 different MEF 
preparations  per  genotype,  passaged  on  a  3T9  protocol.  B,  Low-density 
seeding focus-forming assay on Npm
+/+ and Npm
+/- MEFs at different passages 
(described  in  Methods).  Inset  shows  a  representative  image  of  the  results 
obtained at P12. C, A representative image of soft agar colony-forming assay 
on P13 Npm
+/+ and Npm
+/- MEFs upon double infection with Ras+E1A. D, 
Soft agar assay on P15 Npm
+/+ and Npm
+/- MEFs upon infection with single 
oncogenes. Empty vectors were used as control. Results are presented as mean 
± s.d. 
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+/+ 
+/- 
Ras + E1A  
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MEFs from wild type littermate controls (Figure 3A), and consistently showed higher 
efficiency in forming foci in low-density seeding assays (Figure 3B).  This further 
corroborates the notion that the growth disadvantage of NPM-deficient cells is due to 
upregulation of a functional p53 protein.   
In soft agar assays, low passage Npm
+/- MEFs (P4) were not transformed to the 
same extent as wild type controls by the combination of Ras
V12 and E1A oncogenes 
when cells were assayed immediately after infection/selection.  However, if the same 
infected cells were further cultured for 5-10 passages before soft agar plating, Npm
+/- 
cells reproducibly yielded >50% more foci than control cells (Figure 4C).  A similar 
outcome was obtained upon infection of already immortalized wild type and Npm
+/- 
MEFs (P15) with single oncogenes such as E1A and Myc (Figure 4D).   
It is worth noting that another laboratory also developed a similar Npm knockout 
model and found that the growth defect of Npm
-/- MEFs is not only rescued in a p53
-/- 
background, but Npm
-/-p53
-/- MEFs are more susceptible to transformation
53, further 
corroborating our findings. 
Even though the proliferation rate at early passages directly correlated with the 
Npm  dosage  (Npm
-/-<Npm
hy/hy<Npm
+/-<Npm
+/+),  only  Npm
+/-  cells  overcame 
senescence  after  multiple  passages  and  acquired  a  proliferative  advantage.    For 
example, Npm
-/- MEFs displayed massive senescence and eventually died after several 
passages (Figure 3C).  
Since Npm knockout resulted in embryonic lethality between E11.5 and E12.5 and 
Npm
hy/hy  mutants  also  died  in  utero  at  ~E16.5,  we  could  only  assess  the  cancer 
susceptibility in Npm
+/- mice.  Heterozygous mice were viable and appeared to thrive, 
but crossing of heterozygous mice resulted in progeny born with a slightly altered 
Mendelian ratio (Figure 3D).  Interestingly, approximately 80% of the Npm
+/- mice 
analyzed at 6-18 months of age (n=22) showed one or more features of human MDS, a  
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pre-leukemic  syndrome.    Peripheral  blood  from  Npm
+/-  mice  showed  significantly 
increased mean corpuscular volume (MCV; P=0.02) and red cell distribution width 
(RDW;  P=0.0089)  values  (Figure  5a),  indicating  an  overall  increase  in  size  and 
anysocytosis of the erythrocytes.  This was not accompanied by reticulocytosis (Figure 
5a), with very low reticulocyte counts found in a few Npm
+/- mutants (Figure 5a).  The 
platelet  counts  showed  a  wider  scatter  in  the  mutants  compared  with  wild-type 
littermates (Figure 5a).  In the bone marrow of Npm
+/- mice, we detected the presence 
of dyserythropoiesis.  We found a high proportion of dysplastic erythoid precursors, 
among  which  were  binucleated  cells  and  cells  with  abnormal  mitosis  (Figure  5b).  
Megakaryocyte dyspoiesis was observed in a fraction of these mice (Figure 5c): cells 
with multiple separated nuclei with small oval nuclei in mature cytoplasm or with 
hypolobated nuclei.  Bone marrow of Npm
+/- mice showed hypercellularity of RBC 
precursors, evaluated as expression of the erythroid surface marker TER119 (Figure 
5d).  Npm
+/-  bone  marrow  also  showed  an  increased  relative  percentage  of 
TER119
hiCD71
hi-expresing  cells  (markers  that  identify  an  immature  erythroblast 
population;  Boxes  A  and  B  in  Figure  5e),  and  a  decrease  in  TER119
hiCD71
low-
expressing cells (indicating more advanced stages of erythroid differentiation; box C 
in Figure 5e).  Cell cycle analysis of TER119
hiCD71
hi precursors revealed a significant 
increase  in  the  fraction  of  tetraploid  cells  in  the  Npm
+/-  mutants  (Figure  5e,  right 
panel).  In bone marrow in vitro colony-forming assays, the Npm
+/- CFU-E/BFU-E 
colonies  often  contained  binucleated  cells  (5-10%;  Figure  5f).    Together,  these 
findings demonstrated the presence of dysplastic features in the Npm
+/- mice.  
 
 
 
  
  16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Npm
+/- mice show myelodysplastic features. A, Peripheral blood from 
Npm
+/- mice has elevated MCV and RDW values compared to Npm
+/+littermates. 
Reticulocyte and platelet counts are shown in lower panels. B, Dyserythropoiesis 
in Npm
+/- mice. Representative images of bone marrow samples from one Npm
++- 
and one Npm
+/-mouse; arrows point to binucleated erythroid cells and abnormal 
mitotic  figures.  Histograms  show  the  incidence  of  dyserythropoietic  cells  as 
percentage of the total erythroid population (mean ± s.d.). A total of 16 sex- and 
age-matched Npm
+/+ mice and Npm
+/- mice were analyzed. For each mouse, 5 
independent counts of total erythroid cells (n=100) were performed. C, Dysplastic 
megakaryocytes.  Representative  bone  marrow  samples  from  Npm
+/+  mice  and 
Npm
+/- mice show megakaryocytes with a small oval nucleus in mature cytoplasm, 
multiple  separated  nuclei  or  a  hypolobated  nucleus  in  Npm
+/-  mice.  Histogram 
shows the number of dysplastic megakaryocytes per counts of 10 cells (mean ± 
s.d.). A total of 11 Npm
+/+ mice  and 12 Npm
+/- mice were analyzed; for each 
mouse, 5 independent counts were performed. D, Bone marrow FACS analysis of 
TER119-expressing cells in Npm
+/+ and Npm
+/- mice. E, Increased percentage of 
TER119
hiCD71
hi-expressing  (box  A  and  B)  and  decreased  percentage  of 
TER119
hiCD71
low-expressing (box C) cells in Npm
+/- mouse bone marrow. Cell 
cycle analysis of cell population in box A (TER119
hiCD71
hi) is shown on the right. 
F, Representative images of cytospins from CFU-E/BFU-E colonies generated in 
in vitro colony-forming assays using Npm
+/+ and Npm
+/- bone marrow.  
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Npm
+/- mice are more susceptible to develop malignancies
*6 
Characterization of primary cells from Npm
+/- mice in vitro indicated that NPM 
could exert tumor suppressive functions.  However, whether NPM functional loss may 
lead to cancer susceptibility in vivo remained unclear.  We hypothesized that since it 
takes  multiple  passages  before Npm
+/-  MEFs  overcome  growth  arrest  and  become 
transformed in vitro, spontaneous tumor development will occur late in life in Npm
+/- 
animals with features of MDS. 
To  examine  whether  Npm
+/-  mice  are  more  prone  to  tumor  development,  we 
conducted  a  2-year  follow-up  on  a  colony  of  102  mice  (47  wild  type  and  55 
heterozygous mice), and have evaluated incidence, latency, and pathological features 
of neoplasias occurring in these mice compared with wild type littermates. 
Strikingly, Npm
+/- mice displayed higher susceptibility to tumorigenesis than wild 
type  mice.    Of  the  55  heterozygous  mice  under  investigation,  16  mice  developed 
malignancies (Table 1).  By comparison, tumors were identified in only 3 mice of wild 
type population (P<.01).  As predicted, tumors in Npm
+/- mice were observed after a 
long-latency that ranged from 10 to 24 months. 
Pathological analysis revealed that 75% of the diseased Npm
+/- mice were affected 
by hematologic malignancies (Figure 6A), while no abnormalities were detected in the 
hematopoietic organs of wild type animals analyzed.  Interestingly, three quarters of 
the hematologic neoplasms developed by Npm
+/- mice were myeloid malignancies, 
with a myeloproliferative disease-like leukemia having the highest incidence.  MPD-
like ML was characterized by leukocytosis (WBC count = 18.1 ± 0.7 ×10
9/L) and 
extreme expansion of well-differentiated myeloid cells in bone marrow (Figure 6D),  
 
                                                 
* Portions of this section adapted from Paolo Sportoletti, Silvia Grisendi, Samia Majid, Ke Cheng, John 
Clohessy, Agnes Viale, Julie Teruya-Feldstein, Pier Paolo Pandolfi, “Npm1 is a haploinsufficient 
suppressor of myeloid and lymphoid malignancies in the mouse”. Blood (2008) 111(7):3859-3862.  
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Table 1. Tumor spectra and incidences in Npm
+/- and Npm
+/+ mice.  
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Figure  6.  Features  of  Npm1
+/-  mice  hematological  malignancies.  A,  Pie  chart 
showing tumor spectrum in Npm1
+/- mice. B, Bone marrow cytospin (60X) from an 
ML  Npm1
+/-  mouse  showing  blasts  with  intracytoplasmic  vacuoles,  high 
nuclear/cytoplasmic ratio, basophilic cytoplasm and multiple nucleoli (arrow heads). 
C, Spleen section (10X) from the same mouse showing mass involving the red pulp 
composed of atypical mononuclear cells. The inset is a 40X magnification of the 
immunohistochemical staining for muramidase indicating blasts originating from the 
myeloid lineage. D, Flow cytometry analysis of bone marrow from an MPD-like ML 
Npm1
+/- mouse demonstrates an expansion of Gr-1/Mac-1 mature cells. E, Spleen 
section (10X) from the same mouse in D showing both red and white pulp replaced 
by atypical mononuclear infiltrate. F, Liver section (40X) from the same mouse in D 
showing infiltration of periportal area extended into the parenchyma as well. G, 
Npm1
+/- enlarged spleen is compared to a wild-type littermate control. 
G  
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spleen (Figure 6E), and infiltration to other nonhematopoietic tissues, such as liver 
(Figure 6F).   
The  remaining  mice  affected  by  myeloid malignancies  presented  with  myeloid 
leukemia.  ML was characterized by severe anemia (HGB level = 6.9 ± 8 g/L), mild 
leukocytosis (WBC = 17.4 ± 0.5 ×10
9/L), and thrombocytopenia (PLT count = 290 ± 
60  ×10
9/L).    Both  peripheral  blood  and  bone  marrow  contained  a  significant 
percentage  of  leukemic  blasts  (20%  ±  4%  and  36%  ±  2%,  respectively).  
Morphologically, blasts represented immature myeloid cells with increased nucleus-
cytoplasm ratio and highly vacuolated cytoplasm (Figure 6B arrowheads).   
Hepatomegaly and splenomegaly were invariably detected in these leukemic mice 
(Figure  6G).    Pathologically,  spleen  and  liver  were  filled  with  a  large  amount  of 
leukemic  blasts  that  compromised  the  architecture  of  the  tissues  (Figure  6C).  
Immunohistologic  analysis  of  spleen  and  liver  sections  identified  cells  whose 
cytoplasm was positive for muramidase (lysozyme) staining, and positivity is usually 
associated with monocytic differentiation in human and mouse leukemias (Figure 6C 
inset).  These are all features distinctive of myeloid leukemia in the mouse. 
In  addition  to  an  increased  rate  of  myeloid  malignancies,  Npm
+/-  mice  also 
developed a number of malignancies in other tissues which were not observed in wild 
type littermates, such as B- and T-cell lymphomas, lung adenocarcinomas and salivary 
adenocarcinomas (Table 1).  In addition, both the wild type and the null allele of Npm 
were retained in Npm
+/- tumors (Figure 7).  Taken together, we demonstrate that Npm 
is  a  halpoinsufficient  tumor  suppressor  in  the  mouse.    Npm
+/-  mice  are  prone  to 
spontaneous  tumor  formation  and  in  particular  to  the  development  of  myeloid 
malignancies.  
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Figure  7.  Absence  of  loss  of  heterozygosity  (LOH)  and  retained  Npm 
expression in Npm
+/- hematological malignancies. A, Southern blot on tail and 
blast  DNA  from  representative  myeloid  leukemia  affected  Npm
+/-  mice.  B, 
Hematoxylin  and  eosin  staining  (top  panels)  and  Npm  immunohistochemistry 
staining  (bottom  panels)  from  Npm
+/+  and  representative  myeloid  leukemia 
affected Npm
+/- mice.  
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Npm
+/-;NPM/RARα compound mice does not recapitulate human APL 
Having confirmed the tumor suppressive role of NPM in vitro and in vivo, we next 
asked: can NPM heterozygosity cooperate with oncogenes, especially those generated 
by NPM chromosome rearrangements, in tumorigenesis?  
In  patients  with  Acute  Promyelocytic  Leukemia  (5;17),  one  allele  of RARα  is 
translocated to a region on chromosome 5q35 containing NPM.  We hypothesize that 
NPM/RARα heterodimerizes with the endogenous NPM and inhibits its physiological 
activity.    Previously  in  our  lab  we  had  generated  NPM/RARα  transgenic  mice 
expressed  in  the  myeloid  lineage  under  the  hcG  promoter.    However,  these  mice 
developed acute monocytic leukemia instead of acute promyelogenous leukemia with 
long latency (average 16 months) and low penetrance (13%)
54.  This suggests that the 
transgene is necessary but not sufficient for leukemogenesis.  By crossing the hcG-
NPM/RARα transgenic mice with Npm
+/- mice, we expected either of the following in 
Npm
+/;NPM/RARα compound mice: 
1)  NPM/RARα monocytic leukemia will be exacerbated by Npm heterozygosity, 
resulting in a better recapitulation of the human APL condition where NPM is 
reduced to hemizigosity as a result of the translocation, or 
2)  Npm
+/- MDS-ML or ML will be exacerbated by NPM/RARα oncogene since 
the fusion protein might act as a dominant negative of NPM. 
We generated an experimental colony of 85 mice (20 wild type, 20 Npm
+/-, 20 
NPM/RARα and 25 Npm
+/-;NPM/RARα compound) and conducted a 2-year follow-up 
on  the  incidence,  latency,  and  pathological  features  of  neoplasias  occurring  in  the 
compound mice compared with wild type, Npm
+/- and NPM/RARα  single mutants 
alone.    Since  the  Npm
+/-  and  hcG-NPM/RARα  mice  are  under  different  genetic 
backgrounds, all the experimental mice used in this study were derived from the F2 
generation.  
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Surprisingly, Kaplan-Meier cumulative survival analysis (Figure 8A) showed that 
there  is  no  significant  difference  in  terms  of  lifespan  between  Npm
+/-;NPM/RARα 
mice and NPM/RARα, Npm
+/- or wild type littermates.  If anything, there seems to be 
a  slight  deceleration  in  the  compound  mice  compare  to  NPM/RARα  mice.    As 
expected, NPM/RARα transgenic mice developed monocytic leukemia starting from 
14 months (Figure 9) and died significantly faster than wild type littermates.  It is also 
worth to note that although Npm
+/- mice eventually develop a number of malignancies 
as shown in the last section, their overall survival is not significantly different from 
those of wild type littermates.  Before the known leukemia onset of either NPM/RARα 
transgenic mice or Npm
+/- mice, 2 animals from each genotype were also sacrificed at 
specific time points (8, 10 and 12 months) for morphological and flow cytometric 
analysis  to  determine  whether  the  compound  animals  show  exacerbation  of  the 
leukemia pathological features in NPM/RARα  or Npm
+/- controls.  We did not find an 
increase in the number of myeloid cells in Npm
+/-;NPM/RARα mice before one year 
(Figure 8B), again suggesting there is no acceleration in leukemogenesis. 
These negative results can be interpreted in several ways that do not contradict the 
tumor suppressive role of NPM: First, if the transgenic dose of NPM/RARα is higher 
than  Npm  (more  than  the  1:1  ratio  of  NPM/RARα:NPM  in  APL  patients)  in  the 
myeloid  lineage,  then  the  NPM/RARα  oncogene  may  already  exert  enough  of  its 
dominant  negative  effect  on  the  endogenous  Npm,  and  further  reduction  in  Npm 
dosage does not  exacerbate leukemogenesis.  Second, as the effect of a transgene 
depends largely on the choice of the promoter, it is possible that if NPM/RARα were 
expressed  under  another  myeloid-specific  promoter,  APL  would  be  better 
recapitulated in the Npm
+/- background. Third, as Npm
hy/hy MEFs
 display a dramatic 
increase in cellular senescence, it is possible that loss of NPM function below 50% in 
Npm
+/-;NPM/RARα compound mice induced senescence and counterbalanced the   
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Figure  8.  Npm  heterozygosity  does  not  cooperate  with  NPM/RARa  in 
leukemogenesis.  A, Cumulative survival of mice with indicated genotype (N=20 
for wt, NPM/RARα and Npm+/-, N=25 for Npm
+/-;NPM/RARα). P values were 
calculated by Mantel-Cox log-rank analysis as follows: P=0.234 for wt vs. Npm
+/-
;NPM/RARα,  P=0.150  for  NPM/RARα  vs.  Npm
+/-;NPM/RARα,  P=0.552  for 
Npm
+/-  vs.  Npm
+/-;NPM/RARα,  P=0.024  for  wt  vs.  NPM/RARα.  B,  Flow 
cytometric  analysis  of  %  of  mature  myeloid  cells  using  Mac1/Gr1  markers  (left 
panel) and immature cells using cKit marker (right panel) in total bone marrow.  
Results are presented as mean ± s.d. 
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Figure  9.  hcG-NPM/RARα  transgenic  mice  develop  acute  myeloid 
leukemia with monocytic features. A, Flow cytometry of total bone marrow 
from  an  AML  NPM/RARα  transgenic  mouse  show  an  expansion  of 
Mac1+Gr1+  mature  cells.  B,  Splenomegaly  and  greyish-white  leukemic 
infiltration in kidney and liver of an AML NPM/RARα mice. C, H&E staining 
of  spleen  section  showing  expanded  red  pulp.  D,  May  Grünwald-Giemsa 
staining of bone marrow cytospin  and spleen touch-prep.  Arrows indicate 
monoblasts  with  intracytoplasmic  vacuoles,  high  nuclear/cytoplasmic  ratio, 
nucleoli and open chromatin; arrowheads indicate erythroid dysplasia. 
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acceleration of leukemogenesis that would otherwise be apparent.  Fourth, as Npm
hy/hy 
MEFs
  are  deficient  in  ribosome  biogenesis
7,  loss  of  Npm  below  50%  in 
Npm
+/;NPM/RARα compound mice may also block cell proliferation due to deficient 
ribosome biogenesis.  Lastly, as NPM-RARα exert its effect by blocking the function 
of RARα as a transcription factor important for terminal cell differentiation, and the 
NPM moiety of NPM-RARα is thought to be important for binding endogenous Npm 
which together form a complex with the corepressor histone deacetylase, loss of the 
endogenous wild-type Npm could inhibit the formation of this complex, thus restoring 
the normal function of RARα as a transcription factor. 
Interestingly, at later time points (>19 months) two Npm
+/-;NPM/RARα mice died 
from megakaryocytic leukemia (Figure 10) or erythroid leukemia.  These types of 
malignancies  were  not  found  in  the  wild  type,  NPM/RARα   or  Npm
+/-  littermate 
controls of the same age.  Since Npm
+/- mice show a phenotype of megakaryocytic and 
erythoid dysplasia with expansion of red blood cell precursors and in a few instances a 
marked increase in the number of megakaryocytes (Figure 5), we investigated whether 
the  NPM/RARα  oncogene  in  Npm
+/-;NPM/RARα  compound  mice  exacerbated  the 
Npm
+/-  phenotype.    However,  preliminary  flow  cytometry  analysis  showed  no 
difference  in  the  expression  levels  of  megakaryocytic  marker  CD41  and  erythroid 
markers Ter119/CD71 in the compound mice compared to Npm
+/- mice at old age 
(Figure 11), suggesting that the megakaryocyte/erythoid lineage is not significantly 
affected.  Given the fact that NPM/RARα under the hcG promoter should be only 
expressed in the myeloid lineage
55, we believe that these cases are probably anecdotal 
and not worth pursuing. 
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Figure 10. One example of Megakaryocytic Leukemia (AML M7) found in 
NPM
+/-;  NPM/RARα  compound  mice  at  22  months.    A,  Hepato-
splenomegaly. B, Flow cytometry of bone marrow showing increased cKit+ 
immature  cells  in  Npm
+/-;  NPM/RARα  megakaryocytic  leukemia.  C,  H&E 
staining  of  spleen  showing  expansion  of  megakaryoblasts  and  dysplastic 
megakaryocytes  with  hyperlobulation.    The  same  immature  cells  infiltrated 
other non-hematopoietic organs such as liver and lung.   
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Figure 11. No significant alterations in erythoid/megakaryocytic lineage in 
Npm
+/-; NPM/RARα compound mice at old age.  Flow cytometric analysis of % of 
erythoid cells using Ter119 and CD711 markers (top) and megakaryocytes using 
CD41 and CD45 markers (bottom) in total bone marrow. Results are presented as 
mean ± s.d.  
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Conclusion           
Taken  together,  we  demonstrate  that  Npm  is  indeed  a  haploinsufficeint  tumor 
suppressor.    Npm  heterozygous  cells  show  increased  susceptibility  to  oncogenic 
transformation  in  vitro  and  Npm
+/-  mice  develop  spontaneous  tumors,  particularly 
myeloid malignancies.  This is relevant not only because of the direct involvement of 
the NPM locus in human cancer, but also because the region to which NPM maps to is 
often lost or translocated in a number of hematopoietic malignancies.  In particular, as 
the pathogenesis of human MDS is not well understood and few mouse models of 
MDS exist, our Npm
+/- mice can serve as a powerful tool to study the mechanisms and 
progression of MDS to AML and to test potential therapeutic regimens.   
At the end, we understand more clearly what the earliest data suggested all along, 
that there is a delicate balance of NPM level dictating normal growth, cancer or cell 
death—overexpression of NPM can lead to oncogenesis due to overactive ribosome 
biogenesis and reduced apoptosis; lowering the level of NPM to heterozygosity leads 
to oncogenesis due to centrosome amplification and destabilized tumor suppressors; 
and further reduction of NPM leads to cell death due to senescence and ribosome 
deficiency.    As  the  Chinese  philosopher  Laozi  says,  it’s  better  to  be  in  between 
extremes. 
 
Materials and Methods   
Mice 
The  hypomorphic  Npm  mutant  mice  (Npm
+/-,  Npm
hy/hy,
  Npm
-/-)  in  C57BL/6 
background  was  generated  by  Dr.  Silvia  Grisendi  in  the  lab
7.    The  hcG-
NPM/RARα  transgenic mice in CBA/BL6 background was generated by Dr. Eduardo 
Rego in the lab
54.  The Npm
+/-; NPM/RARα double mutant mice were generated by  
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crossing Npm
+/- mice with hcG-NPM/RARα  transgenic mice for 2 generations (F2) to 
reduce genetic background variation. 
 
Cell culture, cell-based assays and western blot analysis 
MEFs were prepared from E10.5–E13.5 embryos.  Early passage MEFs (P2–5) 
were used in all experiments except as indicated.  For proliferation analysis, growth 
curves were generated by seeding 2.5×10
4 cells per well in 12-well plates, each clone 
in triplicate.  Plates were fixed on days 0, 2, 4 and 6 except as indicated. Fixed plates 
were stained with crystal violet, extracted with 10% acetic acid, and the relative cell 
number was measured by absorbance at 595 nm.  For 3T9 analysis, 9×10
5 cells were 
passaged into 10-cm dishes every 3 days.  A culture was considered ‘senescent' when 
the number of cells decreased (that is, <9×10
5) over two consecutive passages.  Focus-
forming assays with Npm1
+/+ and Npm1
+/- MEFs were performed by plating a total of 
3×10
3cells per well in 12-well plates (in triplicate) and culturing for 2 weeks before 
staining with crystal violet.  Soft agar colony-forming assays were performed with 
Npm1
+/+  and  Npm1
+/-  MEFs  (passage  number  as  indicated)  infected  with  empty 
control,  pBabe-Puro-Ras
V12,  pBabe-Hygro-E1A  and  pBabe-Puro-Myc  retroviruses, 
separately  or  combined  as  indicated.    Transfections  of  the  packaging  cell  line 
(Phoenix) were done using Lipofectamine Plus in Optimem (Gibco) without serum or 
antibiotics.    Upon  infection,  selection  and  harvesting  of  the  MEFs,  transformation 
assays  were  performed  by  resuspending  5×10
4  cells  in  complete  DMEM  (2×) 
containing 0.3% agarose and seeding (in triplicate) into 35-mm plates containing a 3-
ml layer of solidified 0.6% agar in complete medium.  Foci were scored 15–20 days 
later.  For the analysis of senescent cells, staining for the senescence marker β-Gal 
activity (X-Gal) was performed according to the manufacturer's protocol (Senescence 
Detection Kit, Oncogene Research Products).   
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Histology and immunohistochemistry 
Mouse  tissues  sections  were  stained  with  hematoxylin  and  eosin
  (H&E)  for 
histopathological  examination.  Antibodies  for
  immunohistochemical  staining  were 
CD45R/B220 for B-cell lineage,
 CD3 for T-cell lineage, polyclonal prediluted anti-
lysozyme
  muramidase  (Ventana,  Tucson,  AZ)  for  myeloid  cells,  and  mouse
 
antinucleophosmin/B23  (Zymed,  South  San  Francisco,  CA),  used
  according  to  the 
manufacturer's instructions. Pictures of the
 stained tissue sections were obtained using 
an Olympus BX41
 microscope and a DP20 camera (Olympus, Center Valley, PA). All
 
image acquisition and processing was carried out with Adobe
 Photoshop 7.0 (Adobe 
Systems, Mountain View, CA). 
 
Flow cytometry 
Bone marrow cells were stained with phycoerythrin (PE)-conjugated
 anti-Mac1, 
anti-cKit,  anti-CD71,  anti-CD41  and  allophycocyanin  (APC)-conjugated  anti-Gr1, 
anti-Ter119,  anti-CD45  (BD
  Pharmingen,  San  Diego,  CA)  and  analyzed  using 
FACSCalibur (BD
 Biosciences).  
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CHAPTER 2 
 
THE LEUKEMIA-ASSOCIATED CYTOPLASMIC NPM MUTANT IS 
AN ONCOGENE WITH PARADOXICAL FUNCTIONS: ARF 
INACTIVATION AND INDUCTION OF CELLULAR SENESCENCE
*  
 
Double, double toil and trouble. 
William Shakespeare 
 
Abstract 
Mutations leading to aberrant cytoplasmic localization of Nucleophosmin 1 (NPM1) 
have  been  recently  identified  as  the  most  frequent  genetic  alteration  in  acute 
myelogenous  leukemia.  However,  the  oncogenic  potential  of  this  nucleophosmin 
mutant  (NPMc+)  has  never  been  established,  which  casts  doubt  on  its  role  in 
leukemogenesis.  By performing classical transformation assays, we find that NPMc+, 
but not wild type NPM, cooperates specifically with adenovirus E1A to transform 
primary MEFs in soft agar.  We demonstrate that NPMc+ blocks the p19
Arf (Arf) 
induction  elicited  by  E1A.    Surprisingly,  however,  we  find  that  NPMc+  induces 
cellular senescence and that E1A is able to overcome this response.   We propose a 
model whereby the NPMc+ pro-senescence activity needs to be evaded for oncogenic 
transformation, even though NPMc+ can concomitantly blunt the Arf/p53 pathway.  
These  findings  identify  for  the  first  time  NPMc+  as  an  oncogene  and  shed  new 
unexpected light on its mechanism of action. 
53 
                                                 
* Portions of this chapter adapted from Ke Cheng, Silvia Grisendi, John Clohessy, Samia Majid, Rosa 
Bernardi, Paolo Sportoletti, Pier Paolo Pandolfi, “The leukemia-associated cytoplasmic nucleophosmin 
mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular 
senescence”. Oncogene (2007) 26(53):7391-7400. 
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Introduction 
As aforementioned, NPM1 is one of the most frequent targets of genetic alterations 
in hematopoietic tumors.  Strikingly, somatic mutations of NPM1 has been found in 
about 60% of primary
 adult AML with a normal karyotype
56.  These NPM mutants are 
aberrantly localized to the cytoplasm of leukemic blasts (Figure 12A), and are hence 
termed NPM cytoplasmic positive (NPMc+).  The cytoplasmic localization is caused 
by  frameshift  mutations  in  one  allele  of  the  NPM1  gene  (with  the  most  frequent 
mutation  being  a  TCTG  tandem  duplication),  encoding  novel  proteins  with  an 
additional nuclear export signal motif but without the normal nucleolar localization 
motif
57. Since NPMc+ retains the oligomerization domain of NPM, it can behave as a 
dominant  negative  mutant  sequestering  the  endogenous  NPM  to  the  cytosplasm
57 
(Figure 12B).  At the same time, this genetic event reduces the endogenous level of 
NPM  to  hemizygosity.  It  remains  to  be  addressed  whether  any  tumor-suppressive 
function of NPM are compromised and which novel oncogenic functions are gained 
by  NPMc+.  Two  recent  reports  show  that  exogenous  overexpression  of  NPMc+ 
delocalizes and destabilizes p19
Arf, thus reducing the ability of Arf to initiate a p53 
response and to induce cell cycle arrest in an Arf-inducible cell line
58, 59. 
However,  to  date  there  is  no  published  evidence  that  NPMc+  can  act  as  an 
oncogene and transform primary cells.  On the contrary, it seems to exhibit an anti-
proliferative activity when overexpressed in NIH3T3 cells that do not express p19
Arf 
59.  Here we show that NPMc+ can indeed act as an oncogene when its pro-senescence 
activity is evaded.        
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Figure  12.  NPMc+  is  the  most  frequent  mutation  in  AML.  A,  Aberrant 
cytoplasmic expression of the mutant NPM in leukemic blasts. B, Mutant NPM 
delocalizes  the  endogenous  wild-type  NPM  from  the  nucleolus/nucleus  to  the 
cytoplasm  through  dimerization.    C,  NES  motif  of  the  most  common  NPM 
mutation. Modified from Falini, B. et al., N Engl J Med 2005;352:254-266 and 
Grisendi, S. et al., N Engl J Med 2005; 352: 291-292. 
LWQWRKS 
LCLAVEEVSLRK 
NPM           - 
Mutation A -  
C  
  35 
Results 
Testing the oncogenic potential of NPMc+ in primary mouse embryonic fibroblasts  
To  determine  the  oncogenic  potential  of  NPMc+  in  vitro,  we  first  generated 
retroviral constructs containing Flag-tagged NPMc+, as well as the wild type NPM as 
a control.  We used these constructs to transduce early-passage primary MEFs and 
found,  as  expected,  NPMc+  aberrantly  localized  to  the  cytoplasm  (Figure  13A) 
whereas exogenous NPM mainly localized to the nucleolus (Figure 13B).  In addition, 
endogenous Npm was partially delocalized to the cytoplasm in the NPMc+ expressing 
MEFs (Figure 13A).  This is consistent with previous findings that NPMc+ binds to 
and sequesters endogenous NPM to the cytoplasm
56, 58.   
We next examined the ability of NPMc+ to promote oncogenic transformation by 
performing  transformation  assays  in  soft  agar  with  NPMc+  transformed  primary 
MEFs. This assay is a measure of anchorage-independent growth, characteristic of 
tumor  cells.    It  is  known  that  primary  MEFs  require  at  least  two  cooperating 
oncogenes to become transformed
60.  We thus tested whether co-expression of NPMc+ 
and another oncogenic event could promote the growth of primary MEFs in soft agar.  
We performed these experiments expressing wild type NPM in parallel as a control 
since it has been shown that overexpression of NPM can transform NIH3T3 cells
38. 
As expected, NPMc+ alone did not transform primary wild type MEFs (Figure 
14A).  Unlike the positive control H-Ras
V12, NPMc+ also failed to transform early-
passage Arf
-/- and p53
-/- MEFs (Figure 14B). This is consistent with previous findings 
that NPMc+ failed to transform NIH3T3 cells that are Arf null
59.  In addition, NPMc+ 
did not cooperate with oncogenic H-Ras
V12 to transform primary MEFs, unlike the 
dominant negative p53 positive control (Figure 14C).   
Since in leukemic blasts NPMc+ is frequently associated with Internal Tandem 
Duplication (ITD) of the Fms-like tyrosine
 kinase (FLT3) gene, we tested the   
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A  B 
Figure 13. Expression and localization of NPMc+ vs. NPM in transduced 
primary MEFs.  Cells were fixed, permeabilized and co-stained with an α-NPM 
antibody (green) that does not recognize NPMc+ to visualize endogenous Npm, 
as well as with α-Flag antibody (red) to visualize exogenous Npm and NPMc+.  
DNA is visualized by DAPI staining. A, Endogenous Npm (green) is partially 
delocalized to the cytoplasm by exogenous FLAG-NPMc+ (red) expression. B, 
Endogenous Npm (green) colocalizes with exogenous FLAG-NPM (red) in the 
nucleolus. 
MEFs expressing exogenous NPMc+  MEFs expressing exogenous NPM  
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Figure  14.  NPMc+  does  not  transform  primary  MEFs  alone  or  in 
combination with a variety of oncogenic events. A, Soft agar colony-forming 
assay  of  early  passage  primary  wt  MEFs  expressing  NPMc+.  The  protein 
expression of NPM and NPMc+ were shown in the Western Blots compared to 
Hsp90 as a loading control.  B, Soft agar assay of early passage Arf
-/- MEFs (red) 
and p53
-/- MEFs (blue) expressing NPMc+.  Arf
-/- and p53
-/- MEFs expressing H-
Ras
V12  were  used  as  a  positive  control.    C,  Soft  agar  assay  of  early  passage 
primary wt MEFs expressing NPMc+ in combination with oncogenic H-Ras
V12.  
Dominant negative p53 mutant (p53DD) in  combination with H-Ras
  V12 were 
used as a postive control.  D, Soft-agar assay of early passage primary wt MEFs 
expressing NPMc+ in combination with internal tandem duplication of the FLT3 
gene (FLT3-ITD). 
A 
B 
C 
D  
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oncogenic  cooperation  between  NPMc+  and  FLT3-ITD  in  MEFs.    We  found  that 
together they did not transform primary MEFs in soft agar either (Figure 14D).   
We also noticed that the level of expression of NPMc+ was consistently less than 
NPM in all primary cells transduced with Flag-tagged retroviruses (see Figure 14 and 
Figure 16A).  We found that the lower level of NPMc+ protein expression is not due 
to decreased transcription (Figure 15). This could suggest that NPMc+ has a shorter 
half-life,  that  the  cells  cannot  tolerate  high  levels  of  NPMc+  expression,  or  that 
NPMc+ mRNA is not translated as efficiently. 
 
NPMc
+ transforms primary MEF in cooperation with oncogenic E1A 
Interestingly however, we found that NPMc+ cooperated with the E1A oncogene 
to  transform  primary  MEFs  (Figure  16A  and  Figure  17A).    E1A  alone  or  in 
combination with wild type NPM did not transform primary MEFs in soft agar, thus 
highlighting the novel oncogenic effect of the C-terminal mutant motif in NPMc+. 
The  transformed  colonies  coexpressing  NPMc+/E1A  were  slightly  smaller  than 
Ras
v12/E1A colonies, but were clearly visible by eye after 3 weeks of culture in soft 
agar.    Unlike  E1A  expressing  cells,  NPMc+/E1A  transformed  cells  consistently 
showed high efficiency at forming foci in low-density seeding assays  (Figure 16B) 
and  high  growth  rate  (Figure  16C)  comparable  to  Ras
V12/E1A.    By  contrast, 
NPM/E1A transduced and selected cells started to display a slightly higher rate of 
apoptosis compared to vector/E1A and NPMc+/E1A cells immediately after selection 
(Figure 17B) and became non-adherent upon passaging, therefore we never obtained a 
sufficient number of cells to perform focus-forming assays and growth curve.  We did 
not observe a major difference between vector/E1A, NPM/E1A and NPMc+/E1A cells 
in terms of cell cycling ability after selection (Figure 17C). 
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Figure 15. Differences in exogenous Npm and NPMc+ protein levels are not 
due  to  differences  in  mRNA  levels.  A,  Western  blot  analysis  of  MEF  cells 
infected with PIG empty vector, PIG-FLAG-NPM (NPM) or PIG-FLAG-NPMc+ 
(NPMc+). FLAG-NPMc+ levels appear to be significantly less than the levels of 
FLAG-NPM. B, Real-time quantitative PCR analysis on RNA prepared from the 
same cells showing similar levels of exogenous mRNA encoding for the FLAG-
NPM (NPM) and FLAG-NPMc+ (NPMc+) overexpressed proteins.  
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C 
Figure 16. Oncogenic cooperation between NPMc+ and E1A oncogene. A, 
Early  passage  primary  wt  MEFs  were  transduced  with  empty  vector/E1A, 
NPM/E1A, NPMc
+/E1A and Ras
V12/E1A retroviruses and selected (P3).  Visible 
colonies by eye were counted.  A representative colony from NPMc+/E1A (left) 
and one from Ras
V12/E1A (right) were shown above the diagram.  The expression 
of NPM, NPMc+, E1A, Ras and control Hsp90 were shown by western blots. B, 
Focus-forming assay.  Empty vector/E1A, NPMc+/E1A and Ras
V12/E1A cells 
were seeded at low density and foci were photographed.  The number of colonies 
per well were counted and quantified in the graph. C, Growth curve of empty 
vector/E1A, NPMc+/E1A and Ras
V12/E1A cells.   
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Figure 17. A, An example of much higher number of soft agar colonies generated 
by NPMc+/E1A MEFs at a later passage (P7). Western blot shows the expression of 
NPMc+  in  the  transformed  cells  together  with  an  NPMc+  immunoprecipitation 
positive control. B, Apoptosis analysis of vector/E1A, NPM/E1A, NPMc+/E1A and 
Ras/E1A MEFs immediately after selection (P2). NPM/E1A cells already start to 
show a slight increase in apoptosis seen in percentage of Annexin V pos 7-AAD neg 
cells. We believe that the high number of cells stained positive for 7-AAD in the 
upper quadrants is due to cells still undergoing drug selection unrelated to apoptosis. 
C, Cell cycle analysis of vector/E1A, NPM/E1A, NPMc+/E1A and Ras/E1A MEFs 
immediately after selection (P2). Cell cycle profile shows that there is no significant 
difference in percentage of cells in G1, S and G2/M phases between vector/E1A 
cells and NPM/E1A or NPMc+/E1A cells.  
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NPMc+ rescues E1A-induced Arf/p53 activation 
E1A is an extensively studied adenoviral oncogene
61, 62, and it has been used as a 
tool to dissect molecular pathways of cooperative oncogenic transformation.  E1A 
contains four conserved regions, named CR1-4.  E1A CR2 binds RB family members, 
de-repressing E2F transcription factors and inducing cell cycle progression.  However, 
E1A expressing cells eventually degenerate in soft agar and do not form colonies
63.  
This is largely due to E1A’s ability to induce p53 stabilization through upregulation of 
Arf
64,  CBP/p300  binding
65  and  proteosome  modification  by  E1A  CR1
66.    The 
stabilization  of  p53  leads  to  programmed-cell  death  unless  blocked  by  another 
oncogene.  Indeed, inhibition of apoptosis by E1B
67 or Ras
68 is required for E1A-
induced  cell  transformation.    It  was  shown  that  inactivation  of  Arf  is  a  central 
mechanism for the attenuation of apoptosis in E1A expressing cells
64.  To explain why 
NPMc+ is required for E1A driven transformation, we hypothesize that, since NPMc+ 
blocks Arf
58,  59, it may allow E1A to evade the p53-dependent cell cycle arrest and 
apoptosis.   
Indeed, we found that there was a significant decrease in p19
Arf response in the 
NPMc+/E1A transformed cells, unlike in the NPM/E1A cells (Figure 18A).  The p53 
transcriptional activity was also reduced as seen by the lower levels of the p53 target 
gene p21
CIP (Figure 18A).  This is consistent with recent findings that overexpression 
of NPMc+ in an Arf-inducible cell line causes delocalization of Arf to the cytoplasm, 
destabilization of Arf, and a blunted Arf-induced activation of the p53 transcriptional 
program
58, 59.  This suggests that NPMc+ rescues E1A-induced Arf and p53 activation.  
We also looked at the p19
Arf level and localization in primary cells from our Npm 
hypomorphic series
7.  Interestingly, we found that Arf level was also dramatically 
reduced in Npm
hy/hy MEFs expressing very little endogenous Npm (Figure 18B).  In 
addition, Arf was delocalized to the nucleus and the cytoplasm and no longer co-  
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Figure 18. NPMc
+ blocks Arf, allowing E1A to evade the p53 response. A, 
p19
Arf and p21 levels were reduced in NPMc
+/E1A transformed MEFs, unlike in 
E1A alone or NPM/E1A expressing MEFs. B, Similar reduction in Arf level in 
Npm  hypomorphic  cells.  C,  Arf  was  delocalized  from  the  nucleolus  by  the 
reduction in endogenous Npm dose.  
A 
B 
C  
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localized with the endogenous Npm (Figure 18C).  Since NPM is important for Arf 
stability,  this  result  indicates  that  NPMc+  might  regulate  Arf  either  directly  or 
indirectly through NPM inhibition.  
 
E1A rescues NPMc+-induced senescence 
To understand why E1A is required for NPMc+ driven transformation, we looked 
at  the  possible  effects  of  NPMc+  expression  that  E1A  could  cooperate  with. It  is 
known  that  the  “immortalization”  function  of  E1A  counters  the  senescence  that 
otherwise happens in primary MEFs after multiple cell cycles
69.  Interestingly, we 
found that both NPM and NPMc+ induced growth arrest in early-passage primary 
MEFs (Figure 19A).  This growth arrest is accompanied by a two-fold increase in 
cellular  senescence  as  assayed  by  Senescence  Associated-β-galactosidase  activity 
(Figure 19B).  Interestingly, we found that the addition of E1A completely rescued 
NPMc+  induced  senescence,  as  with  Ras  induced  senescence  (Figure  19B).  
Surprisingly,  we  found  that  NPMc+,  but  not  wild  type  NPM,  triggered  a  3-fold 
induction in cellular senescence, as well as growth arrest, also in early passage Arf
-/- 
MEFs (Figure 19C).  These data suggest that the senescence induced by NPMc+ is 
indeed  Arf-independent,  as  NPMc+  was  shown  to  block  Arf  response  and  p53 
transcriptional activity.  
It has been recently shown that oncogene-induced senescence is associated with 
signs of DNA replication stress
70.  Considering that wild type NPM has a function in 
modulating  chromosome  condensation/decondenstion  and  is  recruited  to  sites  of 
dsDNA breaks
12, we hypothesized that NPMc+ may lead to senescence by blocking 
the  Npm  function  in  DNA  damage  response.    However,  at  the  passage  where 
senescence and growth curve was analyzed, overexpression of NPMc+ in wild type 
MEFs was not accompanied by positivity for markers characteristically induced in   
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Figure 19. E1A rescues NPMc+ induced senescence, which is Arf-independent. 
A, Expression of NPMc+, like NPM, causes growth arrest in primary MEFs. B, 
NPMc+, like NPM, induces cellular senescence in primary MEFs as assayed by 
SA-β-gal activity quantified in the graph. Puromycin empty vector (vector) and 
hygromycin empty vector (Hygro) are indicated. X-gal stainings in the lower panels 
show how E1A completely rescues this senescence induced by NPM and NPMc+, 
as it did with H-Ras
V12. C, NPMc+, unlike NPM, induces cellular senescence (left) 
as well as growth arrest (right) in early passage Arf
-/- MEFs (P4).  
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cells suffering DNA damage as shown by the  scarce nuclear staining of phospho-
histone  H2A.X  (Ser139),  unlike  those  of  the  UV  irradiated  MEFs  (Figure  20A).  
Additionally, Ser15 phosphorylation of p53, another DNA damage marker, was not 
induced  in  NPMc+  expressing  MEFs  (Figure  20B).    We  also  found  that  NPMc+ 
overexpression is not associated with significant alterations in genomic instability and 
in  centrosome  numbers  (Figure  20C).    This  is  perhaps  expected  because  the 
cytoplasmic localization of NPMc+ does not presumably interfere with its ability to 
associate with the centrosome and hence control proper centrosome duplication. 
 
The pRb pathway is inactivated in NPMc+ expressing MEFs 
Finally, we investigated the possibility that NPMc+ induces senescence through 
pRb,  which  is  known  to  be  sequestered  and  inactivated  by  E1A
69.  However, 
overexpression of NPMc+ in Hela and HEK293T cell lines does not seem to cause an 
increase in total pRb level (Figure 21A).  Similarly, in wtMEFs, there is no increase 
but rather a slight decrease in the active (hypo-phosphorylated) form of pRB, together 
with an increase in the inactive (hyper-phosphorylated) form of ppRb
807/811 (Figure 
21B).  This goes along with the observation that p16, a positive-regulator of pRb, is 
found decreased in MEFs expressing NPMc+ but not wild-type NPM, suggesting that 
NPMc+ does not induce senescence through pRb but instead blocks pRb function.  We 
also checked the levels of several other senescence markers such as p27, p15, p21, 
ARF,  S6  and  phospho-4EBP1,  and  none  of  them  are  significantly  upregulated  in 
NPMc+ expressing MEFs (Figure 21B).  In fact, p27, another positive-regulator of 
pRb, is also decreased.  Interestingly, there is also a dramatic decrease in p16 and p27 
in NPMc
++E1A cells, in addition to the decreased ARF levels  seen in these cells 
(Figure 21B).  Together these data suggest that there is alteration and inactivation of 
the pRb pathway in NPMc+ expressing cells.   
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Figure  20.  NPMc+  expressing  MEFs  (P4)  does  not  have  DNA  damage  and 
genomic instability. A, Wild type MEFs grown on coverslips were irradiated with 
60J UV and cultured for an additional 24 hours to be used as a positive control of 
DNA  damage.  Nonirradiated,  UV-irradiated,  empty  vector,  NPM  and  NPMc+ 
infected and selected cells were analyzed for DNA damage by counting the number 
of  cells  stained  positive  for  nuclear  phospho-Histone  H2A.X  (S139)  under  a 
microscope.    Three  independent  counts  were  taken  and  at  least  200  cells  were 
counted/sample.  Immunofluoresence images on the right show the co-localization 
of  phospho-Histone  H2A.X  (S139)  and  DAPI.  B,  Levels  of  total  p53  and 
phosphorylation  of  p53  at  Ser15  in  MEFs  expressing  empty  vector,  NPM  and 
NPMc+ MEFs (P3) was determined by Western blot. UV irradiated and Doxirubicin 
treated  MEF  lysates  were  used  as  positive  controls.  C,  MEFs  expressing  empty 
vector,  NPM,  and  NPMc+  (P4)  were  analyzed  for  centrosome  abnormalities  by 
centrosome  staining  and  counting.  Significant  centrosomes  amplification  (>2 
centrosomes) was not detected in vector, NPM or NPMc+ expressing cells.  
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A 
B 
Figure 21. The Rb pathway is inactivated in NPMc+ expressing MEFs. A, 
Inactive Rb (ppRb) and active Rb (pRb) levels in cell lines transfected with empty 
vector  (pCMV),  NPM  or  NPMc+.  B,  Levels  of  Rb  and  different  senescence 
markers  in  primary  wt  MEFs  transduced  with  empty  vector  (PIG),  NPM,  or 
NPMc+  (left  panels).  Levels  of  senecence  markers  in  primary  wt  MEFs  co-
transduced with PIG+E1A, NPM+E1A or NPMc
++E1A (right panels).  
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Expression of NPMc+ reduces 80S ribosome production 
Since NPM regulates ribosome biogenesis at several levels
12, we looked at the 
effect  of  NPMc+  expression  on  the  biogenesis  of  ribosome  subunits  and  mature 
ribosomes in MEFs.  We find that unlike overexpression of NPM, which increases 
40S  and  60S  ribosome  subunits  but  does  not  affect  80S  ribosome  production, 
overexpression of NPMc+ does not have a dramatic effect on the amount of ribosome 
subunits produced but does reduce 80S ribosomes (Figure 22).  This suggests that 
ribosome  assembly  is  less  efficient  in  NPMc+  expressing  MEFs.    The  reduced 
ribosome production and ribosome stress may be the cause or the consequence of 
NPMc+ induced growth arrest/senescence. 
 
Discussion 
Our data lead us to propose a model of cooperative oncogenic transformation by 
NPMc+ and E1A (Figure 23).  Upon oncogenic stress by E1A, Arf accumulates in the 
nucleolus where Npm normally stabilizes it.  However in combination with NPMc+, 
Arf is destabilized and p53 activation is blocked.  At the same time, E1A rescues 
NPMc+  induced  senescence.    These  reciprocal  antagonistic  signals  eliminate  the 
cellular failsafe mechanisms induced by oncogenes, namely Arf/p53 activation and 
senescence, unleashing the oncogenic potential of E1A and NPMc+.   
Since Npm is required for Arf stability
53, our data suggest two possibilities for the 
dominant  negative  action  of  NPMc+  on  Arf:  NPMc+  delocalizes  Npm  to  the 
cytoplasm  thus  attenuating  Npm’s  protective  role  on  Arf
59,  or  NPMc+  directly 
delocalizes  Arf  to  the  cytoplasm  and  destabilizes  it
58.    Our  data  showed  that  the 
endogenous Npm was only partially delocalized by NPMc+ (Figure 13A), therefore 
supporting the second hypothesis. 
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Figure  22.  Expression  of  NPMc+  reduces  ribosome  biogenesis.  Ribosome 
Profile  of  HEK293  cells  transiently  transfected  with  pCMV  (vector),  pCMV-
Tag2B-NPM  and  pCMV-Tag2B-NPMc+.    Quantification  of  individual  peaks 
suggest that while NPM overexpression increases 40S and 60S ribosome subunit 
production, NPMc+ overexpression decreases 80S mature ribosomes and does 
not significantly affect ribosome subunit production.  
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Figure 23. Proposed model for oncogenic cooperation between NPMc+ and 
E1A. 
Upon oncogenic stress by E1A, Arf accumulates in the nucleolus where it is 
normally  stabilized  by  NPM.  However  in  combination  with  NPMc+,  Arf  is 
destabilized and p53 transcriptional activation is blocked. At the same time E1A 
rescues NPMc+ induced senescence, together leading to transformation.   
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It  is  now  widely  acknowledged  that  ARF  protects  cells  from  oncogenic 
transformation.  Sustained  hyperproliferative  signals  conveyed  by  somatically 
activated oncogenes can induce ARF gene expression and trigger a p53 response that 
eliminates  incipient  cancer  cells
71.    Disruption  of  this  tumor  surveillance  pathway 
predisposes cells to cancer.  Inactivation of ARF and p53 by deletion, silencing, or 
mutation has been frequently observed in many forms of human cancer.  A notable 
exception is represented by the hematopoietic tumors, where genetic alterations of 
members of the ARF/p53 pathway are relatively rare 
72.  In these tumors, functional 
inactivation of ARF might be selected.  Although NPMc+ may very well possess 
novel oncogenic functions by itself, our study confirms that one oncogenic role of 
NPMc+ is to antagonize the tumor suppressor function of ARF.  Furthermore, we 
propose that reactivation of the downstream targets of NPMc+, such as ARF/p53 (e.g. 
through the utilization of HDM2 inhibitors such as nutlins
73), and/or the potentiation 
of  cellular  senescence  may  represent  an  attractive  therapeutic  approach  for  the 
treatment of AMLs harboring NPMc+. 
The induction of premature senescence is typical of a number of oncogenes
74, 75.  
Wild type NPM was previously shown to induce senescence by stabilization of p53
76. 
However, it is surprising that NPMc+ also induced senescence, as it was shown to 
block Arf and the p53 activity. In fact, we found that in primary MEFs expressing 
NPMc+, Arf and p53 levels were not upregulated.  Indeed, senescence-associated β-
gal  activity  and  growth  arrest  were  detected  even  in  early  passage  Arf
-/-  MEFs 
expressing NPMc+ (Figure 19C), suggesting that NPMc+ elicits an Arf-independent 
senescence response.   
Thus, we speculate that NPMc+ doesn’t cooperate with Ras is because Ras may 
not be able to rescue NPMc+ induced senescence, even though in principle NPMc+ 
could block Ras-induced senescence accompanied by ARF induction
77.  Interestingly,  
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NPMc+  inversely  correlates  with  NRAS  mutations  in  AML  patients
78.    The 
observation that NPMc+ does not transform Arf
-/- or p53
-/- MEFs is also in agreement 
with  the  notion  that  NPMc+  induces  senescence  through  an  Arf-independent 
mechanism. 
Analysis in large AML clinical trials demonstrates that 40-45% of NPMc+ AML 
patients  carry  FLT3-ITD
79.      Hence,  our  results  showing  the  lack  of  cooperation 
between  FLT3-ITD  and  NPMc+  in  transforming  MEFs  should  be  cautioned,  first 
because there are no known oncogenes that can cooperate with FLT3-ITD in soft agar 
transformation assay, and second because the cooperation might be tissue specific and 
occurs only in the hematopoietic compartment.  Our experiments performed in MEFs 
may therefore not fully recapitulate the pathological condition in leukemic cells.  In 
addition, the level of NPMc+ expression achieved in MEFs could not reflect those 
observed in the AML blasts.  Therefore additional approaches are required to fully 
examine the role of NPMc+, such as knock-in strategy in vivo. However, it should be 
noticed  that  the  levels  of  NPMc+  in  our  assays  are  lower  than  those  of  Npm 
suggesting that we may be underestimating the biological effects of NPMc+. 
It  is  surprising  that  while  wild  type  NPM  is  thought  to  be  oncogenic  (as  it 
transforms NIH3T3 cells when overexpressed and is upregulated in proliferating and 
cancer cells
11), we did not find that overexpression of NPM cooperated with any of the 
oncogenic events tested here to transform primary MEFs (Figure 14 and Figure 16A). 
Primary cultured MEFs contain fewer mutations than immortalized cell lines such as 
NIH3T3. Hence our NPM overexpression setting in stably infected primary cells is 
probably  much  more  stringent  in  analyzing  cellular  transformation  than  transient 
overexpression experiments done in cell lines. This therefore suggests that wild type 
NPM may not be a very potent oncogene in primary cells.   
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We find that there is a downregulation of pRb and upregulation of ppRb
807/811 in 
NPMc+ expressing MEFs.  Ser807/811 at the COOH terminus of pRb is known to be 
specifically phosphorylated by cyclin D-cdk4 at the late G1 phase.  Interestingly, the 
cdk-inhibitor p16
Ink4a, which blocks cyclinD-cdk4, is also found decreased in NPMc+ 
expressing MEFs.  In addition, another cdk-inhibitor p27
Kip1, which blocks cyclinE-
cdk2 and pRb phosphorylation, is found decreased. Therefore it is likely that pRb is 
inactive  in  NPMc+  expressing  MEFs.    NPM  was  proposed  to  bring 
hyperphosphorylated  Rb  into  the  nucleolus  and  facilitate  cell  cycle  progression 
because it binds specifically to the hyper- and not the hypo-phosphorylated Rb in the 
nucleolus
80.  The accumulation of hyperphosphorylated Rb could be due to the loss of 
nucleolar localization in NPMc+ and subsequent alteration in Rb dephosphorylation or 
other unknown mechanisms of NPMc+ directly on pRb.  Thus, even though we could 
not  find  any  canonical  senescence  markers  as  the  target  of  NPMc+,  the 
downregulation of tumor suppressors p16, p27 and pRb in NPMc+ expressing MEFs 
further lends credence to the oncogenic role of NPMc+.   
In conclusion, we demonstrate for the first time that NPMc+ acts as an oncogene.  
We  also  show  that  it  elicits  an  Arf-independent  cellular  senescence  response  that 
needs to be evaded for NPMc+ to exert its transforming potential.  Collectively, our 
findings suggest that NPMc+ may be a causative event instead of consequence of 
leukemia in the appropriate genetic milieu. 
 
Materials and methods 
Cell culture, transfections, and viral transduction procedure 
Primary  wild  type,  p53
-/-  and Arf
-/-  MEFs  were prepared  from  E13.5  embryos. 
Transfections of the packaging cell line (Phoenix) were done using Lipofectamine 
Plus in Optimem (Gibco) without serum or antibiotics.  Early passage wild type and  
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Arf
-/- MEFs (P1-2) and p53
-/- MEFs (P5) were infected with empty vector PIG, PIG-
NPM, PIG-NPMc+, pBabe-hygro-Ras
V12, pBabe-hygro-E1A, MSCV-hygro-Flt3ITD, 
pBabe-puro-Ras
V12 and pBabe-puro-p53DD retroviruses, separately or combined as 
indicated.  Antibiotic selection was done for 2 days in 2µg/ml puromycin or 4 days in 
75µg/ml hygromycin and in combination of the two.  Cells were then harvested and 
passaged for 1-2 times in selection medium before seeding for transformation assay, 
focus-forming  assay,  growth  curve,  senescence  assay  and  immunofluoresence.  
Lysates for western blots were also prepared at the same time.  
 
Plasmids and constructs 
Human  NPM  (ATCC,  IMAGE  clone  4106023)  was  PCR  amplified  using  the 
following primers: BamHI-F (5′-CGGGATCCATGGAAGATTCGATGGACATG-3′) 
and  EcoRI-R  (5′-GCGAATTCCTATTTTCTTAAAGAGACTTCC-3′).    It  was  then 
cloned  in-frame  into  the  BamHI/EcoRI  restriction  sites  of  pCMV-Tag2B  vector 
containing  a  Flag  sequence  (Stratagene).  The  flag-NPM  were  excised  with 
NotI/EcoRV and cloned into the HpaI site of pMSCV-IRES-GFP puro (PIG) retroviral 
vector.  Site-directed mutagenesis was performed to obtain the most frequent mutation 
of NPMc+ (mutation A) from pCMV-Tag2B NPM.  NPMc+ was amplified with BclI 
ends using the following primers: BclIF-NPMflag (5’-GCTGATCAGCCACCATGG 
ATTAC-3’) and BclIR-stop (5’-GCTGATCACTATTTTCTTAAAGAGACTTCC-3’).  
It was then cloned into the BglII site of PIG retroviral vector.  All plasmids generated 
were sequenced.  Retroviral vectors pBabe-hygro-Ras
V12, pBabe-hygro-E1A, pBabe-
puro-Ras
V12 were obtained from S. Lowe and pBabe-puro-p53DD (dominant negative) 
was obtained from O. Moshe.  Flt3-ITD (provided by G. Gilliland) was cloned into the 
HapI site of pMSCVhygro retroviral vector (Clonetech).   
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Soft agar transformation assay and focus-forming assay  
Transformation assays were performed by re-suspending 5×10
4 cells in complete 
DMEM (2X) containing 0.3% agarose and seeding (in triplicate) into 35-mm plates 
containing a 3-ml layer of solidified 0.6% agar in complete medium. Foci were scored 
3 weeks later from duplicate wells. Focus-forming assays were performed in triplicate 
by plating a total of 2000 cells per well in 12-well plates (in triplicate) and culturing 
for 10-12 days before staining with crystal violet.  Each transformation assay or focus-
forming assay was repeated at least twice, and representative experiments were shown 
in figures.   
 
Proliferation assays 
Growth curves were generated by seeding 2.5×10
4 cells per well in 12-well plates, 
each clone in triplicate. Plates were fixed on days 0, 2, 4 and 6. Fixed plates were 
stained with crystal violet, extracted with 10% acetic acid, and the relative cell number 
was measured by absorbance at 595 nm. 
 
Western blot and immunofluoresence 
For western blot analysis, the following antibodies were used: Flag (2368, Cell 
Signaling),  E1A  (Ab-1,  Neomarkers),  Pan  Ras  (Ab-3,  Oncogene),  p19
Arf  (Ab-1, 
Neomarkers), p53 (CM5, Novocastra), Phospho-p53 (Ser15) (9284, Cell Signaling), 
p21 (F5, Santa Cruz Biotechnology), p27 (554069, BD Pharmingen), p15 (sc-613, 
Santa Cruz Biotechnology), p16 (sc-1661, Santa Cruz Biotechnology), 4EBP1 and 
phospho-4EBP1  (4952  and  9451,  Cell  Signaling),  S6  (2317,  Cell  Signaling),  pRb 
(554316,  BD  Pharmingen),  and  ppRb
807/811  (9308,  BD  Pharmingen).    For 
immunofluorescence, cells grown on coverslips were fixed in 10% formaldehyde.  The 
antibodies used for immunofluorescence microscopy were anti-mouse NPM (B 0556),  
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anti-rabbit  p19
Arf  (Ab-1,  Oncogene),  anti-rabbit  NPMc+  (provided  by  B.  Falini, 
1:100), and anti-rabbit Phospho-Histone H2A.X (Ser139) (2577, Cell Signaling).  For 
detection,  cells  were  incubated  with  FITC-conjugated  and/or  Cy5-conjugated  anti-
mouse and anti-rabbit secondary antibodies (Jackson ImmunoResearch).  DNA was 
stained with DAPI. 
 
Senescence assay 
For the analysis of senescent cells, an equal number of cells (1×10
4) were seeded 
in triplicate in each well of 6-well plates.  After 4 days, staining for the senescence 
marker  β-Gal  activity  (X-Gal)  was  performed  according  to  the  manufacturer’s 
protocol  (Senescence  Detection  Kit,  Oncogene Research  Products)  and  the  images 
taken at the same time. 
 
Cell cycle and apoptosis assays 
Cell  cycle  analysis  was  performed  using  Propidium  Iodide  staining.    Briefly, 
infected and selected cells were harvested and prepared as single cell suspension in 
PBS. After washing two times, half of the cells were resuspended at 1–2×10
6 cells/ml 
and fixed in 70% ethanol overnight at 4°C. After washing, cells were resuspended in 
1 ml of PI staining solution (15 µg/ml containing 50 µg/ml of RNase A) and incubated 
1 h at RT.  Samples were analysed by flow cytometry using CellQuest Pro software on 
a FACScalibur flow cytometer (Becton Dickinson, Germany).  The other half of the 
cells was used for apoptosis using the Annexin V-PE kit (BD Pharmingen).  7-AAD 
was then added to a final concentraion of 10µg/ml and samples analyzed by flow 
cytometry. 
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Real-Time PCR 
Total RNA was extracted using the Trizol method (Invitrogen) and quantitative 
real-time PCR performed.  Briefly, cDNA was produced from 1µg of RNA using the 
SuperScript III system (Invitrogen) using random hexamers as primers as suggested by 
the manufacturer.  Quantitative real-time PCR was performed on a Roche LightCycler 
using the Quantitect SYBR Green PCR kit (Qiagen) and the following amplification 
protocol: 15 min at 95°C, 40 cycles of (15 sec at 94°C; 20 sec at 57°C; 20 sec at 72°C) 
followed by determination/confirmation of amplicon melting temperature.  Reactions 
were  performed  in  triplicates  and  absence  of  amplification  from  non  reverse-
transcribed  RNA  was  confirmed  to  exclude  genomic  DNA  amplification.    The 
sequences  used  for  amplification  of  the  exogenous  FLAG-NPM/FLAG-NPMc+ 
mRNA molecules were FLAG-Fwd (5′-CCACCATGGATTACAAGGATGACG-3′), 
NPM-Rev  (5′-GACATTTTCAAAGTTG  CCAGTGT-3′).    Primers  against  β-actin 
were  used  as  reference  standards:    Fwd  (5′-GGCCAACCGTGAAAAGATGA-3’), 
Rev (5′-TGGATGGCTACGTACATGGCT -3′). 
 
Analysis of centrosome numbers 
Cells grown on coverslips were fixed in cold 100% methanol and stained with 
anti-rabbit γ-tubulin (T5192, Sigma) as a marker for centrosomes.  The number of 
centrosomes/cell was then counted under a microscope.  
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CHAPTER 3 
 
THE CYTOPLASMIC NPM MUTANT HAS INTRINSIC ONCOGENIC 
ACTIVITIES BUT DOES NOT INITIATE AML IN A MRP8 TRANSGENIC 
MOUSE MODEL
* 
 
What seems to be a disaster is actually a fortune in ways unknown to you. 
A Chinese proverb 
 
Abstract 
Despite the fact that NPMc+ mutations are the most frequent genetic lesions so far 
identified  in  AML,  there  is  yet  no  experimental  in  vivo  model  of  NPMc+  to 
demonstrate  its  oncogenicity  and  to  test  the  effect  of  potential  therapeutic  agents.  
Recently we have shown that NPMc+ can cooperate with additional genetic events in 
oncogenic  transformations  in  vitro
33,  now  we  report  the  generation  and 
characterization  of  a  transgenic  mouse  model  harboring  the  most  frequent  human 
NPMc+  mutation  (mutation  A)  driven  by  the  myeloid-specific  human  MRP8 
promoter.  In parallel, we generated a wild-type NPM transgenic model driven by the 
same promoter.  However, no spontaneous AML was found in either MPR8-NPMc+ 
or MRP8-NPM transgenic mice.  This correlated with our preliminary findings that 
NPMc+  expressing  bone  marrow  cells  of  the  transgenic  mice  show  increased 
senescence  compared  to  wild  type  cells.    Interestingly,  MRP8-NPMc+  transgenic 
mice, unlike the MRP8-NPM transgenic mice or nontransgenic littermates, developed 
features of myeloproliferative disease.  A number of NPMc+ transgenic mice also 
developed  epithelial  tumors  and  plasmacytomas  where  NPMc+  expression  was 
                                                 
* This manuscript is under preparation for submission.  Ke Cheng et al.  
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detected in the tumors.  Furthermore, the presence of the NPMc+ accelerated acute 
lymphoblastic  leukemia  induced  by  a  mutagenic  agent,  N-ethyl-N-nitrosourea.  
Together these data suggest that although NPM+ can act as an oncogene in vivo, it 
alone  under  the  MRP8  promoter  is  not  sufficient  to  initiate  AML,  and  additional 
mutations are required to unveil NPMc+ oncogenic activity.  Our findings also lend 
support to the fact that NPMc+ is found in a small percentage of CMML patients.  
These two transgenic models can serve as a tool to identify mutations that cooperate 
with  NPMc+  in  leukemogenesis,  as  well  as  molecular  therapeutic  regimens  that 
specifically target NPMc+ but not NPM.  Furthermore, it prompts the investigation of 
NPM mutation status in other non-hematopoietic tumors.   
 
Introduction 
Cytoplasmic mutations of NPM (NPMc+) has been found in ~35% of adult de 
novo  AML  and  ~7%  of  childhood  AML,  making  it  the  most  frequent  genetic 
abnormality identified in this disease to date
81,  82.  NPMc+ mutations are caused by 
tandem  duplications  at  the  C-terminus  of  one  allele  of  the  NPM,  resulting  in  the 
replacement of the last 7 amino acids with 11 novel residues.  These residues contain a 
nuclear  export  signal  replacing  the  tryptophan  residues  important  for  nucleolar 
localization.  As a result, not only does the mutant localize to the cytoplasm instead of 
the nucleolus, it also acts as a dominant negative sequestering the endogenous NPM to 
the  cytoplasm  through  its  intact  N-terminal  oligomerization  domain  (Figure  12).  
NPMc+  AML  associates  with  normal  karyotype,  and  shows  wide  morphological 
spectrum,  multi-lineage  involvement,  a  unique  gene  expression  signature,  a  high 
frequency  of  FLT3-internal  tandem  duplications,  and  distinctive  clinical  and 
diagnositic feature (e.g. older age, female-association, good prognosis) that will be 
discussed in detail below.    
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Discovery of NPMc+ in AML carrying a normal karyotype (AML-NK) from simple 
observations under the microscope 
NPMc+ was first identified by Falini and colleagues
56 as a result of long-term 
expertise in using immunohistochemistry to detect NPM gene alterations
83 in routine 
biopsy samples and a wide range of human neoplasms including leukemias.  Their 
group  employed  the  use  of  two  different  NPM  antibodies  to  identify  the  site  of 
chromosome  rearrangement,  one  that  recognizes  specifically  the  N-terminus  and 
another  specifically  the  C-terminus  of  NPM.    NPM  translocation  products  (NPM-
ALK, NPM-MLF1 and NPM-RARa) can be easily distinguished since they lack the 
C-terminus  of  NPM  and  stain  positive  for  their  partner  moiety.    Subsequently, 
cytoplasmic  NPM  expression  (NPMc+  AML)  was  found  in  AML  cases  with  no 
known NPM fusion proteins, and in fact, with a normal karyotype.  Gene sequencing 
revealed mutations at exon 12 of NPM1.   
AML is the most common and deadly type of leukemia arising from the myeloid 
line  of  white  blood  cells.    The  World  Health  Organization  classifies  AML  into 
subtypes to produce more clinical and prognostic information, such as “AML with 
characteristic  genetic  abnormalities”  and  “AML  not  otherwise  categorized”.    All 
genetically poorly defined AML, including AML-NK, are included into the “AML not 
otherwise characterizied” category. Although AML-NK leukemia subgroup represents 
40-50% of adult AML
84, molecular alterations in AML-NK have always been difficult 
to study because it lacks chromosome rearrangements that direct researchers toward 
cloning  and  characterization  of  oncogenic  fusion  genes.      With  the  discovery  of 
NPMc+ in two-thirds of AML-NK, a new genetic marker has emerged and this entity 
begs a separate AML subgroup in the WHO classification
85.  
  62 
NPMc+ mutations are consistently heterozygous and a wild-type allele is retained.  
All NPM mutations to date are found at the C-terminus, involving exon 12, 11, or 9
82.  
More than 40 molecular variants of NPM mutations have been described to date in 
AML patients
81,  86, with the most common (so-called mutation A
56) being a TCTG 
tandem  duplication  at  exon  12  occurring  in  ~80%  of  adult  NPMc+  AML  cases.  
Regardless of their type, all NPMc+ mutations generate a novel C-terminus containing 
two alterations that are responsible for their aberrant cytoplasmic localization (Figure 
12C): 1) generation of an additional leucine-rich NES motif (i.e. L-xxx-V-xx-V-x-L 
with x indicating
 any residues), reinforcing Crm1 nuclear receptor-mediated nuclear 
export, and 2) loss of tryptophan residue 288 or 290 or both, which determine NPM 
nucleolar localization
57, 87.   
One might ask: why does wild type NPM mainly localize to the nucleolus if it 
already contains two NES within a.a. 94-102 and a.a. 42-61
88, 89? Studies have shown 
that the combined effect of these two NES is not as strong as the combined effect of 
the two NLS and the C-terminal NoLS, thus although at any given time NPM can be 
found in both the nucleus and the cytoplasm, the steady state equilibrium favors the 
import rather than export.  The addition of the extra NES and the concomitant loss of 
NoLS  at  the  C-terminus  in  NPMc+  are  crucial  for  perturbing  NPM  nucleo-
cytoplasmic traffic.  Most of the NPM mutations have lost both W residues in NPMc+ 
AML.  Interestingly however, in rare cases where only one W residue is lost, the 
mutation is always accompanied by the strongest NES motif, suggesting that selective 
pressure  toward  efficient  export  of  NPMc+  to  the  cytoplasm  is  critical  for 
leukemogenesis
90. 
The  fact  that  NPMc+  mutations  are  heterozygous  raises  another  question:  is 
NPMc+  AML  caused  by  NPM  haploinsufficiency,  similar  to  what  we  showed  in 
NPM
+/-  animals  in  Chapter  1?    The  answer  is  probably  not.    NPMc+  AML  are  
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cytogentically normal and do not have the “mutator” phenotype, suggesting that NPM 
mutants are still effective in binding to, and controlling, centrosome duplication.  In 
vitro data from Chapter 2 also shows that overexpression of NPMc+ in MEFs does not 
alter centrosome number.  Furthermore, NPM mutations are extremely rare in human 
myelodysplasia
91.    Therefore,  NPMc+  most  likely  have  novel  intrinsic  oncogenic 
functions  unrelated  to  genomic  maintenance  that  plays  the  primary  role  in 
leukemogenesis.  However, we cannot exclude the possibility that other effect of NPM 
haploinsufficiency in NPMc+ AML are involved (e.g. C-MYC, p53, ARF). 
 
NPMc+ mutation appears to be the initiating event in leukemogenesis 
NPMc+  mutations  are  identified  in  de  novo  AML
56,  81,  and  rarely  in  therapy-
induced AML (t-AML) or AML progressed from myelodysplasia (t-MDS)
92, 93 which 
generally show an abnormal karyotype.  Furthermore, there is an absence of genetic 
predisposing factors
94 in NPMc+ AML.  This suggests that NPMc+ is the primary 
event in leukemogenesis. One-mutation mathematical model support the hypothesis 
that a single genetic event, the NPMc+ mutation, is sufficient to cause this type of 
leukemia
95.  In addition, NPMc+ is mostly specific for AML
96 (although rare reports 
of NPM1 mutations in chronic myelomonocytic leukemia have been published
91, 97), is 
mutually exclusive with other recurrent genetic abnormalities (with the exception of 
FLT3-ITD which could be a cooperating or secondary event in leukemogenesis)
98, is 
stable  during  the  course  of  the  disease  as  the  same  type  of  NPMc+  mutation  is 
detected at relapse
99, 100, and quantitative RT-PCR shows that it disappears at complete 
remission
101.  These data suggest that NPMc+ is a cause rather than a consequence of 
AML.   
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Pathologic and clinical features of NPMc+ AML 
NPMc+  AML  shows  a  wide  French-American-British  (FAB)  morphologic 
spectrum, although the majority belongs to acute myelomonocytic leukemia (M4) and 
monocytic leukemia (M5)
56, 102, 103.  More than 95% of NPMc+ AMLs lack the CD34 
hematopoietic  stem  cell  marker,  and  involves  several  cell  lineages  (myeloid, 
monocytic, erythroid, and megakaryocytic but not lymphoid)
85.  This is surprising 
considering multilineage involvement is mainly associated with secondary leukemias.  
Interestingly, bone marrow biopsies from NPMc+ AML (especially M4) frequently 
show  increased  number  of  megakaryocytes  carrying  mutated  NPM  and  exhibiting 
dysplastic features
85.  Concurring with the clinical observation that platelet counts are 
significantly higher in NPMc+ AML
79, 102 is the fact that K562 cells expressing a C-
terminal NPM mutant acquire enhanced ability for megakaryocytic differentiation
104.  
These findings suggest that megakaryocytes with NPMc+ mutations retain capacity 
for thrombocytic differentiation.   
NPMc+ mutations are more frequent in female patients
79, 102, 103.  This appears to 
be specific for NPM mutations and is surprising considering AML incidence is higher 
in males
79.  Thus sex-specific differences might underlie the mechanism of NPMc+ 
AML development.  Age-dependency is another characteristic of NPMc+ mutation as 
it is more frequently found in the adults than in pediatrics and in the older age group 
among  the  adult  AML.
99.    Whether  this  is  simply  another  proof  that  childhood 
leukemia  is  very  different  from  adult  leukemia  in  pathogenesis  and  biological 
characteristics or  suggests that additional genetic events are necessary for NPMc+ 
AML is still unclear.  
Strikingly, internal tandem duplication of the FMS-like tyrosine kinase 3 (FLT3-
ITD) targets NPMc+ AML twice as often as AML carrying unmutated NPM
56, 78, 79, 
102, 103. In contrast, the presence of partial tandem duplications within the MLL gene  
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(MLL-PTD)  is  inversely  correlated  with  NPM  mutations  in  NPMc+  AML.    The 
presence of NPMc+ is also not correlated with other known AML mutations, such as 
CEBPA, KIT and NRAS
56, 78, 79, 102, 103.  
The presence of NPMc+ without FLT3-ITD is actually good news to an AML 
patient.    These  patients  usually  have  a  favorable  prognosis  and  respond  well  to 
therapy.  This could be a result of the negative impact of FLT3-ITD (which has a poor 
prognosis
105) or it could be that NPMc+ mutants fail to protect cells from genotoxic 
stress (a role for NPM discussed in Chapter 1) and render them more susceptible to 
radiation/chemotherapy. 
 
Biochemical and cellular studies of NPMc+ 
The  mechanism  by  which  NPMc+  exerts  its  oncogenic  functions  is  just  being 
uncovered.  We have recently reported that NPMc+ can act as a bona-fide proto-
oncogene  in  vitro  under  the  appropriate  genetic  context
33.    Cytoplasmic  NPM 
mutation was also found to have novel functions, sequestering HEXIM1 (an inhibitor 
of transcription factor pTEFb) resulting in higher RNA Pol II transcription
106.  In 
addition, it inactivates NF-κB resulting in increased sensitivity to chemotherapeutic 
agents
107  and  targets  Fbw7γ  (the  E3  ligase  involved  in  the  ubiquitination  and 
proteosome degradation of c-Myc) to the cytoplasm resulting in stabilization of c-Myc 
oncoprotein
108.  A distinctive microRNA signature has been found in NPMc+ AML—
blasts containing NPMc+ downregulate several miRNA family members predicted to 
target HOX genes involved in stem cell maintenance—providing an explanation for 
the increased HOX gene expression in this leukemia subtype
109.  Recently the crystal 
structure of the C-terminal of NPM has also been solved
110.   
Cytoplasmic mutated NPM has now been retained for 8 years in a xenotransplant 
model by subcutaneous injection of patient NPMc+ AML blasts into immunodeficient  
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mice
100.  However, to date there is no publication on in vivo models of NPMc+ to test 
whether it is responsible for the initiation of leukemogenesis.  In addition, it is still not 
known whether the overexpression of NPM would lead to transformation in vivo in 
transgenic models. 
 
NPMc+ AML: what is the cell of origin? 
It  is  not  clear  whether  NPMc+  leukemic  blasts  are  derived  from  a  common 
myeloid progenitor or an earlier progenitor.   It was shown that NPMc+ AML displays 
a unique gene expression profile with upregulation of stem cell maintenance genes, 
including HOX genes
111, suggesting that a hematopoietic stem cell could be the origin.  
In addition, a strong miRNA signature was identified in NPMc+ AML that includes 
the  downregulation  of  miRNAs  normally  involved  in  HOX  gene  repression
109.  
However, a recent study showed that mature B and T cells are not targeted by NPMc+ 
mutations
112, strongly suggesting that the mutation may occur in a common myeloid 
progenitor or an earlier progenitor without the ability to differentiate into the lymphoid 
lineages.    Since  NPMc+  is  found  in  acute  myeloid  leukemia
56  and  myeloid 
sarcomas
113,  the  majority  of  leukemic  cells  are  from  a  myeloid  and/or  monocytic 
lineage.    Thus,  we  chose  to  express  NPMc+  under  the  human  myeloid-specific 
promoter MRP8 for our transgenic mice.   
 
MRP8 transgenic mouse models of leukemia 
Human MRP8 is a S100 calcium-binding protein abundantly expressed in myeloid 
cells  of  neutrophil  and  monocytic  lineages  but  not  in  hematopoietic  stem  cells
114.  
Transgenic mouse models generated under MRP8 were successful in demonstrating 
the  oncogenic  potential  of  several  genetic  alterations  found  in  myeloid  leukemia: 
PML-RARα, p210
BCR/ABL 115 and AML-ETO.  However, with the exception of MRP8- 
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PML-RARα, which progressed at a low frequency over the course of several months to 
overt APL
116, the rest of the MRP8 mouse models never developed acute myeloid 
leukemia by itself without additional oncogenic events.  For example, MRP8-N-RAS 
cooperated  with  MRP8-PEBP2β-MYH11  to  induce  myelodysplasia
117,  MRP8-
p210
BCR/ABL  cooperated  with  MRP8-BCL2  to  induce  AML
115,  MRP8-AML-ETO 
induced AML only in the presence of additional mutations
118, and MRP8-C-MYC
115 
transgenic mice has no apparent phenotype. 
Interestingly, MRP8 is not only found expressed in the myeloid compartment, but 
also in the keratinocytes and T cells.  For example, MRP8-PML-RARa in FVB/N mice 
developed skin papillomas in a dose dependent manner due to the expression of PML-
RARα oncoprotein in the skin
119.  In addition, two of the six MRP8-BCL2 transgenic 
founders developed T-cell lymphoma
115.  These varied types of malignancy are likely 
due to the leakiness of the MRP8 promoter or degree of susceptibility in different 
mouse genetic backgrounds. 
# 
Here we report the generation and characterization of MRP8-NPMc+ transgenic 
mice along with MRP8-NPM transgenic mice.  We find that NPMc+  alone is not 
sufficient  to  initiate  AML  in  vivo  under  the  MRP8  promoter.    However,  MRP8-
NPMc+  mice,  unlike  the  MRP8-NPM  transgenic  mice,  developed  features  of 
myeloproliferative disease after a long latency.  A number of NPMc+ transgenic mice, 
but  not  NPM  transgenic  or  wild  type  littermates  of  the  same  age,  also  died  from 
epithelial  tumors  and  plasmacytomas.    These  tumors  could  arise  from  the  leaky 
expression of the MRP8 promoter in the keratinocytes and B cells, as NPMc+ protein 
was detected in the tumor lysates.  Our results suggest that NPMc+ can act as an 
oncogene in vivo with additional mutations.   
  
  68 
Results 
Generation of MRP8-NPMc+ and MRP8-NPM transgenic mice 
To study the role of NPMc+ mutation in hematopoiesis and leukemogeneis in vivo, 
we  generated  NPMc+  transgenic  mice  harboring  the  most  common  cytoplasmic 
mutation  of  NPM  (mutation  A
56:  TCTG  duplication)  driven  by  the  human  MRP8 
promoter.  As a control for the exogenous expression of the mutated NPMc+, we also 
generated transgenic mice expressing wild type NPM under the same MRP8 promoter.  
Both  constructs  are  Flag-tagged  at  the  N-terminus  of  the  NPM  gene  for  epitope 
detection  (Figure  24A).    Seven  mice  carrying  the  MRP8-NPMc+  transgene  were 
identified after injection of the transgene into BL6/CBA zygotes (Figure 24B) and six 
out of seven founders gave germ-line transmitted offspring.  NPMc+ founder #4 did 
not  produce  NPMc+  progenies  after  a  few  litters.    Similarly,  eight  MRP8-NPM 
transgenic  mice  were  identified  and  six  out  of  eight  founders  gave  germ-line 
transmission of the transgene (Figure 24B).  It is interesting to note that 6 out of 7 
positive NPMc+ founders were females whereas 7 out of 8 positive NPM founders 
were males despite the fact that male and female founders were born at approximately 
equal ratio.  
 
Myeloid expression of NPMc+ and NPM in transgenic mice 
RT-PCR analyses were performed to detect the expression of the transgene mRNA 
in the total bone marrow cells from MRP8-NPMc+ and MRP8-NPM transgenic mice.  
NPMc+ mRNA can be clearly detected in line #4, #24, and #28 (Figure 24C) whereas 
line #29 has lower level of expression (Figure 24D).  Four out of six MRP8-NPM 
transgenic  lines  showed  detectable  transgene  mRNA  expression  with  line  #65 
expressing the highest level.   
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Figure 24. Generation of hMRP8-NPMc+ and hMRP8-NPM transgenic 
mice. A, Schematics of the human MRP8-driven Flag-NPMc+ or Flag-NPM 
(~1KB) constructs. B, Southern blot analysis with BamHI digest and the 3’ 
probe  shows  a  expected  2.5KB  band  in  the  positive  founders.  PCR 
genotyping  using  NPM874F  and  MRP8R  primers  confirms  Southern  blot 
analysis. C, The mRNA expression of the transgenes in bone marrow cells . 
Lines  expressing  exogenous  NPMc+  or  NPM  shows  a  specific  band  of 
~500bp using Exon1F and NPM500R primers. Asterisks indicate the highest 
expressing lines. NT, nontransgenic. 
hMRP8-NPMc+ 
hMRP8-NPM  
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Figure 24 (continued). D, Protein expression of NPMc+ in bone marrow cells 
by western blot using a monoclonal Flag antibody (top) and a human NPMc+ 
specific antibody (bottom) that does not recognize the mouse endogenous NPM. 
Immunofluorescence  using  the  same  NPMc+  antibody  (right  panels)  show 
cytoplasmic  staining  of  NPMc+  in  bone  marrow  granulocytes.    E,  Protein 
expression of exogenous NPM (hNPM) in bone marrow cells by western blot 
(left panels) and immunohistochemistry (right panels) using a polyclonal Flag 
antibody (top) or a NPM antibody recognizing  both human and mouse  NPM 
(bottom).  Note  that  the  Flag-tagged  hNPM  is  slightly  larger  than  the  mouse 
endogenous NPM.  
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As shown in Figure 24D, protein expression of NPMc+ was detectable in total 
bone  marrow  cells  of  MRP8-NPMc+  line  #28  by  western  blot  using  an  NPMc+-
specific antibody (gift of Brunangelo Falini) as well as a monoclonal antibody against 
the  Flag  epitope.      Immunofluorescence  shows  that  NPMc+  is  expressed  in  the 
cytoplasm of bone marrow granulocytes as expected.   
Exogenous NPM protein expression was easily detectable in the highest mRNA-
expressing MRP8-NPM line #65 using a polyclonal Flag antibody as well as a full-
length NPM antibody recognizing both the endogenous mouse Npm and the slightly 
larger Flag-tagged human NPM.  Similarly, in bone marrow immunohistochemical 
studies of line #65, Flag-NPM was detectable in the nucleus using Flag antibody and 
the  staining  of  total  NPM  was  much  stronger  in  the  nucleolus  compared  to 
nontransgenic (NT) control (Figure 24E). 
Based on the expression levels, we analyzed MRP8-NPMc+ line #28 and MRP8-
NPM line #65 in greater detail compared to other lines.  However, we also followed a 
cohort of ~20 mice each from NPMc+ line #24, NPMc+ line #29, NPM line #67, and 
NPM line #43 for 18 months to monitor leukemia development. 
 
MRP8-NPMc+ animals develop features of myeloproliferative disease 
At 2-months-old, no signs of disease could be found in NPMc+ line #28 transgenic 
mice  (data  not  shown).    However,  extramedullary  hematopoiesis  was  found  in  6-
month-old NPMc+ transgenic mice (Figure 25A), and flow cytometric analysis of BM 
and spleens demonstrated increased mature myeloid (Mac1+/Gr1+) populations in the 
affected NPMc+ transgenic mice versus NT littermates (Figure 25B).  On average, 
there is a trend toward an increase in bone marrow cellularity, percentage of myeloid 
cells, and common myeloid progenitors (CMP) accompanied by a concomitant  
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A 
Figure  25.  MRP8-NPMc+  transgenic  mice  develop  features  of 
myeloproliferative  disease.  A,  Enlarged  spleen  in  6-months-old  NPMc+ 
transgenic mice from line #28 compared to a wild-type NT littermate. H&E 
section  of  the  spleen  on  the  right  shows  extramedullary  hematopoiesis  in 
NPMc+ (20X). of B, Flow cytometric analysis of cells from bone marrow 
(BM) and spleen of the same mice in A shows myeloid expansion in NPMc+ 
transgenic mice over NT mice. 
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Figure  25  (continued).  C,  Multiparameter  flow  cytometry  analysis  of 
hematopoietic  compartment  of  6-month-old  NPMc+  transgenic  mice.  On 
average there is a trend toward increased myeloid cells in bone marrow and 
spleen  of  NPMc+  mice  over  NT  animals  with  a  progressive  increase  in  the 
relative proportion of common myeloid progenitors in these mice.  The values 
plotted are from three independent experiments (mean ± s.d. SEM; NPMc+ #28, 
n=5; nontransgenic littermates, n=5).   
C  
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decrease in the percentage of T lymphoid cells and granulocyte-monocyte progenitors 
(GMP) (Figure 25C).   
Other NPMc+ founders expressing the transgene at lower levels, line #24 and line 
#4,  also  developed  a  myeloproliferative  disease  at  23  months  and  19  months, 
respectively. Transgenic NPMc+ founders displayed leukocytosis (WBC = 13.8 ± 4.5 
×10
9/L),  expansion  of  the  red  pulp  and  white  pulp  of  the  spleen,  extramedullary 
hematopoiesis, and expansion of mature myeloid cells in BM and/or spleen (Figure 
26).  On the contrary, the highest expressing NPM transgenic founder #65 (Figure 
26B) and founder #67 (data not shown) did not display any of these signs at the same 
age.    Together  these  preliminary  data  suggest  that  expression  of  NPMc+,  but  not 
NPM, can lead to myeloproliferative disease in this mouse model.  We followed 66 
NPMc+ and 44 NPM transgenic mice from different lines for 18 months and none of 
them developed AML over the course of 18 months.   
A number of NPMc+ transgenic mice from line #28, but not NPM transgenic or 
NT  littermates,  died  from  plasmacytoma  at  around  1-year-old,  as  reflected  on  the 
overall survival curves (Figure 27).  The BM and spleen from the affected animals 
were completely replaced by immature plasmacytoid B cells, which infiltrated other 
non-hematopoietic  organs  such  as  the  liver  (Figure  28).   Importantly,  cytoplasmic 
NPMc+  expression  was  detected  in  these  infiltrating  cells  both  by 
immunohistochemistry  using  a  NPM  antibody  recognizing  the  wt  and  the  mutant 
NPMc+ (Figure 28C), as well as by western blot of liver lysates from the affected 
animal (data not shown).  In addition, several NPMc+ transgenic mice from other lines 
also  presented  with  lymphocytosis  and  infiltration  of  lymphoid  cells  to  non-
hematopoietic organs (Figure 29), suggesting that NPMc+ could have a role in the 
lymphoid as well as the myeloid compartment in promoting proliferation, presumably 
due to the leakiness of the MRP8 promoter in the lymphoid cells
120.  
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Figure  26.  Founders  from  other  NPMc+  expressing  lines,  but  not  NPM 
transgenic  lines  and  nontransgenic  littermates,  also  developed  features  of 
MPD. A. NPMc+ line #24 founder compared to a littermate NT founder. Western 
blot shows NPMc+ expression in the bone marrow; H&E shows expansion of the 
red and white pulp in NPMc+ enlarged spleen. Flow cytometric analysis shows 
myeloid expansion in NPMc+ transgenic mice over NT mice. 
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Figure 26 (Continued). B, NPMc+ line #4 founder compared to a NT littermate 
and NPM line #65 founder. Flow cytometry shows expansion of myeloid cells in 
spleen  of  NPMc+#4  founder  (top);  H&E  (10X)  of  spleen  sections  shows 
extramedullary hematopoiesis in NPMc+ founder compared to NT founder and 
NPM founder (bottom). 
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Figure  27.  Cumulative  survival  of  hMRP8-NPMc+  and  hMRP8-NPM 
transgenic  mice  compared  to  nontransgenic  littermates.  P  values  were 
calculated by Mantel-Cox log-rank analysis.   
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Figure  28.  A  small  percentage  of  NPMc+  transgenic  mice  develop  lethal 
plasmacytoma. A, Spleno-hepatomegaly in a NPMc+ transgenic mouse (J54) from 
the highest expressing line #28.  B, H&E sections show a homogenous population 
of plamacytoid B cells in BM and infiltrating other organs in the same mouse.  
Immunohistochemistry of BM section showing strong staining for a plasmacytoma 
marker  CD138.  C,  Immunohistochemistry  of  liver  sections  shows  cytoplasmic 
staining for NPMc+ in the infiltrating plasmacytoma. H&E  of the liver section is 
shown at the bottom. 
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Figure  29.  Lymphoproliferation  in  NPMc+  transgenic  mice.  May-
Grunwald/Giemsa  staining  of  peripheral  blood  shows  lymphocytosis  and  H&E 
sections  show  lymphoid  infiltration  in  non-hematopoietic  organs  of  NPMc+ 
transgenic mice.   
PB   
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MRP8-NPMc+ animals develop epithelial tumors 
Interestingly,  NPMc+  founder  #29  and  ~10%  of  its  progeny  developed  skin 
tumors.    These  mice  presented  with  spleno-hepatomegaly,  epithelial  tumors  with 
squamous differentiation, as well as features of myeloproliferative disease (Figure 30).  
Since  MRP8  is  highly  expressed  in  non-differentiating  and  differentiating 
keratinocytes
119, 121, we checked the expression of NPMc+ in these tumors.  NPMc+ 
protein expression can be clearly detected in both the bone marrow and the tumor 
lysates of the affected animal by western blot (Figure 30C).  It should be noted that 
this line is a low NPMc+ expressing line compared to line #28, as shown by semi-
quantitative RT-PCR (Figure 30D) and the protein expression of NPMc+ is normally 
undetectable (data not shown).  However, it seems that in the affected animals NPMc+ 
expression is upregulated in the bone marrow (compare lane 3 and 4 in Figure 30C). 
 
NPMc+ expression accelerates ENU-driven acute lymphoblastic leukemia 
The  observation  that  NPMc+  transgenic  mice  develop  features  of 
myeloproliferative disease with long latency suggests that NPMc+ itself is insufficient 
to  trigger  leukemogenesis.    The  low  penetrance  of  skin  tumors  also  suggest  that 
NPMc+ has intrinsic oncogenic activities, but additional mutations that cooperate with 
NPMc+ might be necessary to unleash its oncogenic potential.  To test this hypothesis, 
the  newborn  progeny  from  NPMc+  transgenic  line  #28  and  NT  littermates  were 
injected fractionally with a total dosage of 300 mg/kg ENU, a strong DNA alkylating 
mutagen (see Materials and Methods for details).  ENU has been previously used to 
induce T-cell acute lymphoblastic leukemia (T-ALL) in wild-type mice, and to trigger 
AML in several mouse models
118, 122.   
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Figure 30. MRP8-NPMc+ transgenic mice develop epithelial tumors. A, A 
representative  mouse  from  NPMc+  line  #29  with  spleno-hepatomegaly  and  a 
tumor growing on the upper left limb. B, H&E (10X) of the same tumor shows 
areas of squamous differentiation forming large cystic spaces (arrow) filled with 
laminar keratin. C, Protein and mRNA expression of NPMc+ in the tumor and 
affected  organs.  D,  mRNA  expression  of  NPMc+  in  bone  marrow  cells  of 
NPMc+ line #29 compared to line #28 shows that it is a low-expressing line. E, 
Flow cytometric analysis of cells from peripheral blood (PB), BM and spleen of 
the same mice shows myeloid expansion in NPMc+ transgenic mice over NT 
mice. 
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In as fast as 2 months after the ENU injections, the NPMc+ transgenic mice and 
NT  mice  became  ill  with  symptoms  and  signs  of  cachexia,  anemia,  and  labored 
breathing.  The peripheral blood shows leukocytosis (WBC = 32.3 ± 34.3 ×10
9/L), 
anemia  (HGB  level  =  7.5  ±  4  g/L),  thrombocytopenia  (PLT  count  =  398  ±  294 
×10
9/L),  and  many  immature  lymphoblasts.    All  of  the  mice  died  or  were  killed 
because of a moribund condition within 7 months.  The survival curves in Figure 31 
show the latency period after ENU treatment.   
Due to the aggressiveness of the T-ALL, the survival curves between NT-ENU 
and NPMc+-ENU mice are not significantly different.  However, at later time points 
NPMc+ transgenic mice die faster than NT controls.  Upon post-mortem examination 
(Figure 31B), all of the mice showed enlarged thymus and pale femurs.  Most also 
showed  splenomegaly,  hepatomegaly  or  lymphomas.    The  bone  marrow  was 
hypercellular,  infiltrated  with  more  than  90%  lymphoblasts  undergoing  mitosis 
(Figure  31C).  These  lymphoblasts  also  systemically  infiltrated  other  non-
hematopoietic organs.  Flow cytometric analysis of the representative bone marrow 
samples show that the malignancy is of T cell origin because they expressed CD4, 
CD8,  or  CD3  on  the  cell  surface  (Figure  32).    Normal  hematopoiesis  (myeloid, 
erythoid, megakaryocytic lineages) is severely suppressed in these mice. 
Although no AML was found in NPMc+ transgenic mice treated with ENU, 3 out 
of  5  NPMc+  transgenic  mice  analyzed  so  far  with  T-ALL  showed  mild  myeloid 
hyperplasia, with one developing a myeloproliferative disease and epithelial tumor 
(Figure 31 and Figure 32).  In these mice, mature myeloid cells (Figure 31B) could be 
found  in  the  bone  marrow,  indicating  that  myeloid  hematopoiesis  was  not  totally 
suppressed.  In contrast, none of the 3 NT mice analyzed so far showed this expansion 
of myeloid cells by flow cytometry and pathological examination.  Together these  
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Figure 31. NPMc+ accelerates ENU-driven Acute T-Lymphocytic Leukemia. A, 
Kaplan-Meier overall survival curves of nontransgenic (NT) vs. NPMc+ line #28 
transgenic mice after ENU treatment. Untreated transgenic mice and WT mice are 
shown as controls. B, RT-PCR showing expression of NPMc+ in the thymus. C, T-
cell  acute  lymphoblastic  leukemia  characterized  by  enlarged  thymus  and  spleno-
hepatomegaly in NT mice treated with ENU. Epithelial tumor is found in NPMc+ 
transgenic mice treated with ENU. C, May-Grunwald/Giemsa staining of PB and BM 
cytospin and H&E sections (40X) show lymphoblasts infiltrating non-hematopoietic 
organs. The insets are pictures taken with 60X magnification.  The arrow in BM 
H&E of NT-ENU shows lymphoblasts undergoing mitosis. The arrow in BM H&E of 
NPMc+-ENU shows mature granulocytes. 
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Figure  32.  NPMc+  transgenic  mice,  but  not  NT  mice,  treated  with  ENU 
develop features of myeloproliferative disease.  Representative flow cytometry 
of NT mice treated with ENU shows expansion of CD4+CD8+ T cells in BM and 
thymus. Representative flow cytometry of NPMc+ transgenic mice treated with 
ENU show expansion of myeloid cells in PB, BM and spleen. 
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preliminary data suggest that the expression of MRP8 in the lymphoid lineage may 
account for the slight acceleration in ENU-driven acute lymphoblastic leukemia and 
epithelial  tumor,  and  again  confirm  that  NPMc+  expression  contributes  to  the 
development of myeloproliferative disease in this transgenic model. 
 
Biological and functional impact of NPMc+ expression in the myeloid compartment  
Since we previously showed that NPMc+ induces senescence in primary mouse 
embryonic fibroblasts
33, we performed senescence assays in ex-vivo cultured NPMc+ 
expressing bone marrow cells from the transgenic mice.  Preliminary data suggest that 
there is an increase in the number of β-gal positive cells in NPMc+ compared to NT 
bone marrow cells (Figure 33A).  Sorted mature myeloid cells from the bone marrow 
of NPMc+ transgenic mice show that the level of apoptosis is not affected (Figure 
33B), but interestingly these cells are smaller compared to those from NT or NPM 
transgenic mice (Figure 33C). 
 
Discussion 
Following the discovery of NPMc+ as the most frequent mutation in AML, no in 
vivo model of NPMc+ has been published.  Here we report a transgenic mouse model 
expressing the most frequent NPMc+ mutation under the control of a myeloid-specific 
promoter from the human MRP8 gene.  We test its leukemogenic potential compared 
to the MRP8-NPM transgenic model generated in parallel. 
Surprisingly, MPR8-NPMc+ transgenic mice did no develop AML.  This suggests 
that NPMc+ alone is not sufficient for AML in mice when expressed under the human 
MRP8 promoter.  Alternatively, it could be due to the relative low expression of the 
transgene compared to the level of endogenous Npm in the myeloid lineage.  While 
we can detect NPMc+ mRNA in four out of six transmittable lines, we have difficulty  
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Figure 33. Effects of NPMc+ expression on senescence, cell size and apoptosis 
within the bone marrow hematopoietic compartment. A, Increased senescence as 
measured  by  β-gal  staining  of  primary  bone  marrow  cells  cultured  ex-vivo  (see 
Materials and Methods) from NPMc+ transgenic mice compared to NT littermates. 
Results  are  plotted  as  mean  ±  s.d.  from  two  independent  experiments.  B, 
Representative  graph  of  smaller  Mac1+Gr1+  sorted  myeloid  cells  in  NPMc+ 
transgenic mice over NT or NPM transgenic mice as determined by forward scatter 
values in flow cytometry. C, Apoptosis is not affected in NPMc+ Mac1+Gr1+ sorted 
myeloid cells.  
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detecting NPMc+ protein in all but one of these lines (line #28).  Therefore, it is 
possible that the use of a stronger promoter would lead to full-blown AML.  On the 
other hand, it is also possible that high expression of NPMc+ causes cell death through 
unknown mechanisms that result in embryonic lethality or selectively loss of NPMc+ 
cells from the myeloid population.  Targeting NPMc+ expression at a different stage 
of myeloid development or knock-in models of NPMc+ may also prove to be better in 
recapitulating AML than our MRP8 transgenic model.  Although several other groups 
have used the MRP8 promoter to successfully establish mouse models with abnormal 
myelopoiesis
115, 117, 118, 123, modeling spontaneous acute leukemia using this promoter 
has been difficult, with the exception of PML-RARα in APL
116.  
Nevertheless,  we  find  that  transgenic  founders  expressing  NPMc+  mRNA 
developed  a  chronic  myeloproliferative  disease  (MPD)  with  expansion  in  the 
monocytic  compartment.   Features  of  myeloproliferative  disease  are  also  found  in 
NPMc+ progenies starting at 6 months, with increasing penetrance as the animal age.  
These preliminary but consistent data suggest that NPMc+ is involved in MPD, and 
support  the  finding  that  NPMc+  is  found  in  a  small  percentage  of  human  MPD-
CMML patients and disappears with disease remission
91,  97.  They also support the 
current concept that AML development is believed to be a consequence of more than 
one oncogenic hit
124.  Since NPM is hemizygous in NPMc+ AML, we also checked if 
lowering the endogenous dose of Npm to heterozygosity could lead to AML.  We 
crossed  NPMc+  line  #24  with  our  Npm
+/-  mice  and  followed  15  NPMc+;NPM
+/- 
compound mice for 18 months.  However, we did not find any cases of AML in these 
mice (data not shown).  These data suggest that the reason we did not find AML in our 
NPMc+ transgenic mice is not due to the presence of both alleles of endogenous Npm.  
Instead, we favor the hypothesis that either NPMc+ is not expressed high enough to  
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exert  its  leukemogenic  potential  in  the  MRP8-NPMc+  transgenic  mice,  or  high 
expression of NPMc+ induces embryonic lethality and/or cell death. 
Interestingly,  a  number  of  MRP8-NPMc+  transgenic  mice  developed 
plasmacytomas  and  epithelial  tumors.    At  first  sight,  the  low  frequency  of 
plasmacytomas could be simply explained by the reported occurrence of spontaneous 
plasmacytomas  in  old  mice  of  similar  strains
125,  126.   However,  the  fact  that these 
tumors were not found in NT or MRP8-NPM transgenic mice, in addition to the fact 
that NPMc+ protein expression can be clearly detected in these tumors suggest that the 
leaky expression of MRP8-NPMc+ in keratinocytes
121 and lymphoid cells and may 
lead  to  the  observed  malignancies.    In  fact,  MRP8-PML-RARα  transgenic  mice 
developed skin papillomas
119.  Therefore, NPMc+ appears to be an oncogene in vivo.  
A  summary  of  malignancy  cases  found  in  MRP8-NPMc+,  MRP8-NPM  and  NT 
cohorts are shown in Figure 34.  
To further test its oncogenic activity, we challenged the MRP8-NPMc+ transgenic 
mice with ENU and found that there is a slight acceleration in T-ALL development.  
Considering the fact that MRP8 is known to be expressed in the T cells
115, these data 
further suggests that NPMc+ is oncogenic in vivo.  Again, while no AML was found 
after treatment, some NPMc+ transgenic mice but not NT mice developed features of 
MPD.  It is possible that the high dose of ENU administered in this study partially 
masked the effect of NPMc+ in the myeloid lineage.  
 Taken  together,  these  data  support  our  in  vitro  findings  that  cooperating 
oncogenic events are needed to unveil NPMc+ oncogenic potential
33.  Nevertheless, 
analysis of expression of NPMc+ in different sorted populations of B cells, T cells, 
megakaryocytes,  erythoid  cells,  granulocytes,  and  keratinocytes  of  transgenic  mice 
will render these conclusions more solid. 
Since the role of NPMc+ in hematopoietic cell differentiation and proliferation is   
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malignancy  type of malignancy 
NT  11-26  23  0  0  none 
NPM#65/#67  11-26  7  0  0  none 
c+#24  26  1  1  0  MPD 
c+#4  19  1  1  0  myeloproliferation 
c+#29  6-26  13  2  1  MPD (19mo.), epithelial tumor (26mo.) 
c+#28  6-15  9  4  3  MPD (6 mo.), plasmacytoma (11-15mo.) 
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Figure 34. Total number of malignancy cases confirmed in NPMc+ transgenic 
mice compared to NT and NPM transgenic mice.    
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unclear,  we  performed  functional  studies  of  NPMc+  expressing  cells  from  the 
transgenic  mice.    Preliminary  data  suggest  that  while  NPMc+  does  not  affect 
apoptosis, it can induce senescence.  This is in agreement with our in vitro findings.  
The finding that NPMc+ expressing myeloid cells are smaller compared to NT or 
NPM expressing myeloid cells could suggest a role of NPMc+ on ribosome biogenesis 
(see Figure 23 and Part II) or differentiation.   
It is also interesting to note that while the wild-type NPM is thought to be an 
oncogene in vitro when overexpressed, MRP8-NPM transgenic mice did not develop 
any  kind  of  malignancy  during  their  lifetime.    This  demonstrates  that  moderate 
overexpression of NPM is not oncogenic in the myeloid lineage.  
Our model provides a useful tool for studying the role of NPM and NPMc+ in 
hematopoiesis and the novel role of NPMc+ in leukemogenesis.  It is also useful in 
identifying cooperating mutations that lead to NPMc+ AML and the development of 
therapeutic approaches to specifically target NPMc+ and not NPM.  While NPMc+ is 
not found in patients with multiple myeloma, it would be interesting to investigate the 
mutation status of NPM in the non-cycling plasmacytomas or epithelial tumors. 
 
Materials and Methods 
Generation of Transgenic mice 
  Flag-NPMc+ (mutation A
56) or Flag-NPM cDNA was PCR amplified from the 
pCMV-Tag2B-NPMc+ or pCMV-Tag2B-NPM plasmid with primers containing BclI 
ends:  forward  (5’-GCTGATCAGCCACCATGGATTAC-3’)  +  reverse  (5’-
GCTGATCACTATTTTCTTAAAGAGACTTCC-3’).  The  resulting  1-kb  fragment 
was subcloned into the compatible BglII site of the hMRP8 cassette
123 in pBluescript 
II SK (+).  The MRP8-NPMc+ and MRP8-NPM transgenes include the human MRP8 
gene upstream regulatory element, human MRP8 gene sequence (exon 1, intron 1 and  
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part of exon 2), either Flag-NPMc+ or Flag-NPM cDNA, followed by part of human 
MRP8 exon 3 and the downstream flanking sequence of the human MRP8 gene.  Both 
transgene cassettes were sequenced and released from pBlueScript KS(+) by digestion 
with ClaI and XbaI and injected into zygotes from (C57BL/6J × CBA) F1 hybrid 
mice. 
 
Expression analysis 
Tail genomic DNA was prepared and digested with BamHI.  Southern blot was 
performed using a [
32P] dATP-labeled, 0.6-kb probe amplified from the C-terminus of 
NPM  to  the  downstream  flanking  sequence  of  MRP8.    All  transgenic  mice  were 
screened by PCR using the following primers: NPM874F (5’-GGTTCTCTTCCCAAA 
GTGGAAGC-3’)  +  MRP8R  (5’-GAGGTATTGATGACTTTATTATTCTGCAGG-
3’).   
Transgene mRNA was detected by RNA isolation followed by DNaseI digestion, 
and  semi-quantitative  RT-PCR  using  1µg  of  RNA  and  two  sets  of  primers: 
MRP8Exon1F  (5’-ATGTCTCTTGTCAGCTGTCTTTC-3’)  +  NPM500R  (5’-
CAGATATACTTAAGAGTTTCACATC-3’); FlagF (5’-CCACCATGGATTACAAG 
GATGACG-3’) + NPM500R. The first set of primers can discriminate the effect of 
cDNA from genomic DNA contamination—a 500-bp product is amplified from cDNA 
as  a  result  of  splicing  or  a  1-kb  product  from  genomic  DNA.    All  PCRs  were 
performed with 40 cycles of (30 sec at 94°C; 30 sec at 55°C; 30 sec at 72°C) followed 
by 7 min of final extension at 72°C. 
For western blot, bone marrow cells or homogenized tissue were lysed with RIPA 
buffer  and  electrophoresed  on  a  12%  SDS  polyacrylamide  gel.    Cell  lysate  from 
HEK293 cells transfected with pCMV-Tag2B-NPMc+ was used as a positive control.  
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For  immunofluorescence,  RBC-lysed  bone  marrow  cells  were  cytospined  onto 
slides  and  fixed  in  4%  paraformaldehyde.    The  following  antibodies  were  used: 
polyclonal Flag (2368, Cell Signaling), monoclonal Flag (A8592, Sigma), polyclonal 
NPMc+ (gift of B. Falini, 1:500), and monoclonal NPM (B0556, Sigma).  
 
Histology and immunohistochemistry 
Formalin-fixed mouse tissues sections were stained with hematoxylin and eosin
 
(H&E)  for  histopathological  examination.    Immunohistochemical  staining  of 
plasmacytoma  using  CD138  (553712,  BD)  antibody  was  performed  by  the  Dana 
Farber Histopathology Service Core.   Immunohistochemistry detection of NPMc+ 
was performed with 10% formalin-fixed tissues using monoclonal NPM (clone 376, 
M7305, Dako).  Detection of NPM was performed with 4% PFA-fixed tissues using 
monoclonal NPM (32-5200, Zymed) and polyclonal Flag (F7425, Sigma).  Pictures of 
the
 stained tissue sections were obtained using an Olympus BX41
 microscope and a 
DP20 camera (Olympus, Center Valley, PA).  All
 image acquisition and processing 
was carried out with Adobe
 Photoshop 7.0 (Adobe Systems, Mountain View, CA). 
 
Flow cytometry 
For  analysis  of  HSC  (LSK),  CMP,  GMP,  MEP,  and  CLP  populations,  bone 
marrow mononuclear cells were isolated from age-matched littermates between 2-6 
months of age, flushed from femurs with PBS + 0.2% BSA, lysed on ice with red 
blood cell lysis buffer (10-548E, Lonza), and depleted for the following lineages with 
a biotin magnetic separation system (130-090-485, Miltenyi Biotec): IL7R, TER119, 
Mac1, Gr1, CD4, CD8a, CD3, B220, IgM and CD19.  The lineage depleted cells were 
blocked  with  CD16/32  Fc  antibody  and  stained  with  the  following  monoclonal 
antibodies that were conjugated to either PE, FITC, PE-Cy7, APC, or APC-Cy7: cKit,  
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CD34, FcγR, Sca1 for 30 min and then stained with Streptavidin to discriminate Lin- 
from  biotinylated  Lin+  cells.    Flow  cytometric  analysis  of  RBC-lysed  single  cell 
suspension from spleen, thymus, bone marrow, and peripheral blood were performed 
with the following monoclonal antibodies conjugated to either PE, FITC, or APC: 
Mac1, Gr1, CD3ε, B220, CD4, CD8, cKit, Ter119, CD71, CD41, CD45. All data were 
collected  on  a  LSRII  instrument  (Becton  Dickinson,  Mountain  View,  CA)  and 
analyzed by FlowJo software (TreeStar, Ashland, OR). 
 
Hematological analysis 
Animals were monitored three times a week for the presence of disease by general 
inspection and palpation.  Peripheral blood was collected by submandibular bleeding 
using  EDTA-treated  tubes  and  automated  and  differential  blood  cell  counts  were 
determined using Hemavet 950 (Drew Scientific).  Collected blood was also used to 
prepare blood smears, which were stained with May-Grunwald (MG500, Sigma) and 
Giemsa (GS500, Sigma).  Following sacrifice, mice were examined for the presence of 
tumors  or  other  abnormalities,  and  organs  were  collected  for  further  cell  and 
histopathologic  analysis.    Hematopoietic  organs  (spleen,  liver,  thymus,  BM)  were 
frozen at -80°C for expression analysis.   
 
Functional studies 
Freshly harvested bone marrow mononuclear cells were stained with Mac1-PE and 
Gr1-APC and sorted for double positive cells using a FACSAria instrument, followed 
by Annexin-V and 7-AAD staining and analysis on a LSRII instrument.  Cell size was 
determined  based  on  the  intensity  of  forward  scatter  of  Mac1+Gr1+  sorted  bone 
marrow cells.  For senescence assays, total bone marrow cells harvested from 10 mice 
for each genotype at 2-months-old were pooled, lysed for RBC, and cultured overnight  
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in RPMI medium supplemented with 50µg/ml of cytokines (IL-3, IL-6, SCF).  An 
equal number of cells (1x10
5) were seeded into each well of 4-well chamber slides 
(177399, Nunc) pre-coated with 5µg/ml fibronectin (F2006, Sigma).  After 4 days of 
culture in RPMI medium supplemented with cytokines, staining for the senescence 
marker  β-Gal  activity  (X-Gal)  was  performed  according  to  the  manufacturer’s 
protocol (Senescence Detection Kit, Oncogene Research Products).  Two independent 
bone marrow harvests were performed and used for senescence assays. 
 
N-ethyl-N-nitrosourea (ENU) injection 
Newborn pups (less than 15 days old) from the breeding of transgenic mice and 
wild-type littermates were IP injected with ENU (100mg/kg per injection).  One gram 
of ENU (N3285, Sigma) was dissolved in 10ml of 95% ethanol and then added to 
90ml of phosphate-citrate buffer as described
118.  Mice were injected weekly for 3 
weeks.  ENU solution was stored at -20°C and a fresh solution prepared after 2 weeks.  
The total ENU dosage was 300mg/kg.  
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PART II. 
 
ELUCIDATING THE ROLE OF RIBOSOMES IN TUMORIGENESIS USING NPM 
AS A PARADIGM  
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CHAPTER 4 
 
THE “ABERRANT RIBOSOMES IN CANCER” HYPOTHESIS 
 
Sometimes the road less traveled is less traveled for a reason. 
Jerry Seinfield 
 
 
 
 
Abstract 
Ribosomes, always viewed as unalterable machines in the cell, are essential for protein 
synthesis and cell growth.  It is known that overactive ribosome biogenesis resulting in 
greater  ribosome  quantity  can  directly  contribute  to  cancer.    Here,  I  propose  that 
qualitatively different ribosomes exist in mammalian cells and may also contribute to 
cancer though several mechanisms.  Since NPM was shown to have a role in ribosome 
biogenesis and cancer, I will test the hypothesis of whether loss of NPM can alter 
ribosome  integrity  and  function  contributing  to cancer  in  Chapter  5.    By  studying 
whether aberrant ribosomes contribute to cancer, we may in the future identify novel 
diagnostic and therapeutic targets of cancer.  
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Cancer is the result of uncontrollable cell growth and proliferation.  Cell growth is 
a limiting factor for cell division and requires the synthesis of proteins, which are 
faithfully and efficiently produced by ribosomes.  Thus, the availability of functional 
ribosomes constitutes one of the most fundamental rate limiting steps for cancer.   
Such is the idea of the field of translational control of cancer that emerged in the 
early  1990s.    Since  proteins  direct  function,  translation  is  the  last  step  to  affect 
functional  outcome  and  keep  a  cell  from  becoming  cancerous.    After  all, 
transcriptional factors involved in cancer, oncogenes and tumor suppressors, enzymes, 
all need to be translated.  In addition, translation is the fastest way to affect cellular 
function,  and  the  effect  on  translation  precedes  the  transcriptional  response  in 
oncogenesis
127.    Interest  in  this  field  has  been  bolstered  by  the  fact  that  drugs 
specifically  targeting  the  mTOR  kinase,  such  as  rapamycin,  have  proved  to  be 
effective in certain cancers.  The Akt-mTOR pathway is a major oncogenic pathway 
that feeds into translation, and ribosomes are the most downstream players of this 
pathway. 
The challenge in this field, like the more established transcriptional and signaling 
field of cancer, is the identification of a ‘druggable target’ that is specific to cancer.  In 
addition, given the complexity of dysregulated  pathways and the shear number of 
proteins involved in tumorigenesis shown to date, targeting of a single protein—even a 
master regulator of cell growth pathway or an important oncogene—to cure cancer 
seems more unrealistic than optimistic (with exceptions such as Gleevec® that target 
the  oncogene  driving  the  cancer).    Targeting  of  an  aberrant  cellular  organelle  or 
macromolecule  in  cancer  cells  represents  an  alternative  possibility.    In  the  recent 
years,  we  have  seen  a  revived  interest  in  mitochondria,  endoplasmic  reticulum, 
nucleolus, vacuoles and centrosomes in an attempt to find not only their quantitative 
alterations but also functional alterations in cancers.  
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Quantity matters—the current view of translational control of cancer 
The  ribosome  is  often  considered  a  static,  monochromatic  machine  that  has 
persisted more or less unchanged for the past three billion years.  The mammalian 
ribosome is about 25nm in diameter and is composed of 4 rRNA molecules and 79 
structurally distinct proteins
128 organized into the 40S and 60S ribosomal subunits.  
Ribosome biogenesis is a complex and highly coordinated process that takes place in 
the  cell  nucleolus.    Soon  after  synthesis  in  the  cytoplasm,  ribosomal  proteins  are 
transported to the nucleus and subsequently accumulated in the nucleoli where they 
associate with pre-rRNAs, which are processed into mature 5.8S, 18S, and 28S rRNA 
molecules in multiple steps.  The ribosomal subunits are eventually exported to the 
cytoplasm, assembled into 80S ribosomes and polysomes (Figure 35A).  Assembly of 
ribosomes is achieved with the assistance of several nonribosomal nucleolar proteins 
such as NPM.  
It is hard to imagine how perturbation to ribosome integrity could not only be 
tolerable  but  even  advantageous  to  cell  growth.    However,  it  is  easy  to  see  that 
increased  number  of  ribosomes  and  deregulated  control  of  translation  might 
participate  in  cancer  pathogenesis.    Indeed,  components  of  the  ribosome  and 
translational apparatus are frequently overexpressed in tumors
129.  Thus, the field of 
translational control of cancer has been focused on the understanding of signaling 
pathways that contribute to translational initiation, and whether excessive amount of 
translational machinery is the cause or consequence of cancer.   
Upstream of the ribosome, the AKT-mTOR pathway (Figure 35B) has emerged as 
a  key  oncogenic  pathway  and  the  central  regulator  for  both  specific  mRNA 
translation
130 as well as global translation
131, 132.  Activation of the PI3K pathway by 
growth  factors,  hormones  and  mitogen  stimuli  phosphorylates  Akt,  which  in  turn 
activates the mTOR kinase through inhibition of two negative regulators, PRAS40  
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Figure  35.  Current  view  of  the  ribosome  biogenesis  (A)  and  the 
translational  control  of  cancer  (B).    Adapted  from  Ruggero,  D.  et  al., 
Oncogene 2005;24:7426-7434. 
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and TSC2
133. At this point mTOR amplifies the growth signal through several ways:  
1)  It modulates the activity of transcriptional factors important for Pol I activity 
and  rRNA  synthesis,  thereby  regulating  ribosome  biogenesis  and  global 
protein synthesis, 
2)  It  activates  S6K  and  ribosomal  protein  S6,  thus  increasing  the  affinity  of 
ribosomes for mRNAs with a 5’ terminal oligopyrimidine tract (5’ TOP).  This 
structural hallmark is found in a group of mRNAs encoding many components 
of  the  translational  machinery  (e.g.  ribosomal  proteins,  elongation  factors, 
NPM).      Synthesis  of  components  of  translational  machinery  can  in  turn 
regulate global protein synthesis, and 
3)  It  activates  the  eIF4G  and  the  rate-limiting  factor  for  CAP-dependent 
translation  initiation,  eIF4E,  thus  regulating translation  of  specific  mRNAs. 
This specificity is achieved because growth-promoting mRNAs, such as cyclin 
D1, c-myc and VEGF, contain extensive secondary structure in their 5’UTR 
and  are  normally  less  competitive  for  binding  to  eIF4E  than  housekeeping 
genes with short, unstructured 5’UTR.  
Although  it  was  generally  assumed  that  the  overexpression  of  translational 
apparatus  is  simply  a  consequence  of  cancer,  as  cancer  cells  might  require  more 
ribosomal  components  to  sustain  increased  proliferation,  there  is  also  evidence 
suggesting that it can directly contribute to oncogenesis both in vitro and in vivo. A 
well-known example is the oncogenic activity of translation initiation factor eIF4E.  
Overexpression  of  eIF4E  transforms  NIH3T3  cells  and  normal  human  mammary 
epithelial  cells;  eIF4E  transgenic  mice  developed  cancer  with  high  incidence  and 
modest overexpression of eIF4E markedly accelerated lymphomagenesis in another 
mouse model
134.   Experimental overexpression of another initiation factor, eIF4G, has  
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also been linked with cell transformation
135.  Finally, overexpression of ribosomal 
protein S3a induced transformation of NIH3T3 cells and formation of tumors in nude 
mice
136.  However,  the  mechanisms  by  which  hyperactivation  of  translational 
components contribute to cancer remain unclear. 
 
Evidences that deficient ribosome biogenesis can contribute to cancer 
Interestingly, a number of studies suggest that instead of upregulated ribosome 
biogenesis,  deficient  ribosome  biogenesis  can  also  cause  cancer.    Much  of  the 
evidences come from the major component of the ribosome, the ribosomal proteins 
(RPs).  For example, RPL9 and RPL26 are lost or mutated in UV-induced murine 
cancers
137.  Loss of expression of the Drosophila homolog of human RPS6 caused 
overgrowth of the hematopoietic organs and melanotic tumor formation
138.  Strikingly, 
loss of one allele of 11 different ribosomal protein genes caused malignant tumor 
formation in zebrafish
139.  Finally, a comprehensive microarray database analysis of 
biological  pathway  alterations  in  human  head  and  neck  squamous  cell  carcinoma 
showed global down-regulation of ribosomal genes
140.  Although the current thought 
is that RPs stabilize p53 by inhibiting MDM2 through their extra-ribosomal roles
141, 
two studies now suggest that there is a general mechanism that links alterations in 
dosage of the RPs, and perhaps of functional ribosome, to the regulation of p53
142, 143.  
Either  way, it  is  plausible  to  assume  that  loss  of  these  crucial  constituents  of  the 
ribosome can result in a reduced translational capacity.  In fact, the young tumor-prone 
heterozygous rp zebrafish display a slight growth defect
142 and dramatically decreased 
ribosome  content  (Lees  JA,  personal  communication),  suggesting  that  global 
translation is downregulated prior to tumorigenesis.  
A human cancer-susceptibility syndrome that is directly associated with defects in 
ribosome biogenesis is Diamond-Blackfan Anemia (DBA), which is characterized by  
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anemia and increased susceptibility to hematopoietic malignancies.  This disease has 
been  associated  with  mutations  in  RPS19,  providing  direct  evidence  that  loss  of 
ribosomal  protein  function  can  predispose  cancer
144.    Patients  with  DBA  have 
hypotrophy at birth and show severe growth retardations, indicating impairment in 
ribosome function. 
Deficient processing or production of the other component of the ribosome, the 
ribosomal RNA (rRNA), has also been linked to tumorigenesis.  RNA may have been 
the  most  primitive  component  of  the  ribosome  and  carries  important  catalytic 
functions in the ribosome
145.  Mutations in the DKC1 gene, encoding a protein that has 
an essential function in the modification of rRNA and telomerase maintenance, are 
responsible for Dyskeratosis Cogenita (DC).   Patients with DC have premature aging 
and increased susceptibility to cancer.  Interestingly, hypomorphic DKC mutant MEFs 
show defects in rRNA pseudouridylation and hypersensitivity to ribosome inhibitors, 
and  mutant  mice  develop  cancer  at  early  generations.    These  data  suggest  that 
deficient ribosome function, in a telomerase-independent manner, may have led to 
cancer in this model
146.  In addition, loss of ribosomal proteins in the zebrafish tumor 
models mentioned above also resulted in an overall decrease in the amount of rRNA—
primarily  in  the  ribosomal  subunit  with  which  the  mutant  gene  product  was 
associated
139.   
 
Quality over quantity—A provocative hypothesis 
In  an  attempt  to  rationalize  the  paradoxical  findings  that  both  overactive  and 
deficient ribosome biogenesis can contribute to cancer, I ask: “Is there a difference in 
ribosome quality in cancer cells?”    
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And  suppose  there  is—can  I  dictate  mRNA  translation  by  affecting  ribosome 
integrity?  Is it possible to target such aberrant ribosomes?  In fact, do all cancers have 
the same qualitative difference?  
However  I  hesitate  to  ask:  “can  difference  in  ribosome  quality  cause  cancer?” 
Although  interesting  to  ponder,  the  answer  to  this  question  requires  experimental 
techniques not yet optimized for mammalian cells.  Moreover, an understanding of the 
alteration  in  ribosome  structure,  composition  and  function  in  cancer  cells  is  first 
needed.  For example, suppose I wanted to test if the ribosomes isolated from cancer 
cells can directly result in altered mRNA translation, an in vitro reconstitution and 
translation  assay  must  be  performed.    To  test  if  aberrant  ribosomes  can  cause 
oncogenic  transformation  in  normal  cells,  knowledge  of  which  components  of  the 
ribosome are altered and an effective in vivo method for targeting those components is 
needed. 
 
Defining ribosome quality 
The following alterations can in theory result in a qualitatively different ribosome:  
1)  Ribosome composition: An altered relative ratio of RP and/or rRNA due to 
gain or loss of individual components on the ribosomes, or an alteration in the 
identity of ribosome components.  For example, the dogma is that cells manage 
to balance RP production so as to end up  with equimolar quantities in the 
ribosome
128, but the precise stoichiometry of RP in ribosomes of cancer cells 
has  never  been  examined.    Moreover,  it  has  never  been  proven  that  the 
ribosomes  in  mammalian  cells  are  in  fact  composed  of  identical  RPs  and 
rRNAs.    Several  studies  suggest  that  assembly  of  RP  paralogs
147,  RP 
isoforms
148, as well as post-translational modifications of RP
149 contribute to 
alterations in ribosome composition.  
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2)  Ribosome structure: An altered overall 3-D structure of the ribosome.  The 
structure of the mammalian ribosome has only been solved at high resolutions 
by  cryo-electron  microscopy  in  recent  years
150.    For  example,  mis-
assembly/mis-positioning of RPs and rRNAs in the ribosome may contribute to 
change in ribosome structure.  Altered ribosome composition may also affect 
ribosome structure. 
 
Importantly, ribosome heterogeneity has been shown to exist in yeast
147,  151,  152.  
For example, Loc1p is a yeast protein involved in ribosome biogenesis and physically 
associates with the 60S ribosome subunit.  Komili et al. recently reported
147 that it 
dictates the assembly of compositionally and functionally different ribosomes:  Loc1p 
assembles slightly different RP paralogs into functionally distinct ribosomes required 
for  the  regulated  translation  of  a  specific  mRNA.    Furthermore,  using  a  powerful 
system  biology  approach  they  found  that  there  is  virtually  no  overlap  between 
functional  categories  affected  by  paralogous  gene  deletions,  suggesting  that  RP 
paralogs have specialized cellular roles beyond their effects on a single mRNA.  This 
study challenges the traditional view of identical ribosomes, and shows that at least in 
yeast, ribosomes are far more versatile than anyone had imagined.  It supports the 
existence of a “ribosome code” at the translational level similar to the “histone code” 
at  the  transcriptional  level  that  the  cell  utilizes  to  carry  out  specific  functions.  
However, they did not address how RP paralogs identical in amino acid sequence 
could assemble into functionally different ribosomes, whether this phenomenon also 
occurs in mammalian cells, and what is the mechanism in which these heterogeneous 
ribosomes regulate mRNA translation.    
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Mechanisms in which altered ribosome quality could contribute to cancer 
Let us assume there are aberrant ribosomes, which I set out to test in Chapter 5, 
how could it affect ribosome function and directly or indirectly “translate cancer”?   
A  brief  overview  of  eukaryotic  translation  may  be  useful  before  speculation. 
Protein translation occurs with the crucial support of several initiation factors (eIFs), 
elongation factors (eEFs) and release factors (eRFs) though the following major steps 
(Figure 36A): recruitment of capped mRNA and initiator tRNA to the small ribosomal 
subunit, scanning of the start codon, joining of the large ribosomal subunit, tRNA 
charging, peptide bond formation, translocation of the ribosome and dissociation and 
recycling of ribosomal subunits for the next round of translation.  Translation control 
appears primarily at the initiation rather than the elongation stage. 
Several evidence-based hypotheses in which aberrant ribosomes could contribute 
to cancer are among my favorites:  
1)  Selective recruitment of mRNA to ribosomes:  An aberrant ribosome could 
result  in  increased  recruitment  of  oncogenic  mRNAs  and  decreased 
recruitment of tumor suppressor mRNAs by its effect on RP-mRNA affinity or 
rRNA-mRNA affinity.  The causal role of differential mRNA translation in 
oncogenesis is already supported by several studies
153-155.  The general notion 
that ribosome heterogeneity can lead to differences in the relative efficiencies 
of  translation  of  various  messages  is  also  known  as  the  “ribosome  filter 
hypothesis”
156.  It predicts that the 40S ribosome subunit itself is a regulatory 
element  or  filter  that  mediates  interactions  between  particular  mRNAs  and 
components  or  the  translation  machinery.    Complementarities  between 
sequences  in  mRNA  and  rRNA,  as  well  as  structural  differences  among 
ribosomes  in  difference  cell  types  affect  how  efficiently  individual  mRNA 
compete for ribosomal subunits.   
  106 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
Figure 36. Steps of eukaryotic translation (A) and polysome microarray 
(B).  Adapted from Cell Signaling Technology, Inc. and Rajasekhar, V.K. et al., 
Oncogene 2004;23:3248-3264.  
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2)  Mistranslation: An aberrant ribosome could mistranslate normal proteins into 
“oncogenic” proteins
157 or misfolded proteins that contribute to cancer.  It is 
known  that  many  components  of  translation,  including  ribosomal  proteins, 
rRNA, tRNA and elongation factors are all involved in translation fidelity
158.  
Ribosomes, like RNA polymerases, are relatively faithful machines with an 
error rate of 10
-4 to 10
-5 under normal growth conditions.  Although a mistake 
during  translation  will  rarely  do  more  harm  than  render  one  out  of  many 
proteins  defective,  mistranslation  can  contribute  to  a  number  of 
neurodegenerative diseases that are sensitive to  protein misfolding
159.  It is 
known  that  protein  misfolding  of  p53  can  also  contribute  to  cancer
160.  
However, the hypothesis that mistranslation plays a major role in contributing 
to p53 misfolding in cancer seems unlikely, especially since p53 (or any other 
oncogenes/tumor suppressors for that matter) is not a highly translated protein 
and presumably less subjected to mistranslation.  Selective mistranslation of 
normal  proteins  directly  into  “oncogenic”  proteins  is  equally  provocative, 
although not impossible.  For example, is it possible that aberrant ribosomes 
always  make  the  same  mistakes  on  a  specific  set  of  oncogenic/tumor 
suppressor  mRNAs  because  they  have  a  consensus  codons  more  prone  to 
tRNA mischarging?   
3)  Extraribosomal functions:  Since there is normally a balance between the pool 
of available free RPs and those assembled onto translating ribosomes, loss or 
gain of RPs from the ribosome could regulate their extraribosomal functions 
important in tumorigenesis.  As mentioned before, non-conventional roles of 
RPs outside the ribosome include stabilization of p53, induction of apoptosis 
and  stabilization  or  silencing  of  specific  mRNA  transcripts.    Notably, 
mutations that prevent ribosomal protein binding to MDM2 have been reported  
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in  human  cancers
161.    Furthermore,  it  has  been  shown  that  under  certain 
conditions  in  mammalian  cells,  the  entire  cellular  pool  of  RPL13a  is 
phosphorylated, released from the 60S ribosome subunit, and binds to specific 
mRNA elements to silence their translation
151.  This indicates that not only do 
heterogeneous ribosomes exist in mammalian cells; loss of an individual RP 
from the ribosome results in altered extraribosomal function. 
4)  Aberrant signaling:  Since ribosome biogenesis is metabolically expensive and 
rate-limiting  in  cell  division  and  growth,  ribosome  integrity  is  closely 
monitored  by  a  variety  of  pathways
129.    Aberrant  ribosome  integrity  or 
disruption of a normally well-coordinated process such as ribosome biogenesis 
may  activate  cell  cycle  checkpoints  and  signaling  pathways  through  yet 
unidentified  mechanisms  leading  to  cancer.    In  yeast,  ribosome  shortage 
activates the master regulator of ribosome biogenesis, Sfp1, which affects the 
compensatory feedback loop and induces RP transcription
162.  Similarly, loss 
of  a  ribosome  component  in  mammalian  cells  could  send  a  signal  to 
constitutively turn on RNA Pol I
163 leading to overactive ribosome biogenesis 
and cancer. 
 
Using NPM as a paradigm to test the “aberrant ribosome in cancer” hypothesis  
NPM is a good candidate to test the hypothesis that aberrant ribosomes exist in 
cancer cells for two reasons.   
First, it controls ribosome biogenesis and translation at numerous levels
12, 89, 164-166: 
1) it possess intrinsic endonuclease activity in vitro and cleaves the ITS-2 site of pre-
rRNAs generating mature 28S rRNA, a major RNA component in the 60S ribosomal 
subunit, 2) it assists the assembly of ribosomal subunits, 3) it is a chaperone for pre-
ribosomal particle and rRNA export and physically associates with the 60S ribosomal  
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subunit  in  mature  ribosomes,  4)  it  is  selectively  deposited  to  all  polyadenylated 
mRNAs and may be important for mRNA export.  Downregulation of NPM by RNA 
interference resulted in the blockage of 28S rRNA maturation and a marked decrease 
in  its  levels  without  changes  to  the  18S  rRNA
31.    In  addition,  Npm
hy/hy  MEFs 
(expressing  <50%  endogenous  Npm)  have  fewer  ribosomal  subunits  and  80S 
ribosomes in the cytoplasm
7.  Together these data strongly suggest that loss of NPM 
can lead to problems with ribosome biogenesis.   
Interestingly,  NPM  bears  striking  functional  similarity  to  the  Loc1  protein 
dictating  yeast  ribosome  heterogeneity
147.    Loc1  is  also  found  in  the  nucleolus, 
involved in the cleavage of rRNA at the ITS-2 site, assembles and exports the 60S 
ribosome subunit to the cytoplasm, and physically associates with the large ribosome 
subunit. Therefore it could be a good model system to test if specialized ribosomes 
also exist in mammalian cells. 
Second, as  shown in  Chapter 1, NPM loss can directly lead to cancer.  Since 
Npm
+/- cells are more susceptible to oncogenesis—an observation attributed to Npm’s 
role  in  the  maintenance  of  genomic  stability
7—I  aim  to  study  whether  there  are 
qualitatively different ribosomes in Npm
+/- cells preceding the onset of centrosomes 
amplification.  It should be noted, however, that these cells are not transformed per se.  
Thus even if I do find aberrant ribosomes in Npm
+/- cells, I cannot say that aberrant 
ribosomes exist in cancer cells, nor that they cause cancer. I can only say that aberrant 
ribosomes exist in “normal cells” preceding oncogenesis; they are not a consequence 
of cancer and in fact could be a pre-requisite/early event in oncogenesis. 
 
Methods for testing the hypothesis 
In the next chapter, I provide several experiments to test both the existence of 
aberrant ribosomes as well as altered ribosome function in Npm
+/- cells.  Specifically, I  
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will test alterations in ribosome composition and selective recruitment of mRNAs to 
polysomes.    An  overview  of  the  experimental  techniques  and  their  rationales  are 
provided below. 
Ribosome profile:  Cytoplasmic ribosomes are sedimented on a sucrose gradient 
and absorbance at OD254 is measured
167.  Profiles reveal the position and relative 
amount of ribosomal subunits, free ribosomes, and translating polysomes in the 
gradient.  This method measures ribosome quantity rather than quality. 
Ribosome isolation-WB:  Ribosomes are purified by sucrose gradients and run on 
a western blot for detection with specific RP antibodies.  This sensitive method 
assesses altered ribosome stoichiometry by identifying individual RPs present on 
the ribosome and measuring their amount relative to each other.   
Metabolic labeling: [
35S]-methionine pulse labeling followed by autoradiography 
measures the amount of newly synthesized proteins produced in a given time, and 
is a measurement of global translational. 
Polysome  microarray:    This  method  assesses  altered  ribosome  function  by 
measuring the relative ribosomal loading of all mRNAs to the polysomes (Figure 
36B).  Pooled polysomal mRNAs are processed for Affymetrix GeneChip array 
hybridization and normalized to their total mRNAs
153.  This normalization ensures 
that the change in translation is not simply the result of a corresponding change in 
transcription.  
CAP-dependent  translation  assay:  This  in  vitro  reporter  assay  assesses  altered 
ribosome  function  by  measuring  the  efficiency  of  capped-mRNA  translation.  
Since  one  theory  states  that  increased  CAP-dependent  translation  results  in 
upregulation of highly structured growth-promoting mRNAs, it is a measurement 
of specific rather than global translation. 
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Ribosome quantity vs. quality in cancer: therapeutic implications 
By studying the molecular mechanisms through which an aberrant ribosome is 
formed and contribute to tumorigenesis in vitro and in vivo, we will gain a better 
understanding of protein synthesis control and in the future identify novel therapeutic 
agents to target the translational machinery in cancer cells.  
If  the  ribosomes  in  cancer  cells  are  exactly  the  same  as  those  in  normal  cells 
except more in quantity, as the current view predicts, then the use of an irreversible 
inhibitor of ribosome function in low dosage may restore translation to a normal level 
in cancer cells, thus curbing uncontrollable proliferation.  In this respect, a drug such 
as rapamycin that targets mTOR, which controls the initiation of protein translation, 
acts  as  a  powerful  anti-cancer  drug  in  clinical  trials
168.    Rapamycin  targets  the 
translational pathway by blocking the activation of S6K1 to regulate ribosomal protein 
translation and ribosome biogenesis, and by activating the 4E-BP1 to suppress eIF4E 
in  the  cap-dependent  translation  of  mRNAs  such  as  c-myc  and  many  oncogenes, 
which have extensive 5’-untranslated region secondary structure.  However, despite 
the fact that rapamycin is reversible and cytostatic, it is believed to be effective only in 
a subset of cancers because certain cancers are  more sensitive to the relief of the 
feedback inhibition of AKT from S6K1
169.  Furthermore, since normal cells at any 
point  can  upregulate  translation  in  response  to  a  variety  of  environmental  and 
physiological  growth  conditions,  targeting  overactive  translational  machinery  in 
cancer  does  not  truly  represent  specificity.    Nevertheless,  direct  targeting  of 
translational machinery downstream of mTOR may prove to be more effective
170 and 
may even escape the S6K negative feedback loop. 
On  the  other  hand,  if  there  is  qualitative  differences  in  the  composition  and 
structure of ribosomes between normal and cancer cells, then drugs that specifically 
target the “cancer” ribosomes might be more effective in cancer therapy.  Since the  
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qualitative  ribosome  hypothesis  predicts  that  mRNA  translation  is  affected 
specifically, by understanding the nature of the aberrant ribosomes in cancer it may be 
possible to normalize translation of oncogenic mRNA.  It could represent the “one 
stone, two birds” solution to solve both challenges in therapeutic targeting of cancer: 
the qualitatively different ribosome is a macromolecule that represents specificity.  
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CHAPTER 5 
 
ABERRANT RIBOSOME STIOCHIOMETRY AND CAP-INDEPENDENT 
DIFFERENTIAL TRANSLATION OF GROWTH-PROMOTING MESSENGER 
RNA PRECEDE ONCOGENESIS
*  
 
It is quality rather than quantity that matters. 
Seneca 
 
Abstract 
We have previously shown that mouse embryonic fibroblasts heterozygous for one 
allele  of  a  gene  involved  in  ribosome  biogenesis  (Npm1)  are  more  susceptible  to 
oncogenic transformation.  Here we report that the composition of ribosome is altered 
in Npm
+/- MEFs.  In addition, a subset of mRNA important in cell proliferation is 
differentially  recruited  to  polysomes  and  translated  in  the  Npm
+/-  MEFs.    These 
include  upregulation  of  transferring  receptor  (Tfrc)  and  downregulation  of 
neurofibromatosis  1  (Nf1).    Interestingly,  both the  upregulated  and  downregulated 
targets share common secondary structures within the coding regions of their mRNA.  
Consistent with the decreased Nf1 expression, MAPK pathway is activated in Npm
+/- 
MEFs.    Due  to  the  known  functional  role  of  Npm  in  ribosome  assembly,  we 
hypothesize that a ribosome code may exist involving the formation of heterogeneous 
ribosomes, which in turn affect cellular pathways through altered polysome loading 
and  translation  of  specific  mRNAs.    These  findings  open  a  novel  paradigm  for 
investigating whether aberrant ribosomes resulted from assembly errors could indeed 
                                                 
* This manuscript is under preparation for submission.  Ke Cheng et al.  
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lead to cancer.  Intriguingly, this is the first direct evidence that the 79 mammalian 
ribosomal proteins can exist in non-equimolar ratios on ribosomes.  
 
Results and Discussions 
NPM controls ribosome biogenesis and translation at numerous levels
12, 89, 164-166.  
We have previously reported that heterozygous loss of Npm leads to oncogenesis both 
in vitro and in vivo: Npm
+/- mouse embryonic fibroblasts (MEFs) are more susceptible 
to oncogenic transformation
7 and Npm
+/- mice develop features of human MDS which 
eventually leads to myeloid and lymphoid malignancies
26.  Since aberrant ribosome 
function and altered translation is known to contribute to cancer
134, 153, 171, here we test 
the hypothesis that Npm
+/- cells have altered ribosome function which contributes to 
its  increased  cancer  susceptibility,  and  that  this  effect  precedes  the  onset  of 
centrosome amplification.  Specifically, we hypothesize that the recruitment of mRNA 
to polysome is affected in Npm
+/- cells.   
Using early-passage Npm
+/- MEFs (P4) where genomic instability has not been 
detected, we looked at global translation as well as the translation of specific mRNAs.  
As shown in Figure 37, we did not detect significant alterations in global translation as 
measured by metabolic labeling of newly synthesized proteins (Figure 37B).  The total 
amount of ribosomal subunits are also not decreased in Npm
+/- cells (Figure 37A), 
suggesting that heterozygous loss of Npm does not affect overall ribosome synthesis.  
Next, we measured the translational efficiency of capped vs. IRES mRNA in Npm
+/- 
MEFs using a renilla-luciferase reporter assay.  In contrast to the current contention 
that  an  increased  CAP-dependent  translation  is  responsible  for  the  increased 
translation of growth-promoting mRNAs leading to tumorigenesis
172, we find that the 
cancer-susceptible  Npm
+/-  MEFs  have  a  lower  efficiency  in  CAP-dependent 
translation compared to that of IRES mRNAs (Figure 38A).  This preliminary data is   
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A  B 
Figure 37. Global translation is not affected in Npm
+/- MEFs.  A, Ribosome 
profiles  suggest  that  wt  and  Npm  heterozygous  MEFs  have  relatively  equal 
amount of ribosomes. B, Wt and Npm heterozygous MEFs were labeled with 
[
35S] methionine for 40 min and protein lysates from equal number of cells were 
separated on a one-dimensional SDS-PAGE.  Autoradiography shows that the 
amount of newly synthesized protein is  similar in wt and Npm heterozygous 
cells. 
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Figure  38.  Npm  level  directly  and  specifically  affects  CAP-dependent 
translation.  A,  Translation  efficiency  of IRES or  CAP  mRNA  in  Npm
+/+  vs. 
Npm
+/- MEFs (P4). B, Translation efficiency of IRES or CAP mRNA in HEK293 
cells  overexpressing  empty  vector  (pCMV)  vs.  Flag-tagged  NPM  (NPMwt).  
Expression of exogenous NPM is shown on the right. 
A 
B 
pCMV  NPMwt  
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consistent with the fact that overexpression of  NPM in HEK293 cells leads to an 
increase in CAP-dependent translation but not IRES-mediated translation (Figure 38B) 
suggesting  a  functional  role  for  NPM  in  CAP-dependent  translation  of  specific 
mRNAs.  
To obtain additional insights into the translation of global mRNAs, we performed 
polysome microarray analysis in early-passage Npm
+/- MEFs (P4) (Figure 39).  We 
measured the net ribosome loading of all mRNAs by calculating the relative ratio of 
polysome RNA to total  RNA intensities from the microarrays.  This allows us to 
exclude any transcriptional effects on the levels of mRNAs.  Surprisingly, despite the 
fact that CAP-dependent reporter translation is decreased in Npm
+/- MEFs, we found 
specifically an enrichment of growth-promoting/oncogenic mRNAs in the upregulated 
targets (Figure 40A).  These include Tfrc, Hmmr, Flt1, Plk1, Vegfb and Tgfbr1.  On 
the other hand, a known tumor suppressor, Nf1, is found in the downregulated targets.  
Furthermore,  functional  analysis  of  all  translational  targets  shows  that  cancer 
associated targets are the highest affected in Npm
+/- MEFs (Figure 40B).  Together 
these  data  could  explain  the  cancer-susceptibility  observed  in  Npm
+/-  MEFs  and 
Npm
+/- mice.  Other pathways significantly affected at the translational level in Npm
+/- 
MEFs  include  organismal  survival,  neurological  disease,  cellular  growth  and 
proliferation, and hematological system development and function.  These pathways 
could  even  explain  some  of  the  phenotypes  found  in  Npm
-/-  embryos,  in  which 
embryonic lethality and defects in neurological and hematopoietic development are 
seen.   
So  far  we  validated  two  targets  from  the  polysome  microarray  (Figure  41A): 
transferrin receptor (Tfrc; CD71), from the upregulated list; and neurofibromatosis 1 
(Nf1), from the downregulated list.  These two targets are especially interesting to us 
for several reasons.  First, both are among the mRNAs most affected in polysome   
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Figure 39. Polysome microarray in Npm
+/+ and Npm
+/- MEFs. Ribosomes 
were fractionated on a linear sucrose gradient and RNA extracted. Northern 
blot shows that actin mRNA is enriched in the polysome fractions as expected. 
The last 10 fractions (polysome RNA) as well as total RNA from wt and Npm
 
heterozygous MEFs were collected for microarray analysis.  
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RNA 
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Figure 40. Differenial recruitment of cancer-related mRNAs to polysomes 
of Npm
+/- MEFs.  A, Top 50 mRNAs selectively recruited (left) and selectively 
decreased at the Npm
+/- polysomes (right). Microarray data were analyzed by 
GC-RMA platform correcting for total RNA (see Materials and Methods). FC, 
fold  change.  Yellow  highlighted  genes  are  targets  verified  by  western  blot.  
Genes in red are used for subsequent analysis of mRNA secondary structure. B, 
Top 10 cellular functions affected by selective mRNA recruitment in Npm
+/- 
MEFs. P value threshold is set at 0.05. 
A 
B 
FC Gene Symbol Gene Title
5.79 Tfrc transferrin receptor
3.76 Gucy1b3 guanylate cyclase 1, soluble, beta 3
3.70 Spag5 sperm associated antigen 5
3.59 --- ---
3.55 Pold1 polymerase (DNA directed), delta 1, catalytic subunit
3.52 Hmmr hyaluronan mediated motility receptor (RHAMM)
3.27 Flt1 FMS-like tyrosine kinase 1
2.85 Ednra endothelin receptor type A
2.79 Nes nestin
2.74 Nfatc4 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4
2.63 Gng2 guanine nucleotide binding protein (G protein), gamma 2 subunit
2.54 4933439F18Rik RIKEN cDNA 4933439F18 gene
2.47 Phf3 PHD finger protein 3
2.42 A930025J12Rik RIKEN cDNA A930025J12 gene
2.41 Prkcn protein kinase C, nu
2.24 BC002230 cDNA sequence BC002230
2.20 Dock6 dedicator of cytokinesis 6
2.20 Atp11a ATPase, class VI, type 11A
2.01 Tnpo2 transportin 2 (importin 3, karyopherin beta 2b)
1.99 Serf1 small EDRK-rich factor 1
1.99 Plk1 polo-like kinase 1 (Drosophila)
1.97 D2Ertd217e DNA segment, Chr 2, ERATO Doi 217, expressed
1.96 Rnf12 ring finger protein 12
1.96 Tap1 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)
1.94 Mccc2 methylcrotonoyl-Coenzyme A carboxylase 2 (beta)
1.93 5730507H05Rik RIKEN cDNA 5730507H05 gene
1.90 Cln8 ceroid-lipofuscinosis, neuronal 8
1.90 BC023055 cDNA sequence BC023055
1.89 Sp1 trans-acting transcription factor 1
1.83 MGI:1354723 neuropathy target esterase
1.83 Jarid1a jumonji, AT rich interactive domain 1A (Rbp2 like)
1.81 Pftk1 PFTAIRE protein kinase 1
1.80 2210018M03Rik RIKEN cDNA 2210018M03 gene
1.79 Angel2 angel homolog 2 (Drosophila)
1.77 Tgfbr1 transforming growth factor, beta receptor I
1.77 Ankmy2 ankyrin repeat and MYND domain containing 2
1.75 9430063L05Rik RIKEN cDNA 9430063L05 gene
1.73 Epha3 Eph receptor A3
1.70 Spag5 sperm associated antigen 5
1.70 Pigo phosphatidylinositol glycan, class O
1.69 Atf2 activating transcription factor 2
1.69 Arl6ip2 ADP-ribosylation factor-like 6 interacting protein 2
1.67 Uba52 /// LOC332993 ubiquitin A-52 residue ribosomal protein fusion product 1 
1.65 Sfrs7 splicing factor, arginine/serine-rich 7
1.60 Vegfb vascular endothelial growth factor B
1.57 Ampd3 AMP deaminase 3
1.54 Vps18 vacuolar protein sorting 18 (yeast)
1.53 1110005A03Rik RIKEN cDNA 1110005A03 gene
1.51 Acbd3 acyl-Coenzyme A binding domain containing 3
1.46 Blzf1 basic leucine zipper nuclear factor 1
FC Gene Symbol Gene Title
-12.54 C1qb complement component 1, q subcomponent, beta polypeptide
-5.89 C1qa complement component 1, q subcomponent, alpha polypeptide
-5.47 --- PREDICTED: hypothetical protein XP_489268 [Mus musculus], mRNA sequence
-3.26 Cd68 CD68 antigen
-3.16 C1qg complement component 1, q subcomponent, gamma polypeptide
-3.16 Tnfrsf21 tumor necrosis factor receptor superfamily, member 21
-3.03 Atf3 activating transcription factor 3
-2.73 Dph5 DPH5 homolog (S. cerevisiae)
-2.47 Plcb4 phospholipase C, beta 4
-2.43 Ahdc1 AT hook, DNA binding motif, containing 1
-2.40 Entpd5 ectonucleoside triphosphate diphosphohydrolase 5
-2.37 Gli2 GLI-Kruppel family member GLI2
-2.16 Ulk2 Unc-51 like kinase 2 (C. elegans)
-2.14 Laptm5 lysosomal-associated protein transmembrane 5
-2.09 Glt28d1 glycosyltransferase 28 domain containing 1
-2.09 Zbtb20 zinc finger and BTB domain containing 20
-2.07 Anxa7 annexin A7
-2.07 1110060D06Rik RIKEN cDNA 1110060D06 gene
-2.06 Jarid2 jumonji, AT rich interactive domain 2
-2.05 Slc25a29 solute carrier family 25 (mitochondrial carrier, palmitoylcarnitine transporter), member 29
-2.02 Dapk1 death associated protein kinase 1
-2.00 Spsb4 splA/ryanodine receptor domain and SOCS box containing 4
-1.98 Pitpnm2 phosphatidylinositol transfer protein, membrane-associated 2
-1.96 Satb2 special AT-rich sequence binding protein 2
-1.95 Mtf2 metal response element binding transcription factor 2
-1.94 Sipa1 signal-induced proliferation associated gene 1
-1.90 Csdc2 cold shock domain containing C2, RNA binding
-1.90 Apeg1 aortic preferentially expressed gene 1
-1.89 2210012G02Rik RIKEN cDNA 2210012G02 gene
-1.89 Hoxc9 homeo box C9
-1.88 Bcl2a1a /// Bcl2a1b /// Bcl2a1d B-cell leukemia/lymphoma 2 related protein A1a///A1b /// A1d
-1.88 Pdk2 pyruvate dehydrogenase kinase, isoenzyme 2
-1.88 Lrrn6a leucine rich repeat neuronal 6A
-1.87 C1qb complement component 1, q subcomponent, beta polypeptide
-1.87 Pax1 paired box gene 1
-1.86 Mdm4 transformed mouse 3T3 cell double minute 4
-1.85 Cbx2 chromobox homolog 2 (Drosophila Pc class)
-1.84 Fcer1g Fc receptor, IgE, high affinity I, gamma polypeptide
-1.81 Nf1 neurofibromatosis 1
-1.81 BC024479 cDNA sequence BC024479
-1.80 1810048J11Rik RIKEN cDNA 1810048J11 gene
-1.79 Mapk11 mitogen-activated protein kinase 11
-1.78 Vps54 vacuolar protein sorting 54 (yeast)
-1.78 Sec61a1 Sec61 alpha 1 subunit (S. cerevisiae)
-1.77 Echdc1 enoyl Coenzyme A hydratase domain containing 1
-1.74 Cdk6 cyclin-dependent kinase 6
-1.73 Sh3d19 SH3 domain protein D19
-1.72 Tnrc6b trinucleotide repeat containing 6b
-1.72 A630054L15Rik RIKEN cDNA A630054L15 gene
-1.70 Casp7 caspase 7 
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Figure 41. Target validation and a mechanism for differential recruitment of 
mRNAs  to  Npm
+/-  polysomes.    A,  Western  blots  showing  transferrin  receptor 
(Tfrc; CD71) is upregulated whereas neurofibromatosis 1 (Nf1) is downregulated 
in  Npm
+/-  MEFs.  Quantification  of  band  intensities  normalized  to  wt  MEFs  is 
shown  above  W,  wt  MEFs.  H1  and  H2,  Npm  heterozygous  MEFs  from  two 
different  preparations.  B,  Western  blot  showing  phospho-ERK  is  upregulated 
indicating activation of p42/p44
MAPK pathway. This pathway is also activated in 
NPM
-/-(NPM
f/f Cre) MEFs at P2. C, Early-passage Npm
+/- MEFs is more sensitive 
to the MEK inhibitor U0126. Growth at Day4 and Day6 are normalized to Day2. D, 
Translationally  upregulated  mRNAs  with  oncogenic  activities  share  significant 
common secondary mRNA structures. The numbers refer to the nucleotide position 
of two aligned mRNAs.  Connecting lines indicate shared mRNA structures. 
A 
B  C 
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6382-3219 
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loading,  with  5.8-fold  increase  and  1.8-fold  decrease,  respectively.    Second,  the 
average CD71 level is higher in an equal number of bone marrow cells from Npm
+/- 
mice  than  from  wild-type  mice
7.    Third,  overexpression  of  TRFC
173  and 
downregulation of NF1
174 can both contribute to oncogenic transformation.  Fourth, 
NF1 protein is significantly decreased
175,  176 and circulating transferring receptor is 
significantly increased
177 in patients with MDS and myeloid malignancies.   
As shown in Figure 41A, the steady-state protein level of Tfrc is higher in Npm
+/- 
MEFs compared to wild-type MEFs at P5, but also at earlier passage P2.  In addition, 
we find that the basal level Nf1 is lower in Npm
+/- MEFs compared to wild-type MEFs 
(Figure  41A),  and  its  level  is  dramatically  increased  upon  NPM  overexpression 
(Figure 42A).  Furthermore, the transcription of Nf1 is not affected in Npm
+/- MEFs 
(Figure 42B).  Together these data support the role of Npm in the direct upregulation 
of  Nf1  mRNA  translation.    Interestingly,  the  leukemia-associated  NPM  mutant 
(NPMc+) expression in HEK293 did not cause a similar increase in Nf1, pointing to a 
possible tumor-suppressive function of NPM lost in NPMc+.  Since Nf1 is a critical 
negative regulator of the Ras/MEK/ERK signaling cascade, we checked the activation 
of this pathway in Npm
+/- MEFs.  There is a consistent increase in phospho-ERK in 
Npm
+/- compared to wt MEFs in all passages we checked (Figure 41B and data not 
shown).  Strikingly, Npm
-/- MEFs also show similar ERK activation (Figure 41B left 
panels).  Furthermore, preliminary data show that Npm
+/- MEFs are hypersensitive to 
the MEK inhibitor U0126 in growth curve assays at late time points (Figure 41C), 
suggesting that the ERK pathway is affected in Npm
+/- MEFs.  Although it is possible 
that  translational  regulation  by  Npm  can  contribute  to  the  MDS-like  phenotype 
observed in Npm
+/- mice, at this time we do not have sufficient in vivo data to support 
this claim. 
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Figure  42.  A,  NPM  overexpression  cause  increase  in  Nf1  protein  level.  
HEK293 cells transiently transfected with empty vector (pCMV), Flag-tagged 
NPM,  or  Flag-tagged  NPMc+.  B,  Nf1  transcription  is  not  altered  in  Npm
+/- 
MEFs. Semi-quantitative RT-PCR shows that while the total amount of Nf1 
mRNA  is  similar  in  Npm
+/-  compared  to  wt  MEFs,  the  amount  loaded  on 
polysomes is less.  Poly, polysomes. The quantification was calculated based on 
the ratio of Nf1 (at 35 cycles) to HPRT (at 25 cycles).  
A 
B  
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The  polysome  data  suggests  that  contrary  to  the  current  belief,  “oncogenic 
mRNAs”  can  be  selectively  recruited  to  polysomes  though  a  CAP-independent 
mechanism.  To explain why these oncogenic mRNAs are recruited in Npm
+/- MEFs 
even  when  CAP-dependent  translation  is  blocked,  we  hypothesize  that  there  are 
common secondary RNA structures within the coding regions of target mRNAs that 
could affect their binding to polysomes and their translation efficiency.  It is known 
that RNA stem/loops affects translation initiation by eukaryotic ribosomes
178, and that 
various sites of mRNA can interact with rRNA/ribosomal subunits
156.  We picked four 
targets—Tfrc, Tgfbr1, Flt1, Vegfb—from the most upregulated genes known to have 
oncogenic activities and three random targets—C1qb, Nf1, Anxa7—from the most 
downregulated  genes  to  perform  RNA  secondary  structure  alignment.    MFOLD 
program  was  first  used  to  determine the  most  stable  secondary  structure  from  the 
coding  sequences,  and  RNAforester  program  was  then  used  to  align  secondary 
structures, particularly those located on the surface of the molecule.  Interestingly, we 
find  that  there  are  several  significant  structure  similarities  among  the  upregulated 
“oncogenic mRNA” targets (Figure 41D and Figure 43).  In addition, there is also 
significant structure similarity among the downregulated targets we analyzed (Figure 
44).  Together these data suggest that the upregulated targets or downregulated targets 
indeed  have  common  secondary  RNA  structures  that  could  affect  their 
recruitment/block in polysome loading.   
Finally, to understand the basis for Npm
+/- polysomes exerting altered affinities for 
these  common  mRNA  structures,  we  asked  if  ribosome  quality—in  particular, 
ribosome composition/ribosomal protein stoichiometry—is different in Npm
+/- MEFs.  
Although the dogma is that cells manage to balance ribosomal protein production so as 
to  end  up  with  equimolar  quantities  in  the  ribosome  subunit  polypeptides
128,  the 
precise stoichiometry of ribosomal proteins in ribosomes of cancer cells has never   
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Figure 43. mRNAs selectively recruited to the polysomes of Npm
+/-  MEFs 
share common secondary structures. A, A representative secondary structure 
shared  by  Tgfbr1,  Tfrc,  Flt1  and  Vegfb  mRNAs.  B,  Another  representative 
secondary  structure  shared  by  these  four  mRNAs.    Numbers  refers  to  the 
nucleotide positions of the cDNA at the start of alignment from the 5’ end. Solid 
red lines indicate complete complementarity. Dotted lines indicate less similarity. 
Compensatory base changes are indicated in red; gene-specific sites are in green 
and blue. Black indicates identical nucleotides. Positions within the structures are 
numbered every 20 nucleotides from the start of the 5’ alignment and not 5’ UTR.  
These four genes were chosen from the list of most upregulated polysome targets 
with known oncogenic activities.  
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Nf1 
533
3 
441
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9 
381 
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C1qb-Nf1 
268 - 3647 
Figure 44. mRNAs selectively decreased at the polysomes of Npm
+/- cells also 
share  common  secondary  structures.  A  representative  secondary  structure 
shared by Anxa7, C1qb and Nf1 mRNAs. These three mRNAs were randomly 
chosen from the list of highly downregulated polysome targets.  
  126 
been  examined.    Recent  studies  suggest  that  ribosome  heterogeneity  exists  in 
eukaryotic  cells
147,  151.    Using  a  ribosome  purification-western  blot  method  (see 
Materials  and  Methods),  our  preliminary  data  suggest  that  the  ribosomal  protein 
stoichiometry is altered in Npm
+/- ribosomes.  As quantified in Figure 45A, there is 
significantly  more  ribosomal  protein  S4  and  L37  and  less  ribosomal  protein  L5 
compared to S6, L26, L28, L7a, or p-S6 in Npm
+/- ribosomes (compare the two right 
lanes between different panels). Actin and an ER marker, Pdi, are not found in the 
ribosome lysates, confirming that the preparation contains highly purified ribosomes 
enriched for ribosomal proteins.  In fact, we loaded ~15X less proteins from ribosome 
lysates  (3µg/lane)  than  from  total  lysates  (50ug/lane),  and  the  level  of  ribosomal 
proteins are still comparable.  Furthermore, we find that the effect of altered ribosomal 
stoichiometry cannot simply be due to the upregulation of total S4 and downregulation 
of total L5, as these ribosomal proteins are found in similar levels between wt and 
Npm
+/- MEFs (compare the two left lanes in S4 and L5 blots).  Considering the fact 
that NPM is known to function in transport and assembly of ribosomal proteins
12, 166, 
and loss of Npm specifically blocks the export of L5 to the cytosol
89, it is tempting to 
speculate  that  ribosomal  proteins  are  mis-assembled  onto  ribosomes/polysomes  of 
Npm
+/- MEFs.  Finally, we confirm that Npm is indeed present in the ribosome lysates 
as previously reported
89, 166, although it is not as abundant as the ribosomal proteins.  
Interestingly, Npm
+/- cells also have significantly less Npm in the ribosome lysates.  
This suggests that Npm loss on the ribosomes could lead to the observed difference in 
ribosomal protein stoichiometry between wt and Npm
+/- MEFs. 
Taken together, our data show for the first time that ribosome heterogeneity exists 
in mammalian cells prior to oncogenic transformation, and suggests that the specificity 
of the “ribosome code” in regulating cellular functions is achieved in mammalian cells  
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Figure 45. A, Ribosome composition is altered in Npm
+/- MEFs. Four western 
blot membranes were stripped and successively probed with different antibodies. 
B,  A  hypothetical  model  for  how  aberrant  ribosome  quality  could 
contribute to cancer. 
aberrant ribosome composition 
differential translation of mRNAs 
activation of oncogenic pathways 
cancer 
altered affinity for polysomes to bind certain mRNA structures 
A 
B  
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as in yeast
147.  We propose a possible mechanism to explain how functionally distinct 
ribosomes can result from the assembly of identical ribosomal proteins: ribosomal 
protein stoichiometry on mature ribosomes can change.  This raises the unexpected 
possibility that the there might be more than one occupancy site for each ribosomal 
protein per ribosome in different cell types.  Npm
+/- mice are born despite the
 presence 
of  these  “aberrant”  ribosomes.    Furthermore,  we  find  that  a  subset  of  growth-
promoting mRNA is preferentially translated in Npm
+/- MEFs compared to wt MEFs, 
despite the fact that CAP-dependent translation is decreased in Npm
+/- MEFs.  These 
data challenge the current concept that recruitment of “oncogenic mRNA” is CAP-
dependent.    Altered  translation  of  mRNA  in  Npm
+/-  MEFs  correlated  with  an 
activation of the MAPK pathway known to play a role in tumorigenesis.  Although we 
have  not  shown  that  aberrant  ribosome  composition  can  directly  lead  to  aberrant 
mRNA  translation  and  cancer,  we  propose  a  hypothetical  model  based  on  our 
convincing  correlative  observations  (Figure  45B)  for  future  in  vitro  and  in  vivo 
validation.  As another measure of ribosome quality, an interesting experiment would 
be to determine the ribosome structure in Npm
+/- MEFs, especially since ribosome 
structure was recently shown to be altered in Npm
hy/hy cells
166.  Another question is 
whether  post-translational  modification  of  ribosomal  proteins  is  altered  in  Npm
+/- 
ribosomes.  Validation of this model and study of ribosome quality in human cancers 
will lead to unexplored territories in the translation field of cancer. 
 
Materials and Methods 
Ribosome profile 
Sucrose  density  fractionation  of  ribosomes  was  performed  essentially  as 
described
167.  Mouse embryonic fibroblasts (P4) were lysed using 20mM Tris-HCl 
(pH  7.2),  130mM  KCl,  10mM  MgCl2,  0.5%  NP-40,  0.2mg/ml  heparin,  10µg/ml  
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cyclohexamide,  200U/ml  Rnasin  and  2.5mM  DTT.    Sucrose  gradients  were 
fractionated by a Foxy Jr. fraction collector and absorbance at 254nm was detected 
using an Isco UA-6 monitor (Isco, Lincoln, Nebraska). 
 
Ribosome stoichiometry assay 
MEFs  (P4)  from  eight  150mm-dishes  at  80%  confluency  were  harvested  by 
scraping and lysed in M-PER mammalian protein extraction reagent (#78501, Thermo 
Scientific).  Cell debris was cleared by centrifugation at 14,000rpm for 30 min at 4°C, 
and the supernatants is the total lysate.  Ribosome lysate was prepared as follows: Up 
to 1.2ml of the above supernatant were loaded onto a 2ml 0.5M sucrose pad in Buffer 
A (0.5M sucrose, 40mM HEPES pH 7.6, 5mM Mg acetate, 100mM K acetate, 2mM 
DTT, 100µg/ml cyclohexamide, 200U/ml Rnasin) and centrifuged at 100,000 rpm for 
45 min using TL 100.4 rotor in Optima TLX ultracentrifuge (Beckman).  This “crude” 
ribosome  pellet  was  gently  resuspended  in  250µl  Buffer  A  without  sucrose,  then 
loaded onto a 2 ml 35% sucrose pad prepared in Gradient Buffer (20mM HEPES pH 
7.6,  10mM  Mg  acetate,  100mM  K  acetate,  2mM  DTT,  100µg/ml  cyclohexamide, 
200U/ml Rnasin) and spun for 1 hr at 55,000rpm using TLS-55 rotor at 4°C.  The 
clear  glassy  pellet  containing  pure  ribosomes  was  completely  dissolved  in  150µl 
Buffer A without sucrose and protein concentration was measured by Bradford assay.  
Equal amount of total lysates (50µg/lane) or ribosome lysates (3µg/lane) between wt 
and Npm
+/- MEFs was loaded on a 12% SDS-PAGE.  Standard western blotting was 
performed and the nitrocellulose membranes were probed with various antibodies for 
ribosomal proteins: L7 (A300-741A, Bethyl), S4X and L37 (gift of Martin Wiedmann, 
MSKCC), S6 (2317, Cell Signaling), p-S6 (2211, Cell Signaling), L7a (2415, Cell 
Signaling),  Pdi  (Ab2792,  Abcam),  L26  (A300-685A,  Bethyl),  L5  (gift  of  Jason 
Weber, Ilamm).  Secondary antibody was conjugated with horseradish peroxidase and  
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enhanced  chemiluminescent  detection  was  performed  using  ECL  Plus  Western 
Blotting detection reagents (RPN#2132, Amersham).  Membrane was stripped after 
probing using Restore Buffer (#21059, Pierce). 
 
Metabolic labeling 
MEFs  (P4)  grown  in  60mm-dishes  at  90%  confluency  were  starved  with 
methionine/cysteine-free medium (#21013-024, Invitrogen) + 10% dialyzed FBS for 2 
hrs, and 200µCi [
35S]-methionine was added to the medium for 40 minutes.  Western 
blotting and autoradiography was performed using standard protocols. 
 
Polysome microarray and data analysis  
Total RNA was extracted directly from MEFs (P4) grown in one 100mm-dish 
using RNeasy kit (#74104, Qiagen).   
Polysomes  were  isolated  using  a  standard  protocol
179  with  following 
modifications.    Ten  100mm-dishes  of  MEFs  (P4)  grown  to  80%  confluency  were 
treated with 100µg/ml cyclohexamide for 10 min at 37°C, and washed twice with ice-
cold PBS containing 100µg/ml cyclohexamide.  Polysome Lysis Buffer (0.3M NaCl, 
15mM  Tris-HCl,  5mM  MgCl2,  0.5mM  DTT,  0.1mg/ml  cyclohexamide,  1mg/ml 
heparin, 100U RNasin and 1% Triton X-100) was added at 200µl per dish.  Lysates 
were collected by scraping, and mixed for 30 min at 4°C.  Intact nuclei in cell lysates 
was  confirmed  by  Hoechst  33342  staining  and  observation  under  a  microscope.  
Cellular  debris  was  cleared  by  centrifugation  at  12,000rpm  for  10  min  and 
concentration of RNA in the supernatant was determined at OD260.  500µg of cleared 
lysate  was  loaded  on  an  11ml  10-50%  linear  sucrose  gradient  in  Gradient  Buffer 
(20mM Tris-HCl pH 8.0, 140mM KCl, 5mM MgCl2, 0.5mM DTT, 0.5mg/ml heparin 
and 100U RNasin), and centrifuged at 35,000rpm for 190 min using SW-41Ti rotor in  
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XL-90 ultracentrifuge (Beckman).  Sucrose gradients were fractionated by a Foxy Jr. 
fraction collector and absorbance at 254nm was detected using an Isco UA-6 monitor 
(Isco, Lincoln, Nebraska).  Polysome RNA was prepared from sucrose fractions using 
the RNeasy kit with the following modifications: Each 500µl sucrose fraction was 
mixed  with  500µl  Buffer  RLT,  and  400µl  100%  ethanol  was  added.    RNA  was 
washed twice with buffer RW1 and eluted in 50µl RNase-free water. 10µl of RNA 
from each fraction was run on a formaldehyde gel to verify for RNA quality.   
Total  RNA  and  polysome  RNA  was  processed  by  Sloan-Kettering  Microarray 
Facility and hybridized with Affymetrix MOE 430A 2.0 microarrays.  Normalization 
was  performed  using  the  Lowess  method  in  Genespring  followed  by  GCRMA 
standardization.  Log2 intensity ratio of polysome RNA/total RNA of wt MEFs was 
subtracted by that of Npm
+/- MEFs to exclude the effect of transcription on translation.  
The functional analysis of the interactive genes was performed using Ingenuity 
Pathways Analysis (IPA 5.0) (http://www.ingenuity.com/). The package consists of 
manually  curated  information  about  gene  regulation,  protein  interaction,  and 
metabolic  and  signaling  pathways.  The  significantly  effected  functions/Go 
processes was identified on the P value using Fisher’s Exact Test on the basis of 
user’s data to functional categories reference dataset. It displays the results as score 
(-log P value) as likelihood of gene found in functional category due to random 
chance.  
 
CAP/IRES-dependent translation assay 
Cells were transfected with luciferase reporters containing either a 5’ m
7G cap or 
an  Internal  Ribosome  Entry  Site  sequence,  and  a  standard  dual-luciferase  assay 
(E#1960, Promega) was carried out. 
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Cell culture, cell based assays and western blotting 
MEFs were prepared from E10.5–E13.5 embryos.  Early passage MEFs (P2–5) 
were used in all experiments except as indicated.  For proliferation analysis, growth 
curves were generated by seeding 2.5×10
4 cells per well in 12-well plates, each clone 
in triplicate.  10µM U0126 (9903, Cell Signaling) was added to MEFs on Day 0 and 
plates were fixed on days 2, 4 and 6. Fixed plates were stained with crystal violet, 
extracted  with  10%  acetic  acid,  and  the  relative  cell  number  was  measured  by 
absorbance at 595 nm. HEK293 cells was transfected with pCMV-Tag2B, pCMV-
Tag2B-NPM or pCMV-Tag2B-NPMc+ constructs using Lipofectamine 2000 (11668, 
Invitrogen).  Npm
-/- MEFs were prepared by infected Npm
f/f MEFs with Cre retrovirus.  
Transfections of the packaging cell line (Phoenix) were done using Lipofectamine 
2000 without serum or antibiotics.  Upon infection and selection, Npm
-/- MEFs were 
harvested and lysates prepared.  Antibodies used for western blots are: Flag (2368, 
Cell  Signaling),  actin  (A5316,  Sigma),  transferring  receptor  (13-6800,  Zymed), 
neurofibromin (sc-67, Santa Cruz), p-ERK (9101, Cell Signaling), ERK (9102, Cell 
Signaling),  Npm  (B0556,  Sigma),  Hsp90  (610419,  BD).  Band  intensities  were 
analyzed by densitometry using ImageJ software. 
 
Semi-quantitative RT-PCR 
cDNA from equal amounts of wt and Npm
+/- total RNA or polysome RNA were 
reverse  transcribed  (18080-051,  Invitrogen),  and  amplified  using  the  following 
primers:  Nf1F  (5’-CAGGACAGCAGAACACACATACC-3’)  +  Nf1R  (5’-
CTCATTGTGTCCTTTGGTTGCCC-3’); HPRT1 (5’-CCTGCTGGATTACATTAAA 
GCACTG-3’)  +  HPRT2  (5’-GTCAAGGGCATATCCAACAACAAAC-3’).    PCRs 
were performed with 25 or 35 cycles of (30 sec at 94°C; 30 sec at 55°C; 30 sec at 
72°C) followed by 7 min of final extension at 72°C.  
  133 
 
CHAPTER 6 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
This  thesis  focused  on  the  role  of  NPM  in  cancer.    Using  a  mouse  Npm 
hypomorphic mutant series, we demonstrated that Npm is a haploinsufficient tumor 
suppressor in vitro and in vivo through the following observations: 
•  Npm gene disruption leads to embryonic lethality 
•  Npm heterozygous mouse embryonic fibroblasts are susceptible to oncogenic 
transformation 
•  Npm  heterozygous  mice  develop  a  hematological  disorder  with  features  of 
human  myelodysplastic  syndrome  (erythroid  and  megakaryocytic  dysplasia) 
implicating NPM in the pathogenesis of human MDS 
•  Npm  heterozygous  mice  get  cancer  particularly  myeloid  and  lymphoid 
malignancies,  and  Npm  heterozygous  tumors  do  not  have  loss  of 
heterozygosity (LOH) 
Furthermore, we showed that the leukemia-associated NPM cytoplasmic mutant 
(NPMc+) is a bona-fide proto-oncogene, but cooperating events are needed to unleash 
its full oncogenic activities: 
•  NPMc+ transforms primary mouse embryonic fibroblasts in cooperation 
with adenoviral E1A 
•  NPMc+ acts as a dominant negative of NPM function and destabilizes Arf 
•  NPMc+ elicits an Arf-independent senescence response 
•  NPMc+ alone is not sufficient to cause AML in vivo under the control of 
MRP8 promoter  
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•  MRP8-NPMc+ transgenic mice develop epithelial tumors and features of 
myeloproliferation 
•  MRP8-NPMc+ transgenic mice slightly accelerates ENU-driven acute T-
lymphoblastic leukemia due to the leaky expression of NPMc+ in T cells, 
and ENU accelerates NPMc+-driven myeloproliferation  
Finally,  we  hypothesized  that  one  of  the  mechanisms  in  which  loss  of  NPM 
function could contribute to tumorigenesis is through aberrant ribosome biogenesis.  
We present evidences that aberrant ribosome stoichiometry and differential translation 
of  growth-promoting  mRNAs  procede  oncogenic  transformation  in  Npm
+/-  mouse 
embryonic fibroblasts.   These data suggest that qualitatively different ribosomes exist 
in mammalian cells and may contribute to cancer. 
There are many different ways to extend the present work.  In Chapter 1, the role 
of  NPM  as  a  tumor  suppressor  can  be  further  studied  using  a  conditional  Npm 
knockout model, since complete knockout of Npm is embryonic lethal.  Furthermore, 
the pathogenesis and molecular basis of the MDS are not well-understood
180 and there 
is a lack of animal models of human MDS for therapeutic testing.  Thus, our Npm
+/- 
mice can be used to test the efficacy of the diverse forms of therapy (such as 5-
Azacytidine) currently available to treat MDS patients.  The elevated MCV and RDW 
counts observed in peripheral blood of Npm
+/- mice can be monitored throughout drug 
treatment, and the increased numbers of TER119+CD71+ bone marrow cells can be 
analyzed  by  flow  cytometry  after  sacrificing  treated  Npm
+/-  mice.    In  addition, 
microarray analysis of Npm
+/- cells can be used to identify molecular markers of MDS, 
which  are  currently  lacking.    These  markers  can  be  monitored  for  their 
appearance/disappearance  following  drug  treatment  in Npm
+/-  mice,  especially  if  a 
drug that specifically reverses the Npm
+/- MDS phenotype could be found.  
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By understanding how NPMc+ perturbs the physiological roles of NPM, as well as 
the novel functions of NPMc+, we may gain insights into the mechanism of NPMc+-
induced noncanonical senescence pathway described in Chapter 2.  For example, it 
remains  to  be  addressed  whether  NPMc+  could  induce  nucleolar  stress  and  block 
translation, and whether this could lead to senescence and growth arrest.  To this end, 
the effect of NPMc+ on translation can be determined using standard in vitro assays 
(e.g.  ribosome  profile,  rRNA  processing, 
35S  metabolic  labeling,  polysome 
microarray), and experiments can be performed to rescue the senescence phenotype 
with different domains of wt NPM important for ribosome biogenesis.  It would also 
be interesting to map the domains of NPMc+ and E1A necessary for the cooperative 
oncogenic transformation in MEFs.  Finally, one could in theory use the NPMc+/E1A 
and NPM/E1A MEF models to test for small molecule inhibitors specifically targeting 
NPMc+ and not NPM.    
The preliminary results shown in Chapter 3, although encouraging, need to be 
confirmed.  The cases for NPMc+ transgenic mice with features of myeloproliferative 
disease  need  to  be  increased  by  analyzing  more  mice,  especially  in  line  #28.  
Hematopathologic  analysis  of  more  MRP8-NPM  transgenic  mice  also  needs  to  be 
performed.    Increased  senescence  in  ex-vivo  cultures  of  bone  marrow  cells  from 
NPMc+ transgenic mice compared to NT needs to be confirmed in vivo.  It is essential 
to show cytoplasmic expression of NPMc+ in all MPD and epithelial tumor cases 
using immunohistochemistry.  Finally, to better recapitulate NPMc+ AML, targeting 
NPMc+ expression at a different stage of myeloid development or knock-in models of 
NPMc+ may be necessary.  Genetic crosses of our MRP8-NPMc+ transgenic mice 
with mice carrying another oncogenic event (such as the Flt3-ITD knockin mice
181), or 
bone marrow transplantation of NPMc+ together with other oncogenes in mice may  
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also prove useful in generating better in vivo NPMc+ AML models for therapeutic 
targeting. 
To more convincingly demonstrate that the ribosome composition is different in 
early-passage Npm
+/- vs. Npm
+/+ MEFs in Chapter 5, one could perform SILAC and 
mass spectrometry to quantify all ribosomal proteins in the purified ribosomes of these 
two cell types.  This approach can be extended to other human cancer cell lines or 
primary tumor samples to see if stoichiometric signatures of aberrant ribosomes exist 
in  certain  cancers.    Mass  spectrometry  can  also  address  whether  post-translational 
modification of ribosomal proteins is altered in Npm
+/- ribosomes.  As another measure 
of ribosome quality, an interesting experiment would be to determine the ribosome 
structure in Npm
+/- MEFs.  To demonstrate that aberrant ribosome stoichiometry can 
cause  differential  translation  of  a  subset  of  target  mRNAs  in  Npm
+/-  MEFs,  it  is 
essential to overexpress (e.g. L5) or knockdown (e.g. S4, L37) the aberrant ribosomal 
protein and determine if the differential translation could be rescued.  A luciferase 
reporter  for  one  of  the  Npm  translational  targets  (e.g.  NF1)  can  be  introduced  in 
Npm
+/- cells and its readout monitored after overexpression of wt Npm.  At the end, to 
unequivocally  prove  that  ribosomes  isolated  from  cancer  cells  directly  result  in 
increased  translation  of  “oncogenic  mRNAs”,  an  in  vitro  mammalian  ribosome 
reconstitution and translation assay should be developed.  
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